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ABSTRACT
Bovine papillomavirus-type 4 is associated with benign papillomas which can 
progress to carcinoma in cattle grazing on bracken fern. Bracken is known to 
contain immunosuppressants and cocarcinogens which can act as cofactors and 
these are known to be required for progression in vivo. One of the best 
characterised of these cofactors is the mutagen quercetin. BPV-4 has been shown 
to be capable of partially transforming primary bovine fibroblasts (PalF) cells in 
vitro in the presence of an activated ras and when these cells are additionally 
treated with quercetin they become tumourigenic in nude mice.
The transforming functions of BPV-4 are encoded by the E7 and the E8 
ORF's. BPV-4 is unusual in that it does not possess an E6 ORF. E6 has been 
shown to be one of the major transforming oncoproteins of the human 
papillomaviruses and is known to bind and degrade the tumour suppressor protein 
p53. This abrogation of the p53 protein is known to contribute to tumour 
progression by the high risk papillomaviruses such as HPV-16 and 18. As BPV-4 
does not encode E6 functions, this would suggest that if p53 dysfunction is 
important in BPV-4 cell transformation, it may occur by alteration of the cellular 
gene.
In order to look at possible p53 mutations in alimentary cancer of cattle, a 
14kb genomic clone containing wild type p53 sequence was isolated from a 
bovine liver genomic DNA library and sequenced. This clone was used to 
localise bovine p53 to chromosome 19ql5 which is known to be syntenic with 
human chromosome 17 and mouse chromosome 11 both of which harbour the 
p53 gene.
Immunocytochemical analysis of BPV-4 derived lesions demonstrated that 
elevated levels of p53 protein were detectable in papillomas but not in 
carcinomas. BPV-4 E7 was found to be present at all stages of papillomatosis as 
was BPV-4 viral DNA as detected by in-situ hybridisation. Neither viral DNA 
nor BPV-4 E7 were detected in normal palatine tissue or in carcinomas which is 
coincident with the loss of viral DNA previously reported for tumours in vivo. 
The elevated levels of p53 in some of the papillomas were shown to be a result of 
the presence of mutations in p53 exon 7 as 
determined by SSCP-PCR and sequencing. Mutant p53 was also detected in two 
metastases of upper alimentary canal tumours.
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The addition of mutant p53 to PalF cells in vitro in the presence of BPV-4, ras 
and HPV-16E6 caused these cells to become tumourigenic in nude mice. In these 
tumorigenic PalF cell lines, mRNA expression of the BPV-4 viral oncoprotein E8 
was shown to be elevated. Cotransfected mutant p53 mRNA expression was also 
detectable. This would suggest that p53 mutation plays a role in tumourigenic 
progression by BPV-4 both in vivo and in vitro.
In this study we demonstrate that the lack of an E6 in BPV-4 may be 
compensated by the presence of a mutated p53 gene in BPV-4 induced 
carcinomas. These p53 mutations may arise due to cofactors present in bracken 
fern, and p53 mutations were detected in BPV-4 and ras transfected PalF cells 
that had been treated with quercetin. However, p53 mutations were detected in 
transfected PalF cells which had not been exposed to quercetin treatment. We 
also demonstrate that the additional functions provided by HPV-16 E6 (16E6) in 
vitro are at least in part, independent of the p53 binding and degradation function. 
The data suggests that an exogenous 16E6 can supplement in vitro other functions 
of BPV-4 which are responsible for progression in vivo. HPV-16 E6 was also 
demonstrated to possess a function confering anchorage independence, which 
mapped to the cysteines present in the zinc finger motifs of the protein.
This study has demonstrated BPV-4 lacks more than one function that can be 
provided by an exogeneous E6 oncoprotein and that these functions may be 
independent of p53. In addition, p53 mutations were shown to be present in 
BPV-4 induced papillomas and carcinomas.
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'Everything in this book may be wrong'. 
Richard Bach
Illusions: The story o f the reluctant messiah.
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CHAPTER ONE
INTRODUCTION
1
1.1 Papillomaviruses and Cancer
Cancer is a multistage process and requires many changes to take place 
in order for progression to occur. Most of these changes are a result of a 
combination of activation of cellular protooncogenes, inactivation of tumour 
suppressor genes, and environmental cofactors. This would suggest that 
cancer is a result of an accumulation of a number of events gradually leading 
to malignancy (reviewed in Vogelstein and Kinzler, 1993). Several viruses 
have been identified which can also contribute to these processes in humans 
and other mammals and in this introduction I intend to first discuss 
papillomavirus infection involved in cancer processes, the role of the tumour 
suppressor gene p53 and then deal with papillomaviruses and their 
oncoproteins. Finally I will discuss the link between these and the aims of 
my project.
One of the best characterised of the oncogenic viruses are the 
papillomaviruses which are a member of the papovaviridae family. 
Papillomaviruses were first isolated from cottontail rabbits by Shope and 
Hurst in 1933 and they have been identified as the etiological agents of a 
variety of benign epithelial lesions commonly known as warts (Pfister, 1987). 
These lesions normally regress (Lutzner, 1985) but some are capable of 
undergoing malignant progression to squamous cell carcinoma, however, virus 
alone is not sufficient to induce progression. Epidemiological evidence has 
implicated many environmental agents as sources of cocarcinogens in 
papillomavirus associated carcinogenesis (Smith et aly 1987). The synergism 
between papillomaviruses and cofactors has been studied in rabbits (Rous and 
Freidewald, 1944), cattle (Campo and Jarrett, 1986) and EV 
(epidermodysplasia verruciformis) patients (Orth, 1987). These studies have 
demonstrated the importance of environmental carcinogens and 
immunosuppresants in aiding malignant transformation by the virus in vivo
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(reviewed in Khare et al, 1995) and that papillomavirus infection is a key 
event in the development of neoplasia.
Papillomaviruses infect cells and replicate within differentiating 
keratinocytes. HPV infection usually results in a localised epithelial cell 
proliferation (Croissant et al, 1985) which will regress or persist. For certain 
HPV types further progression leads to premalignant events and can result in 
the development of cancer (Vousden, 1990). The link between 
papillomaviruses and differentiation makes them difficult to grow in 
conventional cell culture systems and the main problem with papillomavirus 
research is the inability to propagate the virus in vitro. Recent advances in in 
vitro HPV expression systems have provided powerful new methods for the 
study of viral mechanisms; these methods include the organotypic or raft 
culture system which mimics the differentiating epithelium that is the natural 
target tissue of the virus (Meyers and Laimins, 1992). The production of virus 
like particles (VLP) is also possible by exploiting the ability of the 
papillomavirus major capsid protein LI to self assemble. Thus the study of 
viral attachment and entry into the cell is now feasible (Schiller and Roden, 
1995).
Papillomavirus DNA is generally present as extrachromasomal 
episomes in benign lesions, however, in high grade lesions, viral DNA is 
frequently integrated with only the E6 and E7 open reading frames (ORF) 
remaining intact (Smotkin and Wettstein, 1986). Integration appears to be a 
non-specific event although it has occasionally been observed to occur in the 
vicinity of cellular oncogenes (Coutourier et al, 1991). This disruption of the 
regulatory papillomavirus genes is suspected to result in uncontrolled 
expression of E6 and E7 (Schwarz et al, 1985). In the case of some 
papillomavirus infections such as bovine papillomavirus type-4 (BPV-4), viral 
DNA is lost during the carcinogenic process and does not appear to be
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required for maintenance of the transformed phenotype (Campo et al, 1985). 
This will be dealt with in greater detail later in this thesis.
There are 70 cloned and sequenced human papillomaviruses and the 
total number of human papillomavirus types is nearer 100 when the 
unclassified and incomplete viral data are included (Van Ranst et al, 1994). 
Generally they are classified as either cutaneous or mucosal viruses according 
to their tissue tropism and clinical manifestation although there are 
papillomaviruses which are capable of infecting both tissue types such as 
human papillomaviruses HPV-57, HPV-7 and HPV-2 (de Villiers, 1989; Van 
Ranst, 1993). Of all the papillomavirus types at least 27 cause anogenital 
infection with HPV-6, 11, 16, 18, 31, 33 and 35 being the most prevalent. 
These are then subdivided as high or low risk papillomavirus infections 
depending on the clinical outcome, i.e, HPV 6 and 11 are classed as low risk 
resulting in benign lesions such as condylomata acuminata, however, HPV-16 
and 18 are high risk resulting in lesions which can progress to carcinoma 
(Vousden, 1989). Other differences between high and low risk will be 
discussed later with respect to viral oncoproteins and their interactions with 
other cellular proteins. The epidemiology of the papillomaviruses has been 
well studied but the molecular mechanisms of infection and progression are 
still being characterised. As many papillomavirus types have been implicated 
as the etiological agents of many cancers, it is important to determine the 
nature of papillomavirus infection and their transformation mechanisms in 
order to prevent or treat infection.
This thesis examines the role of p53 in BPV-4 associated 
carcinogenesis and before considering the viral contribution to the 
carcinogenic process, I will first discuss the role of p53 as a tumour 
suppressor.
4
1.2 The tumour suppressor p 53
The p53 tumour suppressor gene has been shown to be the most 
commonly mutated locus in a wide range of human cancers (Hollstein et al, 
1991). It was first identified as a cellular protein associated with SV40 large 
T antigen (Lane and Crawford, 1979) and originally thought to be a oncogene. 
However, p53 activity as a tumour suppressor became increasingly apparent, 
for example, wild type p53 can inhibit the in vitro transformation of primary 
rodent cells by a variety of oncogenes, wheras tumour derived mutants have 
lost this capacity (Eliyahu et aly 1989). The wild type protein is a potent 
transcriptional transactivator (Fields and Jang, 1990; Weintraub, 1991) which 
stimulates genes that negatively regulate cell growth and division, suppresses 
genes involved in cell proliferation (Ginsberg et al, 1991a) and is integral to a 
cellular checkpoint in response to DNA damage (Kuerbitz et aly 1992). A 
variety of genotoxic agents can induce an accumulation of the wild type p53 
protein in the nucleus of mammalian cells which can lead to either growth 
arrest or to apoptosis (Yonish-Rouach et aly 1991) in a p53 dependent manner. 
p53 has also been implicated in cell differentiation (Shaulsky et aly 1991).
The human p53 gene is located on chromosome 17pl3.1 and is 20 
kilobases (kb) in length (Benchimol et aly 1985). The gene (see figure 1.1) 
itself contains 11 exons, the first of which is non-coding and separated from 
the rest by lOkb of intron (Lamb and Crawford, 1986). The human p53 
promoter appears to lack either a TATA or a non-TATA initiated transcription 
site. However, the murine p53 promoter contains sequences commonly found 
in non-TATA box promoters such as a GC-rich region containing a Spl 
binding site. The processed human transcript is 2.5kb long and yields a 393 
amino acid nuclear phosphoprotein with a molecular weight of 53 kilodaltons 
(kDa).
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p53 is present in almost all cell types although expression of the wild type 
protein is virtually undetectable. The half life of the wild type p53 protein in 
non-transformed cells is between 6 and 20 minutes but in transformed or 
tumour cells this is increased by 5-100 fold as the mutant proteins have 
increased stability (Ginsberg et al, 1991b). Many cellular proteins which 
form complexes with p53 and DNA damaging agents also increase the half- 
life of p53 and raise steady state levels to those which can be detected 
immunohistochemically (Matlashewski et al, 1986).
Generally in tumours, one p53 allelle is found in the mutant form and 
the second wild type allelle is rearranged or lost by deletion. Expression of 
mutant p53 protein is common and the mutant protein has been demonstrated 
to bind the wild type protein in vitro to form inactive aggregates. These p53 
protein aggregates are usually dysfunctional although gain of function 
mutations have also been observed and some are able to enhance cell 
transformation although the mechanism is unclear. Dittmer et al, (1993) 
have shown that expression of murine or human mutant p53 in the absence of 
endogeneous p53 can confer enhanced tumourigenicity upon cells. These p53 
mutants Alal43, Hisl75, Trp248 and His273 were capable of activating 
transcription from the multi drug resistance gene (MDR-1) enhancer-promoter 
element in Saos-2 cells. These cells are derived from human osteosarcomas 
which lack endogeneous expression of wild type p53 (Dittmer et al, 1993). 
This transactivating ability is absent in the wild type p53 protein which 
represses the MDR-1 gene promoter thus the mutant proteins appear to 
predispose the cell to tumourigenicity by acquiring a new function in the 
absence of a wild type allele. This data would suggest that a total loss of p53 
expression is not as detrimental as the presence of certain mutant p53 proteins 
which may provide the cell with some new function conferring growth 
advantage rather than just inactivation. It has been shown that in the majority 
of breast tumours, wild type p53 has been relegated to the cytoplasm and is
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inactive (Moll et al, 1992). This may indicate the influence particular 
environmental carcinogens could have for specific tissues on the p53 gene or 
other cellular factors not yet found.
When a comparison is made between species, there exist five regions 
of 90-100% homology within the p53 protein. These regions are extensively 
conserved from Xenopus through to primates suggesting a role of biological 
importance (Soussi et al, 1990). Most mutations that occur in the p53 protein 
such as deletions, insertions, point and misense mutations have been mapped 
to these conserved domains and throughout the central DNA binding region of 
the protein. These highly mutated sites have been termed hotspots and 
correspond to residues which have been found to be mutated in a variety of 
human tumours. Mutations at residues 175 (CRIII), 248 (CRIV), and 273 
(CRV) are more common, but do not appear to be associated with particular 
forms of cancer (Levine et al, 1991). It should be noted however that 
localisation of a mutation within the gene does not predetermine its effect.
As well as these somatic mutations, p53 germline mutations which are 
inherited have been identified which have been shown to increase the 
susceptibility of certain families to cancer (Srivastava et al, 1990). This 
condition is known as Li Fraumeni Syndrome (LFS) and these families 
develop a wide spectrum of multiple primary tumours and soft tissue sarcomas 
at an early age. Non affected individuals have two wild type p53 alleles while 
affected individuals acquire the wild type p53 and a mutant allele. In tumours 
that develop the wild type p53 allele is lost (Vogelstein, 1990; Srivastava et 
al, 1993).
The importance of p53 as a tumour supressor cannot be ignored as 
>60% of human tumours contain elevated levels of mutant p53 (Hollstein et 
al, 1991). Although p53 mutations occur in many cancers, other mechanisms
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of p53 abrogation have been identified in tumours where the p53 protein is 
wild type, and these mechanisms will be discussed later.
The human p53 protein can be divided into three domains as illustrated 
in figure 1.2, (adapted from Deppert, 1994);
Firstly, the N-terminal domain is highly acidic and largely alpha- 
helical (Sturzbecher et al, 1992). AA 1-42 are required for transcriptional 
activation (Unger et al, 1992). TATA-box binding protein (TBP) binding and 
Adenovirus oncoprotein Elb p55 also bind in this region (Levine, 1990).
The central portion of the molecule is proline rich and highly 
hydrophobic. The highly conserved regions II to V are located in this region 
(Soussi et al, 1990) as is the SV40 large T antigen binding site and the p53 
sequence specific DNA binding domain. The core portion of p53 
(AA102-292) fold to a structural domain containing this sequence specific 
DNA binding function and Cho et al (1994) have crystallised this structure in 
the presence of a consensus DNA site (Cho et al, 1994). The prevalence of 
mutations are found in the central 200AA as shown in figure 1.2 suggesting 
that this region is a target site for p53 inactivation in tumours. The p53 
binding site consists of four copies of the consensus 5'-PuPuPuC(A/r)-3' (El 
Diery et al, 1992).
Figure 1.3 illustrates part of the p53 protein sequence and the 
secondary structures of this region. The majority of conserved region IV is 
located in the L3 loop of the protein. The amino acids in loop 3 are involved 
in interactions with the minor groove of the DNA consensus site. Arg248 an(j 
Arg249 are am0ng the most commonly mutated amino acids in the whole p53 
protein (Hollstein et al, 1991) and 30% of p53 mutations are found in the L3 
loop (Levine et al, 1994). This suggests the importance of this loop in 
protein-DNA interactions and that mutation in this region would lead to an 
inactivated protein. In general, mutations were found to be most frequent in
9
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those regions of the p53 protein core domain that closely contacted the DNA 
(Cho et al, 1994). There are zinc binding sites in the central region and zinc is 
necesssary for DNA binding activity (Pavletich et al> 1993), maintenance of 
the wild type conformation appears to be dependent on metal binding (Hainaut 
and Milner, 1993).
The p53 protein forms a tetramer via an oligomerisation domain in the 
C-terminus at residues 311-364 (Pavletich et al, 1993) and p53 tetramerises as 
a dimer of dimers. The crystal structure of the tetramerisation domain 
(residues 325-356) has been determined (Jeffrey et al, 1995) and Clore et al 
(1994) have shown the 3-D structure of the oligomerisation domain (residues 
319-360) by multidimensional NMR (Clore et aly 1994). Oligomerisation of 
the p53 protein is essential for its tumour suppressor function and mutations in 
this domain have been shown to inactivate this p53 function (Ishioka et al> 
1995). In vivo, oligomerisation deficient p53 cannot transactivate via p53 
binding sites (Peietenpol et al, 1994) and deletion mutants in the 
oligomerisation domain are also defective with regard to DNA binding (Hupp 
et al, 1993) despite retaining the central DNA binding domain.
Point mutations at residues 330, 334, 335 and 349, are located at 
crucial sites in the p-sheet structures of the dimers but it has not been 
established whether they have lost their tumour suppressor activity. It has 
been suggested that disruption of these dimers potentially destabilises the 
tetramer, in vitro tetramerisation is not however, essential for DNA binding as 
the core domain is capable of binding on its own. This would suggest that 
these C-terminal domains are important structurally in facilitating correct 
DNA binding for p53 function.
The C-terminal basic region (residues 330-393) appears to be involved 
in non-specific DNA binding (Pavletich et al, 1993) and is capable of forming 
an amphipathic helical structure (Kern et aly 1991a).
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Figure 1.3 Partial sequence of p53 core domain residues 230-260. 
Conserved region IV is underlined and the ribbon drawing represents 
part of the secondary structure elements of the core domain. The circles 
represent those residues involved in zinc binding and the asterisks 
indicate the residues involved in DIMA binding. S8 and S9 are p-sheet 
structures and L3 is the loop structure. The bars indicate the frequency 
of mutation for the residue.
The C-terminal domain has considerably more characterised functions than 
the other two regions yet few tumour derived mutations map to this region 
(Ishioka et al, 1995). However, it is now apparent that different mutations 
produce functionally different proteins and may exert conformational changes 
in the protein possibly altering p53 in this manner. Milner (1994) proposed a 
conformational model for p53 switching between its suppressor and activator 
forms which may be controlled in the C-terminus. Conformational regulation 
is apparent as the wild type p53 protein undergoes conformational change 
during G1 and adopts a mutant form which may prevent binding to DNA or 
proteins (Milner and Watson, 1990). However, the changes that occur as a 
result of mutation may not be as subtle as a conformational shift, but may 
result in a denatured protein. Thus the role of p53 as a tumour suppressor and 
as a transcriptional activator can be disrupted since mutant conformations may 
prevent activation of the necessary genes required for growth suppression.
The p53 protein is multiply phosphorylated by several different protein 
kinases (reviewed in Meek, 1994). Phosphorylation of murine p53 at serine 
386 by casein kinase II has been demonstrated to be required for its tumour 
suppressor functions in vitro and possibly in vivo (Meek et al, 1990). 
Mutation of serine 386 abolishes the tumour suppressor activity of p53 (Milne 
et al, 1992) and serine 386 is also the proposed attachment site for an unusual 
RNA moiety. It is at present unknown whether serine 386 is a site for 
regulatory phosphorylation, covalent modification or both, however, recent 
data demonstrating p53 as a RNA binding protein may help elucidate further 
biological functions of p53 (Oberosler et al, 1993). The N-terminus is 
phosphorylated by casein kinase I (CKI), double stranded DNA protein 
kinase (ds DNA-PK) and it has been reported that dephosphorylation occurs 
via protein phosphatase 2A (PP2A) (Wang and Eckhart, 1992). Serine 309 in 
mouse p53 protein (ser-315 in human) is phosphorylated by CDKI (p34cdc2) 
suggesting that cell cycle dependent phosphorylation might control p53
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(Bischoff et al, 1990). The ability of p53 to act as a tumour suppressor 
appears to correlate with an increase in phosphorylation of the protein and it 
has been shown that p53 becomes increasingly phosphorylated on entering S 
phase of the cell cycle (Meek and Street, 1992). This results in a p53 protein 
which will activate other cell cycle regulators such as wafl/cipl (El-Diery et 
al, 1993) which is induced by expression of wild type p53 and will be 
discussed later.
Marston et al (1994) also demonstrated that human p53 mutated at the 
CKII and p34cdc2 sites also had no effect on transcriptional activity 
suggesting that p53 phosphorylation is not simply an on-off mechanism but 
may regulate other functions or act as a more subtle method of regulation.
1.3 p 53 and its biological functions.
No single major function has yet been determined for p53 although 
involvement in many biological processes is clear from both its protein 
binding activities, which I will deal with subsequently, and its inactivation in 
most human tumours. The most likely function for p53 is as a transcription 
factor and when fused to the Gal4 DNA-binding domain of yeast, p53 has 
been shown to activate transcription from promoters containing Gal4 binding 
sites. Gene fusion of the N-terminus of p53 (AA 1-73) or of the whole p53 
protein to Gal4 will promote the expression of a reporter gene in yeast or in 
mammalian cells in culture (Raycroft et al, 1990). This positive regulation 
by the p53 protein is in a sequence specific manner. p53 only activates 
transcription when the target contains the p53 consensus binding site (El Diery 
et al, 1992). Several different p53 binding motifs have been identified (Kern 
et al, 1991a; Funk et al, 1992) confirming the complexity of p53-DNA 
interactions. A specific p53 element has also been identified which is only 
bound by wild type p53; this target sequence is found in the wafl/cipl gene
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(El-Diery et al, 1993), the mdm-2 gene (Juven et al, 1993) and the muscle 
creatine kinase (MCK) promoter (Weintraub et al, 1991). The regulatory 
region of the MCK gene contains a p53 responsive element that will activate a 
MCK-CAT reporter gene. Mutant p53 cannot activate transcription in this 
manner and displays a dominant negative effect when cotransfected with wild 
type constructs. However, some mutant p53 proteins can still bind to DNA 
and do not lose their ability to activate transcription (Zhang et al, 1993; 
Dittmer et al, 1993). This is in contrast to previous reports that mutant p53 
proteins fail to bind DNA via the consensus element (Bargonetti et al, 1991). 
This may be explained by the location of the mutants studied with respect to 
the core domain and the oligomerisation/tetramerisation domains. One of the 
mutants used by Dittmer et al, (1993), Alal43} js jn the hydrophobic p~ 
sandwich of the core domain. This domain is not directly linked to the DNA 
binding surface and therefore may not exert a marked effect on p53 
transcriptional activation.
p53 can also regulate its own transcription, however, a direct 
interaction with its own promoter has not been demonstrated. Mutant p53 
defective for transformation and transactivation cannot activate the p53 
promoter. The p53 responsive element within the p53 gene has been 
suggested to be the NF-kB motif (Deffie et al, 1993). The cellular encoded 
transcription factor USF which is involved in the transcription of a number of 
cellular and viral genes can also bind to the p53 promoter possibly regulating 
p53 expression (Reisman and Rotter, 1993). Thus p53 transactivation of 
transcription factors or p53 interactions with other cellular proteins may act to 
regulate its own transcription.
As previously mentioned, wild type p53 levels can be increased by 
agents that result in DNA damage. Kastan et al, (1991) showed that this 
increase in p53 levels mediated a growth arrest at G1 of the cell cycle. Cell 
cycle arrest is thought to prevent the genomic instability associated with many
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cancers by allowing time for DNA repair or when this is not possible by 
inducing programmed cell death or apoptosis (Perry and Levine, 1993, Lane, 
1993). This illustrates a physiological state where cells express high levels of 
wild type p53 and consequently either arrest growth or apoptose. Mutant p53 
or p53 bound by other proteins cannot perform these functions and so increase 
the possibility of genetic mutation.
p53 can function as a cell cycle checkpoint determinant by arresting 
the cell at the transition between G1 and S phase (Livingstone et al, 1992). 
This is supported by studies on cells from patients with the cancer prone 
disease Ataxia Telangiectasia (AT) in which the Growth Arrest and DNA 
Damage gene (GADD45) is absent (Kastan et al 1992). Cells from an AT 
lymphoblastoid cell line are radiosensitive and the p53 protein does not 
increase in response to ionising radiation. In normal cells, ionising radiation 
induces an increase in GADD45 and p53 levels and it was demonstrated that 
the AT gene which is defective in this syndrome is responsible for increased 
p53 levels in response to radiation. Furthermore, GADD45 (which contains a 
p53 responsive element) is dependent on a functional p53 for its induction 
(Kastan et al, 1992). Thus the lack of GADD45 or p53 response following 
irradiation of AT cells allows inappropriate cell survival leading to further 
mutation. As well as responding to radiation induced damage, accumulation 
of wild type p53 in the nucleus has been demonstrated to occur in response to 
cytotoxic anti-cancer drugs and agents such as mitomycin C, cisplatin, 
etoposide and actinomycin D (Fritsche et al, 1993).
DNA damage also results in the induction of the wafl/cipl gene, 
expression of which is regulated by p53 (Liu and Pelling, 1995). W afl/cipl is 
a major candidate as a downstream mediator of p53 function (El Diery et al, 
1993), and is a potent cyclin dependent kinase (CDK) inhibitor which 
interacts with many cyclins and CDK's (Harper et al, 1993; Xiong et al, 
1993). W afl/cipl can also act as a suppressor of cell growth (El Diery et al,
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1993), however, a Val-Ala 138 mutant p53 was unable to induce wafl/cipl 
expression while still retaining the ability to arrest cell growth of rat embryo 
fibroblasts (Hirano et al, 1995), suggesting that p53 can arrest cell growth in 
the absence of wafl/cipl induction. Thus p53 induced growth arrest may 
occur via alternative pathways to prevent the accumulation of genetic damage.
It is important to mention that additional checkpoints exist in G2 and S 
that do not involve p53 (reviewed in Weinert and Lydall, 1993) as identified 
by Rad9 mutants in yeast (Weinert and Hartwell, 1990) and the loss of RCC1 
in mammalian cells (Nishitani et al, 1991). These may also contribute to 
cellular control in the absence of p53.
Apoptosis or programmed cell death is widespread in multicellular 
organisms and plays an important role in developmental processes. Apoptosis 
has been shown in thymocytes to be induced by DNA damaging agents via a 
p53 dependent pathway (Clarke et al, 1993). This pathway appears to respond 
to single strand breaks in the DNA. High levels of p53 can induce apoptosis, 
yet can also induce growth arrest without apoptosis as already discussed. p53 
has been shown to be essential to the process as p53 null mice (Donehower et 
al, 1992) show no apoptotic response even to high levels of radiation (Lowe et 
al, 1993). A p53 independent apoptotic pathway exists as evident by the 
normal development of homozygous p53 null mice with functional immune 
and reproductive systems, although these animals are predisposed to tumour 
formation by the age of six months (Clarke et al, 1993). The mechanism by 
which p53 induces apoptosis is unclear, however other cellular proteins have 
been identified which are involved in the p53 dependent apoptotic response. 
p53 is known to induce a reduction in the expression of bcl-2 and an increase 
in box expression (Miyashita et al, 1994). The bcl-2 protein can block p53 
induced apoptosis (Wang et al, 1993) and bax can form hetrodimers with 
bcl-2 abrogating its ability to suppress apoptosis (Oltvai et al, 1993).
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Increased levels of bcl-2 have been observed in some tumours and p53 is 
either lost or mutated. Thus, these proteins regulate the balance between life 
and death of the cell and loss of p53 mediated repression of bcl-2 may lead to 
bcl-2 overexpression resulting in inappropriate cell survival.
1.4 p 53 and other proteins
p53 has been shown so far to be inactivated by mutation or loss 
however, abrogation of p53 function also occurs as a result of binding to viral 
oncoproteins. p53 also binds cellular proteins and I will deal with these first.
The murine double minute gene product (mdm-2) is a cellular protein 
which has been shown to form complexes with p53 (Momand et al, 1992). 
Mdm-2, a cellular oncogene, was initially characterised as an amplicon on the 
double minute chromosomes of a spontaneously transformed, tumourigenic 
murine cell line (Fakarazedah et al, 1991). The human mdm-2 gene on 
chromosome 12ql3-14 has also been observed to be amplified in many 
human sarcomas leading to the inactivation of wild type p53 by complex 
formation with the mdm-2 gene product mdm-2P90 (p95) (Oliner et al, 1992). 
In cases where mdm-2 amplification occurs p53 mutations are rarely present 
(Oliner et al, 1992) although human and mouse mdm-2 gene products have 
been shown to bind to mutant as well as wild type p53. mdm-2 expression is 
induced by wild type p53 suggesting that mdm-2 is a target for activation by 
p53 (Barak et al, 1993). As m dm -2P^ can act as an antagonist of p53 
activity, this induction of mdm-2 may autoregulate p53 activity in cells. 
Overexpression of mdm-2P90 inhibits the ability of p53 to transactivate genes 
whose promoters contain p53 binding sites, and leads to enhanced 
tumourigenicity (Finlay, 1993). Recently mdm-2P90 was shown to stimulate 
the S-phase inducing transcription factors E2F-1/DP1 (Martin et al, 1995).
18
This response suggests that mdm-2P90 can both abrogate p53 tumour 
suppressor functions and enhance cell growth.
Hypophosphorylated Rb is also associated with the transcription 
factors E2F-1/DP1 as heterodimers preventing the transcriptional activity of 
E2F-1 (Krek et al, 1993). Rb-1 was first identified as deleted or mutated in 
the familial malignancy retinoblastoma (Rb) (Goodrich and Lee, 1993) and is 
known to play an important part in control of the cell cycle (Goodrich et al,
1991). Rb is phosphorylated in a cell cycle dependent manner and is 
hypophosphorylated in G0/G1 and at the Gl/S boundary Rb becomes 
phosphorylated at serine residues by a cdc2-like protein kinase (Goodrich and 
Lee, 1993; Munger and Phelps, 1993). Xiao et al (1995) have shown that 
mdm-2 interacts with Rb both physically and functionally, and, as with p53, 
inhibits the growth regulatory functions provided by Rb. Thus, both p53 and 
Rb may be negatively regulated by the product of the single cellular 
protooncogene mdm-2P^.
It is apparent that loss of both Rb and p53 tumour suppressor functions 
leads to inappropriate cell survival creating an enhanced environment for cell 
proliferation. This situation is mimiced by DNA tumour viruses which target 
both p53 and Rb as will be discussed in section 1.5.
Wild type p53 can repress transcriptional activity from various 
promoters, for example, the fos basal promoter (Seto et al, 1992; Liu et al, 
1993). This occurs through the binding of the basal transcription factors by 
p53 (Ragimov et al 1993) thus preventing these factors binding to the TATA 
motif and activating transcription. Both wild type and mutant p53 can form a 
specific complex in vitro with the human but not the yeast TATA binding 
protein (TBP) (He et al, 1993), however only wild type p53 can prevent the 
stable binding of the TBP to the TATA motif which is the initial step in the 
formation of a preinitiation complex (Ragimov et al, 1993). This could be the 
molecular basis of the transcriptional repressor activity of p53 which is also
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implicated in growth arrest, i.e, activation of p53 leads to an increase in p53 
protein and the binding of other cellular proteins which halt cell cycle 
progression. Unlike p53 transcriptional activation, there appears to be no 
specific sequence requirement for repression of transcription (Ginsberg et al, 
1991a). p53 binds origins of replication and the human and yeast Replication 
protein A (RPA) is bound by the N-terminus of p53 resulting in the inhibition 
of initiation of DNA replication (Dutta et al, 1993). It does so by preventing 
the binding of RPA to single stranded DNA in vitro, however no homologue 
of p53 has yet been identified in yeast, although RAD9 is a possible candidate 
(Prives, 1993). SV40 large T antigen binds to RPA to facilitate SV40 
replication. If p53 binds RPA, then this may prevent SV40 replication 
illustrating the requirement for DNA tumour viruses to inactivate p53 in order 
to replicate in the cell.
In contrast p53 has been shown to downregulate HPV LCR expression 
independent of the TBP interaction (Desaintes et al, 1995) suggesting there 
are as yet unidentified proteins controlling this process.
Interestingly, p53 which has been associated with the response to DNA 
damage, regulates the expression of the Hsp70 stress/heat shock protein. 
Hsp70 is expressed in late G 1/early S phase of the cell cycle and can be 
induced by environmental factors. The hsp70 promoter contains the CCAAT 
element through which transcription is stimulated by the CCAAT binding 
factor (CBF) stimulating transcription from the hsp70 promoter (Agoff et al, 
1993). p53 binds to CBF preventing activation of the hsp70 gene again 
supporting p53 action as a repressor rather than activator of transcription. 
Hsp70 protein is associated with Argl75 p53 mutants (Hinds et al, 1990). 
This amino acid is suspected to have a critical role in stabilising the L2-L3 
loops of the core domain. Hsp70 is know to associate with denatured proteins 
prior to their degradation in the cell. The association of mutant p53 with
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hsp70 may occur as a result of the unfolded p53 protein being targeted for 
removal from the cell.
p53 binds to numerous different proteins and has been implicated in so 
many biochemical and biological functions that it is difficult to determine 
which are physiologically relevant, although it is possible they all are. It is as 
yet unclear how p53 functional activities are controlled, for example, by DNA 
damage. Another puzzle is how p53 directs the choice between apoptosis and 
growth arrest. This may depend on the interactions of other cellular proteins 
such as Rb, which along with p53 expression, can direct the cell to undergo 
either growth arrest or apoptosis. Overexpression of Rb rescued HeLa cells 
from p53 induced apoptosis (Haupt et al, 1995). Thus, if Rb is reduced and 
wild type p53 increased, then apoptosis will occur and if both p53 and Rb 
levels are raised then growth arrest occurs. Therefore, viruses require to 
inactivate both proteins to survive and replicate in the cell.
1.5 p 53 and viral oncoproteins
From the above data it is clear that p53 is a crucial protein in 
regulating cell proliferation. Cellular inactivation of p53 leads to a potential 
tumourigenic situation where cells are allowed to progress and gain genetic 
abnormalities. Viruses have exploited this potential and evolved mechanisms 
which disrupt p53 functions thus creating a favourable environment for viral 
production.
The viral oncoproteins encoded by the DNA tumour viruses have been 
shown to target the p53 protein and prevent its functioning as a tumour 
supressor. The SV40 large T antigen was the first to be found to bind wild 
type p53 (Lane and Crawford, 1979). It blocks p53 binding to DNA 
preventing p53 transcriptional activation (Bargonetti et al, 1992).
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The Adenoviruses express two oncogenes, E l a and E lb  which 
co-operate to transform cells (Yew and Berk, 1992). E la binds Rb-1 (pl05) 
and acts as the major transforming protein of the virus. Non-oncogenic 
human Adenovirus Type 5 E lb p55 protein binds p53 and sequesters it to the 
cytoplasm (Sander et al, 1993), however, the oncogenic Adenovirus Type 12 
(Ad 12) E lb does not form a detectable association with p53 (Zantema et al,
1985). In Ad 12 transformed cells p53 is wild type and is present in the 
nucleus at high levels. This p53 also contributes to the transformation of the 
cells and demonstrates properties normally associated with mutant p53. 
However, E lb  from both Ad5 and Ad 12 is involved in the transformation of 
cells in culture, contributes equally well to transformation and can inhibit 
transcriptional transactivation mediated by p53 (Sander et al, 1993). How 
Ad 12 Elb functions without complexing to p53 is unclear. Nevertheless, p l9  
and p55 encoded by E lb can protect cells from p53 induced apoptosis which 
occurs in cells expressing E la alone (Debbas and White, 1993). Mutant Ad5 
Elb proteins which are defective in p53 binding are unable to transform and 
cannot block p53 induced transcription. Thus, both E la  and E lb  are required 
as both Rb and p53 need to be inactivated for immortalisation to occur.
The oncoproteins of the papillomaviruses are also known to interact 
with p53 and Rb-1 (pl05) in order to abrogate their functions and facilitate 
transformation. The E6 oncoprotein of HPV-16 and 18 binds the tumour 
suppressor protein p53 (Werness et al, 1990) and the E7 oncoprotein binds to 
the retinoblastoma gene product pl05 (Rb-1) (Munger et al, 1989), however, 
these aspects will be dealt with separately.
1.6 Papillomavirus Genome Organisation
The focus of this thesis is to consider the role of p53 in BPV-4 
associated carcinogenesis. The following sections will deal with
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papillomaviruses in general and then with Bovine papillomavirus type-4 
(BPV-4) in particular.
Papillomaviruses have a circular double stranded genome of 
approximately 7-8 kb in length (reviewed in Jackson and Campo, 1992). The 
papillomaviruses all essentially possess the same genomic organisation as 
illustrated in figure 1.4; however functional differences do exist between the 
proteins encoded by different papillomaviruses as will be discussed later.
The viral genes are divided into those which are expressed early (E) or 
late (L) in the viral life cycle. The E l to E8 ORFs are expressed at the early 
stages and are involved in viral replication, transcription and transformation 
with the exception of the E4 ORF which is expressed at later stages of viral 
production along with the structural proteins LI and L2.
Immediately upstream of the early region is the non-coding Long 
Control Region (LCR) which contains the viral origin of replication, 
promoters, enhancer elements and cis acting sequences (McBride et al, 1989). 
The E l and E2 ORFs bind to specific sites within the LCR and are essential 
for viral DNA replication in vivo and must be expressed together for viral 
replication to take place (reviewed in Ham et al> 1991). E2 products modulate 
papillomavirus gene expression and viral replication, thus both transcription 
and viral DNA replication are regulated through elements in the LCR.
Papillomavirus Proteins
Papillomavirus genomes encode transforming proteins which create an 
expanded cell population as a favourable environment for viral replication.
The proteins encoded by the papillomaviruses differ in their functions, 
for example, the E6 oncoproteins of the high risk papillomaviruses HPV-16 
and 18 bind and degrade the tumour suppressor p53. In contrast to the high 
risk HPV E6 proteins, the low risk E6's of HPV-6 and 11 are not capable of 
high affinity binding to p53 and consequently do not facilitate degradation of
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B P V - 1
B P V - 4
Figure 1.4 Genomic organisation of BPV-1 and BPV-4. 
Early ORFs involved in replication and transcription 
Early ORFs involved in transformation 
Later structural ORFs
EH ORFs which have an as yet undefined function.
n.b E4 proteins are known to form a filamentous network which 
interacts with cytokeratins (Roberts etal, 1993), see text, page 34.
p53 (Werness et al, 1990; Scheffner et al, 1990). In this section I will deal 
with the papillomavirus proteins and their functions in general and discuss 
BPV-4 in section 1.7. Although an E6 ORF is not present in the BPV-4 
genome, HPV-16E6 is important in the experimental aspects of this thesis and 
therefore will be discussed in greater detail.
The E6 oncoprotein
The E6 oncoprotein of the papillomaviruses is a small acidic protein of 
approximately 150 amino acids with four C-X-X-C motifs which comprise 
two characteristic zinc finger domains (see figure 1.5). These motifs are 
conserved throughout the E6 encoding papillomaviruses and there is evidence 
that E6 binds zinc in vitro but not in vivo (Barbosa et al, 1989). These zinc 
finger domains are known to be important but only major structural alterations 
appear to affect transformation. The functional domains of HPV-16 (16E6) 
and HPV-18 E6 (18E6) and BPV-1 E6 protein have been dissected (Crook et 
al, 1991a; Pirn et al, 1994; Vousden et al, 1989) and in BPV-1 E6, the 
conserved cysteine motifs are important for the transformation of C l27 cells 
(Vousden et al, 1989). E6 is capable of partially transforming cells on its own 
although it requires the cooperation of the other major papillomavirus 
transforming oncoprotein E7 in order to fully transform cells (Munger et al,
1992). Both E6 and E7 have in vitro transforming activities although E6 is 
usually less active. E6 cooperates with E7 to immortalise primary human 
foreskin keratinocytes (Hawley-Nelson et al, 1989) and E6, like E7, can also 
cooperate with ras to transform primary rodent cells (Storey and Banks,
1993). HPV-6 and 11 E6 failed to cooperate with ras in the BMK 
transformation assay (Storey and Banks, 1993) demonstrating the different 
properties of E6 proteins from oncogenic and non-oncogenic 
papillomaviruses. Pirn et al (1994) mapped the domains of 18E6 responsible 
for cooperation with ras in the immortalisation of primary rodent cells, in
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vitro degradation of p53 and the inactivation of p53 function in vivo. 
Immortalisation appears to be independent of p53 and requires the C-terminal 
portion of the protein. The ability of 18E6 to abolish p53 transactivation is 
independent of p53 degradation. This would suggest that this function is 
mediated via the inhibition of p53 binding to its recognition sequence (Pim et 
al, 1994; Thomas et al, 1996).
E6 also has functions as a transcriptional transactivator (Sedman et al, 
1991; Desaintes et al, 1992) and Sedman et al (1991) have shown that both 
high and low risk papillomaviruses activate transcription at a similar level, 
thus this function may not be related to transformation. This is supported by 
the transactivating and transformation functions of E6 being separable as 
determined by the mutational analysis described previously (Pim et al, 1994).
E6 and p53 interaction
HPV-16E6, HPV-6E6 and BPV-1E6 can all immortalise cells albeit 
the latter less efficiently, however, it appears that only E6 of the high risk 
human papillomaviruses associates with p53 in detectable complexes 
(Werness et al, 1990). The E6 genes from HPV-5, HPV-8, BPV-1 and CRPV 
have oncogenic properties yet many studies confirm that these E6 proteins do 
not interact with p53 (Keen et al, 1994; Lechner et al, 1992; Werness et al, 
1990). In contrast, a study by Band et al (1993) showed that E6 of BPV-1 
does bind p53 with low affinity and Crook et al (1991a) have shown that 
HPV-6E6 can bind p53 with reduced affinity but cannot degrade it. What 
function E6 serves in the low risk HPVs and whether it binds to wild type p53 
with lower affinity is still unclear although new E6 functions now being 
elucidated may be involved.
The E6 oncoprotein binds p53 via an E6 associated protein [E6-AP], a 
cellular protein with an approximate molecular weight of 100 kDa (Huibregtse 
et al, 1991; Huibregtse et al, 1993a). The N-terminal 212AA of E6-AP are
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not required for complex formation or for HPV-16E6 mediated degradation of 
p53 (Huibregtse et al, 1993b). E6 from the high risk papillomaviruses 
promotes the degradation of p53 in vitro by ATP-dependent hydrolysis which 
is suspected to be via the ubiquitin dependent protease pathway (Scheffner et 
al, 1990; Scheffner et al, 1993). However, this E6 induced degradation may 
be targeted to other proteins. The E7 protein of the HPV's are involved in the 
binding of the cellular retinoblastoma product pRB. When the N-terminus of 
HPV-16 E7 is fused with full length HPV-16 E6 then the pRb protein is 
directed for degradation. Although the E6 proteins of HPV-11 and HPV-6 E6 
proteins do not bind to p53 and therefore do not target it for degradation, their 
E7 fusion proteins were still capable of degrading pRb. This suggests that the 
major functional differences between the E6 proteins of the high and low risk 
HPV's may lie in the specific cellular proteins they target for degradation.
To determine if this function was confined to the anogenital HPV's, 
additional fusions of HPV-5, BPV-1 and CRPV E6 were constructed. When 
fused to E7, all bound to pRb but failed to promote its degradation (Scheffner 
et al, 1992a). The E6-AP was not required in the E6/E7 fusion protein 
complexes to facilitate degradation (Scheffner et al, 1992a) as binding was 
mediated via E7 (Huibregtse et al, 1993b). Thus, the anogenital E6 
oncoproteins may possess the common ability to facilitate the degradation of 
any protein they may associate with, which may lead to the identification of 
additional cellular targets.
Additional functions of E6
E6 is known to bind at least seven cellular proteins including p53, 
p212, pl82, plOO, p81, p75 and p33 (Keen et al, 1994). plOO is suspected to 
be the E6-AP protein and along with p33 are the only two directly bound to 
E6, the binding of the other proteins appear to be mediated via cellular factors. 
Histone HI kinase activity was associated with HPV-6, 11, 16 and 18E6, but
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not HPV-5 or 8E6. This E6 associated kinase activity phosphorylated the E6 
associated protein ppl82. This kinase activity appeared to be associated with 
the mucosal HPV types 6, 11, 16 and 18 and not with the cutaneous HPV-5 
and 8E6. Thus E6 may alter the status of cellular proteins and redirect their 
functions.
Recently, a protein described as E6-BP was identified and 
characterised (Chen et al, 1995). E6-BP was found to be identical to the 
endoplasmic reticulum calcium binding protein, ERC55 (Weiss et al, 1994) a 
protein of 317 AA with six calcium binding motifs. E6-BP formed complexes 
with the E6 proteins of other high risk HPV's 16, 18 and 31 and BPV-1, but 
was not found to bind to the E6 proteins of the low risk HPV-6 and 11. The 
transformation activity of BPV-1 E6 mutants (Vousden et al, 1989) was 
examined and found to correlate with the ability of the mutant E6 proteins to 
bind to E6-BP, ie, those mutants defective for transformation could no longer 
bind E6-BP. E6-BP was also found to associate with E6-AP the cellular 
protein that links E6 and p53 in their degradation complex, and 
immunofluorescent studies colocalised E6-BP to cells expressing E6 (Chen et 
al, 1995). Thus, there may be a correlation between the risk of cervical cancer 
as a result of HPV infection, and the ability of E6 to bind E6-BP. The binding 
of E6 to E6-BP may be independent of p53 as no p53 was found in any of the 
complexes studied (Chen et al, 1995).
Calcium is essential for cell differentiation and keratinocytes infected 
with E6 and E7 are resistant to differentiation (McCance et al, 1988; Schlegel 
et al, 1988). Thus, E6 association with the calcium binding E6-BP may be 
significant in the ability of HPV to control the differentiation of infected cells.
E6 and cervical cancer
The binding of E6 to p53 results in an abrogation of G1 arrest in 
response to DNA damage (Kessis et al, 1993) as can expression of HPV-16
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E7 and E l a (Vousden et al, 1993). However, recently Butz et al (1995) 
described residual wild type p53 transactivating activity in HPV positive 
cancer cell lines. They demonstrated that genotoxic treatment of these cell 
lines resulted in an increase in nuclear p53 protein levels and an increase in 
wafl/cipl mRNA confirming the presence of functional p53 in cells 
expressing an E6 protein (Butz et al, 1995). The expression of E6 leading to 
the binding and degradation of p53 in HPV positive cell lines, is not 
functionally equivalent to the mutation of p53 in HPV negative cancers. 
Although the E6/p53 interaction is still important for progression of HPV 
induced cervical carcinogenesis, in the metastatic pathway other processes are 
possibly required, i.e, other E6 functions that do not depend on p53. Cervical 
cancer cell lines lacking HPV DNA sequence appear to possess mutant p53 
and the tumours from which these cell lines were derived were much more 
aggressive and invasive than those of HPV positive tumours (Crook et al, 
1991b). So far no mutations in the p53 gene have been observed in HPV 
positive cancer cell lines and expression of wild type p53 is low (Srivastava et 
al, 1992), however, metastases from HPV positive carcinomas, were observed 
to contain mutant p53 (Crook and Vousden, 1992; Crook et al, 1992). Thus, 
this difference in p53 status may explain the poorer prognosis in HPV 
negative cancers where no wild type p53 is present.
The E7 oncoprotein
The E7 proteins of the HPV's associated with anogenital lesions are 
acidic nuclear phosphoproteins of approximately 100 amino acids in length 
(Greenfield et al, 1991). The N-terminal 38 amino acids of the E7 proteins 
have been shown to be structurally and functionally related to the adenovirus 
E l a protein and to the homologous parts of SV40 large T antigen (Phelps et
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al, 1988). These regions are involved in the binding of the pl05 product of 
the retinoblastoma gene (Rb-1) (Munger et al, 1989). E7 possesses two cys-x- 
x-cys zinc binding domains and a CKII phosphorylation site as illustrated in 
Figure 1.6.
E7 and cell transformation
HPV16 DNA is tumourigenic in NIH3T3 cells and HPV-16E7 can 
cooperate with ras to to fully transform primary rodent cells (Storey et al, 
1988). The E7 proteins require intact zinc finger motifs for binding, 
dimerisation and transformation but not for Rb binding (McIntyre et al, 1993). 
The E7 proteins of the high risk HPVs appear to have a greater transformation 
potential than the E7 proteins of the low risk HPVs. This appears to correlate 
with an increased binding affinity of the high risk E7 proteins for pRb 
(Munger et al, 1991; Barbosa et al, 1991). Barbosa et al (1991) investigated 
whether in vitro biological activities of E6 and E7 varied among the HPV's of 
different oncogenic potentials by studying the complementation of E6/E7 to 
induce anchorage independent growth in NIH3T3 cells and human 
keratinocyte immortalisation assays. HPV-6 E7 demonstrated a considerably 
reduced ability to induce anchorage independent growth in comparison to 
HPV-16 and 18E7. E6 and E7 from the high risk papillomaviruses were 
interchangeable, however, E6 from HPV-6 or 11 was unable to complement 
E7 from HPV-16 or 18 in keratinocyte immortalisation. E7 of low risk HPV 
types was found to lack the potential to undergo splicing events which result 
in efficient translation of high risk E7 suggesting the efficiency of 
transcription may affect E7 activity in vitro (Barbosa et al, 1991). 
Phosphorylation of E7 by CKII also varies according to oncogenic potential 
(Barbosa et al, 1990). Thus, the biological activities of E6 and E7 are 
intrinsically different between the high and low risk papillomaviruses.
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E7 and pRb interactions
In HPV-16 E7 mutation of the pRb binding sites will abolish 
transformation (Storey et al, 1990; Watanabe et al, 1990; Phelps et al, 1992). 
Studies with chimaeric high and low risk E7 proteins demonstrated that the 
biological properties are dependent on the N-terminal portion and that the C- 
terminal portion can be altered without effect (Munger et al, 1991). 16E7 
competitively binds the hypophosphorylated form of Rb in G1 releasing E2F 
which activates transcription. The Rb binding domain of E7 contains the motif 
LXCXE which has also been found in cyclins (Ewen et al, 1993) and is 
conserved between E7 proteins from different papillomavirus types. 
Mutations in the Rb binding domain of both HPV-16E7 and BPV-4E7 abolish 
transformation of primary fibroblast cultures in vitro (Phelps et al, 1992; GJ 
Grindlay; personal communication). In contrast, other studies have shown 
that mutation in the Rb binding domain does not alter the transformation 
capabilities of E7. Jewers et al (1992) showed that 16E7 and ras 
immortalised human primary kertatinocytes and that alteration of both Cys24 
and Glu26 to Glycine had no effect on transformation (Jewers et al, 1992). 
Mutant CRPV E7 which was not capable of binding Rb, could still induce 
warts in rabbits (Defeo-Jones et al, 1993). This is supported by the 
observations of Ciccolini et al (1994) that the efficiency of binding Rb does 
not correlate with the transforming capacity of the HPV E7s. Thus E7/Rb 
interaction alone is not sufficient for transformation and more than one E7 
target is required to be inactivated.
E7 also associates with cyclin A and the p33CDK2 kinase 
(Tommasino et al, 1993) possibly via the Rb related protein pl07 (Ewen et al,
1992). It may be that E7 functions to divert this kinase activity to other 
proteins, i.e, phosphorylation of viral proteins in order to facilitate viral 
replication. This would be analogous to the control of SV40 replication by 
phosphorylation of the SV40 large T antigen (McVey et al, 1989).
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The E4 protein
The E4 ORF encodes a protein of 124 amino acids which is expressed 
in large amounts in the cytoplasm of the upper differentiating layers of the 
papilloma (Doorbar et al, 1986; Anderson et al, 1997). The E4 proteins are 
expressed late in papilloma development and E4 levels vary with papilloma 
type. In cutaneous lesions, E4 is expressed upwards from the basal cell layers. 
This differs from mucosal infections where E4 is expressed in the spinous 
layer and above. E4 proteins form filamentous networks which colocalise 
with cytokeratin intermediate-filament networks when expressed in SV40 
transformed keratinocytes. HPV-16 E4, but not HPV-1 E4, can disrupt this 
keratin network (Doorbar et al, 1991; Roberts et al, 1993) again 
demonstrating the differences existing between papillomavirus types and the 
potential for oncogenesis.
The roles of the E4 proteins are uncertain although it is thought that 
they may allow disruption of the normal processes of keratinocyte 
differentiation to favour virion maturation in productive infection and possibly 
release of virus particles in the cells of the granular layer as has been observed 
for the late proteins of other viruses (Brietburd et al, 1987) and/or viral DNA 
replication (Doorbar et al, 1986) so as to favour high level virus production.
The late proteins
LI and L2 are the capsid proteins of which LI is the major component 
and highly conserved between papillomavirus types. They form the 
icosahedral hexagonal and pentagonal segments of the viral capsomere 
(reviewed in Zhou and Frazer, 1995). LI and L2 are expressed at the later 
stages of viral infection and they are present higher up in the spinous and 
granular layers of the papilloma. The function of the L2 minor capsid protein 
is not clear although several have been implicated, such as interaction with the 
viral DNA to facilitate virion assembly and targeting of LI to the nucleus
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(Zhou and Frazer, 1995). LI is capable of self assembly into virus like 
particles (VLP's) within intact cells in vitro (Zhou et al 1993). These VLP's 
are useful in the analysis of how the virus may enter the cell as the nature and 
distribution of cellular receptors is unknown and production of VLP's and 
advances in technology hopefully will allow us to overcome the problem of 
propagation of papillomavirus in vitro and allow the receptors and mechanism 
of entry to be studied and thus how papillomavirus infection is achieved.
1.7 Bovine Papillomaviruses
There are six known types of bovine papillomavirus (BPV) which are 
divided into two subgroups A and B according to their molecular and 
immunological homology (Jarrett et al, 1984). The subgroup A bovine 
papillomaviruses are BPV-1, BPV-2 and BPV-5; subgroup B contains BPV-3, 
BPV-4 and BPV-6. Viruses in subgroup A cause fibropapillomas which 
produce extensive skin lesions and can also infect the epithelial lining of the 
bladder although such lesions are not productive. Subgroup B viruses are 
epitheliotropic and infection does not involve fibroblastic cells. Both BPV-2 
and BPV-4 have been implicated in cancer in cattle (Campo et al, 1992; 
Campo et al, 1980; Campo and Jarrett, 1986) and this association has been 
experimentally reproduced (Campo et al, 1994a; Gaukroger et al, 1993; 
Gaukroger et al, 1991; Campo and Jarrett, 1986). Bovine papillomaviruses 
from subgroup A have also been identified in other species including the 
sarcoids of donkeys and horses (Reid et al, 1994) and papillomas from llama 
(Peauroi et al, 1995).
BPV-1 DNA was first sequenced by Chen et al (1982), and as the 
most extensively studied papillomavirus, BPV-1 has been used as a model to 
determine the molecular biology of the other papillomaviruses. All of the 
significant ORFs are known to be located on one DNA strand of 7.495kb 
(Chen et al, 1982). This transforming region contains the 'early' ORFs E l,
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E2, E6, E7, E8 and E5. The oncoproteins of BPV-1 are E5, E6 and E7. 
BPV-1 E5 can independently transform NIH3T3 (Schiller et al, 1986) and 
C127 cells (Yang et al, 1985) and mutations in E5 that leave E2 and E4 intact 
result in a loss of transformation potential. BPV-1 E6 is also capable of 
transforming C127 cells (Schiller et al, 1984). E l has a role in viral 
replication and E2 is involved in the control of transcription. E3 and E8 have 
to date no homologies to suggest a function (Giri and Danos, 1986).
BPV-4
BPV-4 infects the mucosal epithelium of the alimentary tract in cattle 
(Campo et al, 1980). Infection results in benign papillomas which can 
progress with high frequency (30%) to carcinomas in cattle grazing on 
bracken fern (Jarret et al, 1978) as illustrated in figure 1.7. Bracken fern is 
known to contain immunosuppressants, cocarcinogens and mutagens (Evans
I.C et al, 1982; Evans W.C et al, 1982) and immunosuppression results in 
widespread persistent papillomatosis which provides the opportunity for 
malignant progression in the presence of other factors (Campo and Jarret,
1986).
Like the other papillomaviruses, BPV-4 possesses both early and late 
ORFs. The 'early' region comprises approximately two-thirds of the genome 
and encodes proteins that control the replication and transcription of the viral 
DNA. These ORFs are involved in cell transformation by BPV-4. The 'late' 
region encodes the viral capsid proteins and a region of about 500bp defines 
the LCR which contains the control elements which determine viral functions. 
Comparison of the BPV-4 genome with BPV-1 reveals several differences 
(see Figure 1.4). BPV-4 has neither an E5 nor an E6 ORF, and no known 
region of E6 homology has been identified in the BPV-4 genome (Jackson et 
al, 1991), however, the product of the BPV-4 E8 ORF has been shown to 
possess a similar hydrophobicity profile and putative transmembrane structure
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BPV-4 CATTLE
PAPILLOMA ►  CARCINOMA
BRACKEN
Figure 1.7 Schematic representation of events which are known to occur 
in vivo as a result of infection with BPV-4 In the presence of cofactors.
as BPV-1 E5. Like BPV-4, the other B subgroup papillomaviruses lack an 
E6 0RF.
The Long Control Region (LCR)
Like the HPVs, BPV-4 gene expression is regulated by both virally 
encoded and cellular transcription factors. Several positive and negative 
elements have been identified within the BPV-4 LCR which bind 
transcriptional factors, including three negative regulatory elements known as 
NR1, NR2 and NR3.(Jackson and Campo, 1991; Jackson and Campo, 1995a). 
Of these negative elements NR2 has been studied in detail. Deletion or 
mutation of the NR2 element in the LCR leads to an increase in enhancer 
activity in fibroblastic cell lines. The C/EBP0 subunit has been shown to 
complex with the NR2 element by EMSA and UV crosslinking experiments 
(McCaffrey and Jackson, 1994). C/EBPp transcription factor functions are 
derepressed by the activation of ras (Kowenz and Leutz, 1994). If ras 
activation can exert an effect on regulation of BPV-4 transcription via 
C/EBPp, this may in part explain the requirement for activated ras for BPV-4 
transformation in vitro which will be discussed later.
The functions of the BPV-4 early proteins are similar to those of 
BPV-1. The late structural proteins BPV-4 LI and L2 have been extensively 
investigated as anti-BPV vaccines. As this aspect of the BPV-4 biology is not 
relevant to this thesis it will not be discussed further.
The BPV-4 E2 protein
The E2 ORF encodes a protein with a predicted molecular weight of 
45-48kDa which has been shown to bind DNA as a dimer (Ham et al, 1991). 
The BPV-4 LCR contains three consensus binding sites for the viral E2 
transcription factor which mediate the action of the E2 protein and a fourth
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degenerate site. The E2 protein can influence LCR promoter activity in 
primary foetal bovine keratinocytes (PalK) cells. E2 acts as a transcription 
regulator and at low concentrations, full length BPV-4 E2 can mediate 
transactivation of the BPV-4 LCR. At higher concentrations, E2 was found to 
completely repress transcription from the LCR (Jackson and Campo, 1995a). 
Mutational analysis of the LCR demonstrated that the four E2 sites each 
perform different functions in the control of transcription and that competition 
between cellular transcription factors and viral E2 proteins is essential in 
regulating the level of viral gene expression during papilloma development 
(Jackson and Campo, 1995a).
The E8 protein
E8, a 42 amino acid hydrophobic protein, is one of the oncoproteins of 
BPV-4 (Pennie et al, 1993) which, when coexpressed with BPV-4 E7 in PalF 
cells, confers anchorage independent growth (Cairney and Campo, 1995). E8 
interacts with the 16k ductin protein (Faccini et al, 1996) a component of gap 
junctions and of the vacuolar ATPase proton pump (Finbow et al, 1991). 
BPV-1 E5 will also bind 16K ductin as will HPV-16 E5 and HPV-6 E5 
(Goldstein et al, 1991). In PalF cells transformed by 
BPV-4 and an activated ras, expression of BPV-4 E8 has been shown to be 
associated with the loss of gap junctional intercellular communication (GJIC) 
(Faccini et al, 1996). This agrees with the study of Oelze et al (1995) who 
found that HPV-16 E5 expressed in a human keratinocyte cell line, inhibited 
GJIC to a similar extent. As previously mentioned, BPV-4 E8 is similar to 
BPV-1 E5 (Jackson et al, 1991). E5 alone will transform cells (Schiller et al, 
1986; Yang et al, 1985), however, overexpression of E8 in PalF cells on its 
own results in accelerated senescence and cell death (Pennie et al, 1993; 
Cairney and Campo, 1995).
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The E7 protein
The major transforming gene of BPV-4 is E7, which possesses two 
Cys-X-X-Cys motifs and a potential pl05 (Rb) binding domain, although it 
lacks the casein kinase II site which is a feature of the £7 proteins of the high 
risk HPVs (Jaggar et al, 1990). Although the functions of the BPV-4 E7 
protein have not yet been studied in detail, this protein may have similar or 
even identical functions to HPV-16 E7.
Although it is not known if BPV-4 E07 (4E7) binds Rb, mutation of the pRb 
binding domain or deletion of the second Cys-X-X-Cys motif abolish 
transformation, demonstrating the importance of these sites and the role of E7 
in cell transformation (Campo et al, 1994b).
PalF cells are only partially transformed by 4E7 in the presence of an 
activated ras and require the addition of 4E8 for anchorage independent 
growth (Pennie et al, 1993). HPV-16E7 (16E7) transformed PalF cells are 
anchorage independent even in the absence of BPV-4 E8 suggesting that 4E7 
may lack functions present in 16E7 (GJ Grindlay and E Wagner; personal 
communication).
For the oncogenic HPVs, E6 is one of the transforming oncoproteins. It is 
unclear why BPV-4 does not require E6 and one of the aims of this thesis is to 
answer this question by examining the E6 functions that BPV-4 lacks.
BPV-4 and Cell Transformation
BPV-4 can transform established cell lines, induce cellular DNA 
amplification (Smith et al, 1989) and rearrangements have been found in the 
bovine ras gene in cancers (McCaffrey et al, 1989; Campo et al, 1990). 
Primary epithelial cells are the natural host of the virus and provide a more 
accurate system in which to study the transformation functions of BPV-4 in
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vitro, thus more recently primary cells have been derived from the palate of a 
bovine foetus and cultured as fibroblasts (PalF) or keratinocytes (PalK).
BPV-4 has an absolute requirement for activated c-Ha-ras to induce 
transformation of PalF cells in vitro (Jaggar et al, 1990) and even then is still 
only capable of partial transformation, the addition of HPV-16E6 being 
required to immortalise the cells (Pennie et al, 1993). HPV-16 is capable of 
transforming immortalised rodent cell lines to tumourigenicity (Yasumoto et 
al, 1986) and in the presence of an activated c-Ha-ras can transform primary 
rodent kidney epithelial cells (Crook et al, 1988) demonstrating a requirement 
for activated cellular oncogenes for in vitro transformation of primary cells 
by papillomaviruses.
One of the best characterised mutagens contained in bracken is the 
flavonoid quercetin (5,7,3',4'-tetrahydroxyflavone). Quercetin is known to 
adduct DNA (Rahman et al, 1990), induce mutation in both bacteria and 
mammalian cells (Bjieldanes and Chang, 1977; Lshikawa, 1987) and cause 
clastogenic damage (Ishidate, 1988). In relation to the latter point, it has been 
observed that cattle fed on bracken fern have a high incidence of 
chromosomal abnormalities (Moura et al, 1988). Quercetin is also capable of 
inhibiting ATP binding by activating phosphatases and downregulating 
kinases in chick embryo fibroblasts (Van Wart Hood et al, 1989).
When PalF cells transfected with BPV-4 and activated ras are treated 
with quercetin for 48 hours they become tumourigenic, thus confirming the 
association of cofactors present in bracken with neoplastic progression of 
BPV-4 induced papillomas in vivo (Campo and Jarrett, 1986; Cairney and 
Campo, 1995; Pennie and Campo, 1992). The minimum requirement for 
tumourigenicity in conjunction with quercetin treatment is the presence of the 
BPV-4 E7 oncoprotein and activated ras (Campo et al, 1994b; Cairney and 
Campo, 1995). These BPV-4 and quercetin treated PalF cells were found not
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to contain any chromosomal abberations or cellular 
rearrangements/amplifications (Cairney and Campo, 1995), however, it should 
be noted that previous studies demonstrating the mutagenic nature of quercetin 
utilised established cell lines and not primary cells. PalF and PalK cells which 
have been treated with quercetin demonstrate an upregulation in LCR activity 
which may result in increased transcription of the viral genes. This may lead 
to an increase in production of viral proteins and a more transformed 
phenotype (JA Connolly; personal communication). This is supported by an 
increase in transformation efficiency observed when 4E2 is cotransfected with 
BPV-4 E7/E8 under control of the homologous LCR in the presence of an 
activated ras (Jaggar et al, 1990).
Aims of this PhD thesis
As discussed, studies have demonstrated the link between 
papillomavirus oncoproteins and the abrogation of cellular functions which 
control cell proliferation. HPV proteins encoded by the early genes subvert 
normal regulatory pathways of infected cells to accomodate viral replication. 
This is accomplished by interactions with cellular proteins including tumour 
suppressor products as illustrated in figure 1.8. As a result of this viral 
targeting, the potential for uncontrolled cell growth in the presence of other 
factors is apparent. It is necessary to dissect these viral mechanisms in order 
to understand the role of papillomaviruses in the carcinogenic process. The 
aims of this thesis, in elucidating the role p53 plays in the transformation of 
cells by BPV-4 in the absence of an E6 protein, are discussed below.
BPV-4 is unusual in that it does not possess an E6 open reading frame 
like the other known papillomaviruses. Sequencing of the closely related 
BPV-3 and BPV-6 demonstrated an identical genome arrangement for all 
three B subgroup bovine papillomaviruses. For this reason we wished to
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HPV infection
All HPV types
Benign cellular proliferation
Cyclin/CDK
E 7 ^  Rb _ high risk HPV
Latency
E6 ^  I  Cofactors
Accumulation of 
p5 3  " I  somatic mutation (s)
Other proteins
Malignant transformation
Figure 1.8 Summary table of the E6 and E7 proteins and their contribution 
to the malignant progression of HPV infected cells
investigate whether p53 inactivation is important in BPV-4 associated 
carcinogenesis and to determine if viral proteins play a role or if an alternative 
mechanism of p53 abrogation exists for BPV-4. The E6 proteins of HPVs 16 
and 18 have been shown to cooperate with E7 in the transformation of 
keratinocytes in culture, to promote the degradation of p53 and to be capable 
of transcriptional transactivation. Since BPV-4 does not possess an E6 ORF, 
yet is capable of successful infection and propagation in vivo and malignant 
transformation both in vitro and in vivo in the presence of chemical cofactors, 
this raises the question of whether E6 functions are unneccessary or whether 
these functions are provided by another viral or host protein. In the case of 
BPV-4, it might be predicted that p53 gene expression and function should be 
unaltered in papillomas in the absence of an E6 product, and that p53 
mutations, perhaps induced by environmental factors, will have occurred 
during progression to carcinoma. On the other hand BPV-4 may have evolved 
another mechanism of evading p53 growth suppression; such an alternative 
pathway might provide useful insights into the mechanism of BPV-4 
transformation and p53 function as a tumour suppressor gene.
It was thus decided to determine the status of p53 in BPV-4 derived 
lesions and to establish the effect mutant p53 could exert on cells transformed 
with BPV-4. This required the cloning and sequencing of the wild type 
bovine p53 gene and analysis of p53 status of BPV-4 induced lesions of cattle.
Amplification of the mdm-2 locus and consequent overproduction of 
the p53 binding mdm-2 protein appears to be a mechanism by which cells may 
escape p53-regulated growth control. The transforming region of BPV-4 
DNA has been shown to induce cellular DNA amplification, therefore, the 
copy number of the bovine mdm-2 gene in papillomas and carcinomas was 
evaluated.
In order to look for possible mutations in p53 in papillomas and 
carcinomas we set out to clone and sequence the bovine p53 gene. It is known
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that one of the effects of p53 mutations can be to elevate steady state levels of 
the protein to an amount that can be detected by immunostaining. A range of 
antibodies to human and mouse p53 were available and the highly conserved 
nature of p53 suggested that some of these antibodies would react with bovine 
p53. This would allow us to determine levels of p53 protein expression in 
papillomas and carcinomas.
BPV-4 DNA is able to partially transform primary bovine fibroblasts 
(PalF) in the presence of activated ras; the additional presence of HPV-16E6 
renders these cells immortal. Thus BPV-4 does appear to lack at least some of 
the functions which can be provided by HPV-16 E6. As mentioned above, 
one of the known targets for the E6 protein of the oncogenic HPVs is the p53 
tumour suppressor gene product. We therefore investigated whether HPV-16 
E6 was able to cooperate with BPV-4 in the transformation of primary cells 
derived from p53 knockout mice, to test whether HPV-16 E6 provides 
transformation functions in addition to its role in p53 degradation.
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MATERIALS
CHAPTER TWO
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2.1 Molecular Biology
Chemicals
Agarose Bethesda Research Laboratories,
Low melting point (LMP) Agarose U.S.A
Ammonium Chloride Aldrich Chemical Company, U.K 
AT Biochem Ltd (FMC2X MDE gel mix
(Mutation Detection Enhancment) Bioproducts, Denmark)
Citric acid
D-Glucose
Dimethylformamide
Formaldehyde
Glycerol
Magnesium chloride
Na2HPC>4 (di-sodium hydrogen orthophosphate)
PEG (Polyethylene Glycol)
Potassium chloride(Analar)
Potassium hydroxide(Analar)
Repelcote silicone treatment 
Sodium chloride(Analar)
Caesium chloride Boehringer Mannheim, Germany
IPTG (isopropyl-P-D-thiogalactopyranoside)
X-gal (5-bomo-4-chloro-3-indolyl-p-D-galactopyranoside)
RNAzol B Cinna-Biotecx Laboratories Inc,
Bactotryptone
Bactoagar
Calcium chloride(Analar)
Difco Laboratories, U.S.A
BD H , U.K
Formamide
U.S.A
Fluka Chemika-Biochemika AG, 
Switzerland
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Ammonium persulphate (APS) Fisons Scientific Equipment, U.K
Boric acid
Chloroform
EDTA sodium salt (EthyleneDiamineTetraAceticcid)
Glycine
Isopropanol
K2HPO4 (Potassium hydrogen orthophosphate)
Magnesium sulphate
Maltose
Methanol
Potassium acetate
Sodium Dodecyl sulphate (SDS)
Sodium hydroxide pellets 
Sucrose
Tri-sodium citrate 
Urea 
Tris base 
Ethanol 
Phenol
30% (w/v) acrylamide:0.8% 
bisacrylamide
40%(w/v) acrylamide: bisacrylamide 
Ethidium bromide 
Ficoll 400,000
MOPS (3-(N-Morpholino)Propanesulfonic Acid)
Polyvinylpyrrolidone 
TEMED
Tween 20 (Polyoxyethylene sorbitan monolaurate)
Yeast extract Beta Laboratories, U.K
Gibco BRL Life Technologies 
James Burrough Ltd, U.K. 
Rathbum Chemicals Ltd, U.K 
Severn Biotech Ltd, U.K
Sigma Chemical Company, U.K
Radiochemicals
a-[32p]_dcrp (400Ci/mmol) Amersham International
Y-[32P]-ATP (3000Ci/mmol) pic, U.K
a-[35s]-dATP
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Nucleic Acids
OX 174 Haell digested DNA
X Hindlll digested DNA
Bethesda Research Laboratories, 
U.S.A
RNA ladder Gibco BRL Life Technologies
pC53-SN3, pC53-SCX3 Dr.B.Vogelstein (Baker et al, 
1990).
pJ4£2 vector, pJ4Q 16E6 
and the B6 mutants
Dr.K. Vousden (Storey et aly 
1988; Crook era/, 1991a).
pIC20H Dr Maria Jackson (Marsh et al, 
1984).
MDM-2 cDNA pMDMFL4 Dr.B. Vogelstein (Oliner et al, 
1992).
pT24 (6.6kb human c-Ha-ras 
in pUC13)
Ros McCaffrey (Santos et al, 
1982)
pBPV-4 (whole genome 
BPV-4 in pAT153)
Margaret Cairney (Campo and 
Spandidos, 1983).
pBabehygro
pHSV-pGAL
pzipneo
Dr. S.Bamett 
Ros McCaffrey 
Ros McCaffrey
Enzymes and kits
Alkaline phosphatase 
T4 polynucleotide kinase
Northumbria Biologicals Ltd, UK
Bovine liver genomic DNA library Clontech, Cambridge Bioscience,
U.K
Geneamp DNA PCR kit Perkin-Elmer Cetus, U.S.A
Geneamp thinwalled reaction tubes
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DNA sequencing kit (dye terminator cycle sequence ready reaction)
Microspin S-400 HC columns Pharmacia Biotech, Sweden
Sephadex G-25 columns
Proteinase K Bethesda Research Laboratories,
U.S.A
Random priming kit Boehringer Mannheim, Germany
Calf Intestinal Alkaline Phosphatase (CIP)
Restriction enzymes Gibco BRL Life Technologies
T4 DNA ligase
BioNick translation system
Taq polymerase
PCR-script SK+ cloning vector kit 
Sequenase version 2.0 kit
Wizard magic PCR prep kit 
Wizard magic miniprep kit
Promega
Stratagene
United States Biochemical 
Corporation, U.S.A 
Promega, U.K
Miscellaneous
Sterile bacteriological plates
X-OMATAR X-ray film 
0.2pM filter membrane 
E.Coli DH5-a competent cells 
Whatman 3MM filter paper 
Hybond -N+ nylon membrane
Bibby-Sterilin Ltd, U.K 
Eastman Kodak Company, U.S.A 
Pall Biodyne Membranes Ltd 
Gibco BRL Life Technologies 
Whatman International Ltd, U.K 
Amersham International pic, U.K
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2.2 Tissue Culture
CeU Lines 
PalF
p53 null
Chemicals
Silicon grease 
Giemsa stain 
Hygromycin B 
DMSO 
Methanol 
MTT
Primary foetal bovine palate fibroblasts, 
pass #3, stocks made by Margaret 
Cairney (PhD thesis). Palate was removed 
from a foetus of less than 5 months 
gestation, obtained from Glasgow 
University Veterinary School.
Primary fibroblasts derived from the skin 
removed from newborn p53 null mice 
(B95). These mice were homozygous null 
for p53 and were provided by Debbie 
Stuart. Transfection criteria for these cells 
were determined by transfecting pHSV- 
PGAL by various methods and determining 
the levels of p-galactosidase produced 
from the lysed cells. This demonstrated 
that CaPC>4 transfection was the best 
method to ensure maximum plasmid entry 
into cell. Kill curves using different 
concentrations of hygromycin were carried 
out to determine amount required to select 
resistant colonies from non-resistant 
background.
BDH Analar, U.K.
Boehringer Mannheim, Germany
Fisons Scientific Equipment, U.K
Sigma Chemical Company, U.K 
(3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide;thiazol 
blue)
HEPES (N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]) 
Trypan blue stain Gibco BRL Life Technologies
Ltd, U.K
G418 sulphate (Geneticin)
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Media
(10X DMEM)
F-10 HAM nutrient mix (lOx) 
Foetal Calf Serum (FCS) 
L-Glutamine (200mM)
MEM amino acids (50x) 
Penicillin (lOOx)
SLM
Sodium bicarbonate (7.5%) 
Sodium pyruvate (lOOmM) 
Streptomycin (lOOx)
Trypsin Solution(lOx)
Miscellaneous
Sterile plastic flasks and plates 
96 and 24-transwells 
MF-1 NuNu mice 
Cryotubes
Gibco BRL Life Technologies 
Ltd, U.K
Worthington Biochemical 
Company, U.K
Becton DickinsonU.K Ltd. 
Costar Corporation, U.S.A. 
Harlan Olac Ltd, U.K. 
Nunc, Denmark.
Dulbeccos modified Eagles medium
2.3 Immunocytochemistry and in-situ hybridisation
Antibodies
CM-1 was provided by Biogenex Ltd. Anti-BPV-4 E7 was produced 
using multiple peptides in rabbit by G.Joan Grindlay (McGarvie et al, 
1995), BPV-4 E8 was also a polyclonal antiserum generated by 
inoculation of a peptide from the carboxyl terminus of E8 conjugated to 
KLH (peptide 67) as described in Pennie et al (1993).
Anti digoxigenin-11 -dUTP Boehringer Mannheim, Germany
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Chemicals
Aquamount
Bovine Serum Albumin fraction 
Powdered trypsin 
Hydrogen peroxide 
Xylene
DPX mounting medium 
Scotts tap water concentrate 
Harris's Hematoxylin 
Eosin
Lugol's Iodine 
Sodium thiosulphate 
Oxoid PBS tablets
Kits
DIG nucleic acid detection kit 
Vectastain ABC peroxidase kit 
anti-rabbit IgG
Miscellaneous
Digoxigenin-11 -dUTP 
Coverslips
BDH Analar, U.K.
Sigma Chemical Company, U.K 
Difco Laboratories, U.S.A 
Fisons Scientific Equipment, U.K
Surgipath Medical Industries Inc. 
U.S.A
Unipath Ltd, U.K
Boehringer Mannheim, Germany 
Vector Laboratories, U.K
Boehringer Mannheim, Germany 
Chance Propper Ltd, U.K
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METHODS
CHAPTER THREE
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3.1 Molecular Biology Techniques
3.1.1 Large scale preparation of plasmid DNA
A 10ml overnight culture of E.coli containing plasmid DNA, wasgrown 
in the presence of 100pg/ml ampicillin, was transferred to a 1 litre flask and 
incubated overnight at 37°C with shaking. All cells were grown in LB except 
for pZipneo and pbabehygro which were grown in high nutrient superbroth to 
ensure maximum yield. Bacteria were spun down at 5000rpm in a Sorvall 
RC5B (GS-3 rotor) for lOmin and the supernatant removed. The bacterial 
pellet was resuspended in 40ml of TEG (25mM Tris.Cl pH7.5, ImM EDTA, 
50mM Glucose), 2 volumes of freshly made 0.2M NaOH/l%SDS were added, 
mixed by inversion and left on ice for lOmin. 1.5 volumes of ice cold 3M KAc 
was then added, mixed by inversion and incubated on ice for 30min. The 
chromosomal clot was pelleted at 8000rpm for lOmin Sorvall RC5B (GS-3 
rotor) and the supernatant filtered through gauze. 0.6 volume of isopropanol 
was added and left at room temperature for at least 15min to precipitate DNA, 
followed by centrifugation at 8000rpm for 15min in Sorvall RC5B (GS-3 
rotor). The DNA pellet was resuspended in 6.5ml of lxTE (lOmM Tris.Cl, 
ImM EDTA pH7.5), and the volume made up to 8ml with lxTE. lOg of CsCl 
was added (resulting in a density of 1.395) and dissolved at 37°C for lOmin, 
880pl of Ethidium bromide (EtBr) (lOmg/ml) was added to visualise the DNA 
band after centrifugation. Samples were spun in a Sorvall ultracentrifuge using
11.5ml Sorvall polyallomer tubes in a T1270 rotor for 24 hours at 50,000rpm, 
20°C. The plasmid band was then removed using a 24 gauge needle and 
transferred to a 15ml falcon tube. The EtBr was removed by several 
extractions with 5M NaCl saturated isopropanol and the CsCl removed by 
dialysing the sample for 3x30 min in lx TE. DNA was then ethanol 
precipitated with 1/10 volume 3M NaAc pH5.2 and 3 volumes of ethanol at -
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20°C overnight.. The concentration was determined by reading the A250 and 
the purity determined by the ratio A260/28O whi°h was typically 1.8-1.9. Any 
plasmids which were used for cell transfection purposes were purified using 
two rounds of CsCl gradient and sterilised by ethanol precipitation; for 
plasmids used in standard laboratory experiments one round of purification was 
sufficient.
3.1.2 Gel Electrophoresis
All analysis was carried out on either agarose or polyacrylamide gels. 
Agarose gels were run using Flowgen apparatus and varied from 0.8% to 2% 
according to the size of the fragment to be visualised. Gels were cast in lx 
TBE and 0.5pg/ml EtBr was added to both the gel and the running buffer, with 
the exception of gels to be Southern or Northern blotted. The separated DNA 
was visualised using short wave UV light and photographed using polaroid 
type 57 high speed film or an Appligene imager.
Denaturing polyacrylamide gels were run in lxTBE buffer and either 6 
or 15% acrylamide (40%w/v) used for sequencing and oligo purification 
respectively. Polyacrylamide gels were run using Cambridge Electrophoresis 
DNA sequencing apparatus.
3.1.3 Restriction digests
Plasmid DNA was incubated with lOu of enzyme per lpg  DNA in the 
buffered solution suggested by the manufacturer. Incubations were at the 
specified temperature for 1-2 hours unless otherwise stated. Digested 
fragments were analysed by gel electrophoresis as described above. Restricted 
fragments were recovered from the gel as described in 3.1.5.
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3.1.4 Oligonucleotide Synthesis
Oligonucleotides were synthesised using a 1) Applied Biosystems 381A 
DNA synthesiser or 2) Applied Biosystems 392 DNA/RNA synthesiser as 
instructed by the manufacturers. Oligonucleotides were provided either as: 1) a 
precipitate in a column which was broken open and the oligonucleotides beads 
tipped into a vial of ammonia, or 2) already eluted into ammonia. The 
oligonucleotides were deprotected overnight at 55°C and separated form the 
beads by centrifugation, if provided as described in (1), then ethanol 
precipitated and resuspended in distilled water. The concentration was then 
determined by A26O an^ the oligonucleotides were either used in this form 
crude or after gel purification as described below.
3.1.5 Purification of DNA fragments
a) Isolation of oligonucleotides or PCR fragments from polyacrylamide gels.
Oligonucleotides were purified on 2mm thick 15% denaturing 
polyacrylamide gels as described above. 50pg of crude oligonucleotides was 
mixed with an equal volume of formamide and heated to 85°C for lOmin 
before loading onto the gel. The gel was prerun for 30min prior to loading and 
then run at 35W for 3-4 hours. A dye lane (0.05% bromophenol blue, 0.05% 
xylene cyanol FF, 20mM EDTA, 95% formamide) was run alongside the 
sample to indicate how far oligonucleotides had electrophoresed. The gel was 
then removed from the plates and covered with saranwrap. A precoated thin 
layer chromatography plate (SILG25, UV254) (Macherey-Nagel, Germany) 
was placed underneath the gel and a handheld shortwave UV light shone onto 
the gel to visualise the bands by shadowing. The oligonucleotides band was 
excised and placed in an eppendorf. 1ml of oligonucleotides elution buffer 
(0.5M ammonium acetate, lOmM magnesium acetate, ImM EDTA pH8.0, 
0.1% SDS) was added and the tube incubated overnight at 37°C with shaking. 
The acrylamide was pelleted by centrifugation for 5min at frill speed in a
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microfuge (Anderman 5415C) and the supernatant removed to a 15ml Falcon 
tube. A further 500pl of elution buffer was added to the remaining acrylamide, 
vortexed briefly, centrifuged and the supernatant added to the previous 
supernatant. The oligonucleotides DNA was ethanol precipitated as described 
in 3.1.1.
b) Isolation using low melting point (LMP) agarose gel
The band of interest in approximately 300-500^1 of agarose was excised 
from the gel and placed in an eppendorf. 500pi of TE was added to the gel 
piece and the agarose melted at 65°C for lOmin. The solution was then 
extracted twice with tris-buffered phenol, twice with phenol/chloroform 
followed by two chloroform (24:1 chloroform/isopropanol) extractions to 
remove contaminating agarose and the remaining aqueous phase was ethanol 
precipitated.
c) Isolation using DE81 filter paper.
The DNA band was excised from the gel, wrapped on three sides by a 
piece of whatman DE81 paper (soaked in 2.5M sodium chloride for 3 hours 
then washed 5x in d l^ O  - stored at 4°C in ImM EDTA pH8.0) and the 'parcel* 
placed back into the gel space with the open end facing upwards. This was 
then electrophoresed at 100V for a further 3Qmin and the gel piece and filter 
paper removed. The filter paper was checked for the presence of DNA by 
short wave UV light, the excess paper trimmed and the remainder placed in an 
eppendorf and macerated in 450pl of elution buffer (1M sodium chloride, 
50mM Tris.Cl, ImM EDTA pH7.5) and the tube vortexed briefly. The tube 
was incubated at 37°C for 15min or 65°C for 3min if the fragment was larger 
than 2kb. The supernatant was removed and the DNA precipitated by the 
addition of 1.1ml of ethanol.
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d) Isolation of DNA using polyallomer wool.
If the fragment to be isolated was less than lkb then the agarose plug 
removed from the gel was spun through sterile polyallomer wool as described 
in Sambrook et al (1989) and the eluted DNA ethanol precipitated.
3.1.6 Cloning Techniques
DNA was subcloned into the vector pIC20H for sequencing purposes. 
5pg of pIC20H was digested with 20U of the appropriate enzymes, ethanol 
precipitated and resuspended in 89(0,1 of lxTE. 10 p,l of lOxCIP buffer and 6U 
of calf intestinal phosphatase (CIP) was added and incubated at 37°C for 
30min. The reaction was stopped using 5mM EDTA, 0.5% SDS and 
proteinase K (50pg/ml) and heated to 75°C for 10 min. The sample was then 
cooled to room temperature and phenol/chloroform extracted. DNA was 
precipitated by adding 1/10 volume of 3M NaAc pH7.0, and 3 volumes of 
EtOH. Following centrifugation at full speed in microfuge (Anderman 5414C) 
for 30min, DNA pellet was resuspended in 15pl of distilled water and 3pl used 
per reaction.
The DNA to be cloned was restricted and mixed with vector, and the 
volume of the mixture was increased to lOOpl with dH20 . After one 
phenol/chloroform extraction and then ethanol precipitation. DNA pellet was 
resuspended in lOpl of ligation buffer and 4U of T4 DNA ligase. Reaction was 
incubated at RT for 2 hours or at 16°C overnight. 3pl of the ligation mixture 
was then used to transform library efficiency DH5-a competent cells (F", decft, 
recA ly end A l  D6 h sd R ll (r^-, m^+), supE44, k 'th i-l, gyrA, relA l) according 
to the manufacturers instructions. Blue/white colour selection was used to 
detect recombinant plasmids on L-agar plates containing lOOmM IPTG /  5% 
X-GAL.
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PCR products were either directly sequenced as described in 3.1.12 or 
cloned into PCRscript vector (Stratagene) as described in the manufacturers 
protocol.
3.1.7 Probe preparation
lOOpg of pC53-SN3 was digested with Bam HI to excise 1.8kb insert 
from vector, the fragment was then gel purified and digested with Smal. The 
1.58kb fragment was cut from the gel and digested with Styl to give a fragment 
of 0.56kb. This was again gel purified and recovered from the gel by spinning 
through polyallomer wool as described above. The fragment was further 
purified by passing through a Wizard magic PCR prep column and resuspended 
in lxTE. This was then used as the p53 probe CR345 and contained conserved 
regions HI, IV and V.
lOOpg pMDM-FL4 was restricted with Apal to excise the 1.3kb insert. 
The insert was purified on a 0.8% LMP agarose gel as described in 3.1.5, and 
further purified using a Wizard PCR prep column.
Probes were either labelled using random priming and a-[32p]_dCTP or 
end labelled with y-[32p]-ATP and unincorporated nucleotides removed by 
purification on a Sephadex G-25 column as instructed by the manufacturers.
3.1.8 Southern and Northern Hybridisation
Southern blotting: 30pg DNA was restricted overnight with lOOu of 
appropriate enzyme and ethanol precipitated and resuspended in 20pl of dH2 0 . 
Samples were run on a 0.8% agarose gel and transfered to Hybond N+ nylon 
membrane using the alkali blotting procedure (Sambrook et al, 1989). 
Hybridisation was carried out according to the manufacturers instructions.
Northern blotting was carried out using 20pg of total RNA in a volume 
of 5-1 Opl of DEPC-H2O diluted in 5 volumes of freshly prepared
Electrophoresis sample buffer. The sample was denatured at 65°C for 15min
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and 3pl of EtBr (lmg/ml) added. The RNA was electrophoresed on a 1.25% 
agarose gel (containing 5% formaldehyde) in lxMOPS buffer. The gel was 
washed twice for 20min in dH20  and then blotted as described in Sambrook et 
al (1989), using Hybond-N+ in 20xSSC overnight. RNA was fixed to the filter 
by UV autocrosslinking using a Stratalinker (Stratagene). The filter was then 
washed briefly in 2xSSC and either stored at 4°C or hybridised immediately.
The RNA prehybridisation mix was made as follows:
5xSSC pH7.4, 5x Denhardts, 50% (v/v) deionised formamide. This 
was mixed and then SDS added to a final concentration of 0.5%. 
Prehybridisation mix was always made fresh and only used if the final solution 
was clear.
40ml of prehybridisation mix plus 800pl of lOmg/ml salmon sperm 
DNA which had been autoclaved and sonicated with lmin bursts at maximum 
amplitude for lOmin, was added to a single bagged filter and incubated at 42°C 
for 4 hours. The probe (prepared as described above) was then added and 
hybridised overnight at 42°C.
Filters were washed twice in 2xSSC, 0.1%SDS for 20min at room 
temperature or as described and then autoradiographed using XR-OMAT fast 
film.
3.1.9 Library Screening and X DNA preparation
A bovine liver genomic library constructed in EMBL-3 X phage 
(Clontech) was used to infect Y1090r- (araD139, hsdR (r^-, i%+) mcrB+, 
r p s \  supF, trpC22::TnlO, Alac U169, Alon, F", X" (pMC9) host cells provided 
with the library. The library was titred according to the manufacturers 
instructions on arrival.
20ml cultures of Y1090r- cells were grown overnight at 37°C in the 
presence of 0.2% maltose. The cells were then transferred to 50ml Falcon 
tubes and spun in a Beckman J-6B centrifuge at 3000rpm for lOmin. The
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Y1090r- cells were then resuspended in 10ml of lOmM MgS04  and the 
O.D550 read. An O.D of 1.0 was calculated to be 8x10** cells. 200pl of a 
1/2000 dilution of the library in SM buffer (lOx; 1M NaCl, 0.1M MgS0 4 , 
0,35M Tris.Cl pH7.5 autoclaved and stored at 4°C ) was added to 9x10** 
Y1090r- cells in a Falcon 2059 polypropylene tube and incubated at 37°C for 
15min. This was added to a bottle containing 50ml of top agarose (50ml LB, 
0.36g agarose autoclaved and equilibrated to 42°C). This was poured onto a 
25x25cm2 square LB (ImM MgS04) agar plate to give approximately 30,000 
plaques per plate. Plates were then incubated overnight at 37°C and then 
chilled in the cold room for about 1 hour. Duplicate plaque filter lifts were 
taken using Pall Biodyne membrane. These filters were hybridised to the 
CR345 fragment of the human p53 cDNA using the hybridisation technique for 
southern blotting as described above. Positive plaques were picked using a 
glass pipette and the plugs stored in 1ml of SM buffer with a drop of 
chloroform.
Lambda DNA was purified by the liquid lysate method as follows: 
250p,l of phage was incubated with lOOpl of Y1090r- cells at 37°C for 15min. 
4ml of LB and 5mM CaCl2 was added and incubated overnight at 37°C. 75pi 
of chloroform was added and the tube incubated at 37°C with shaking for 
15min. The cell debris was then pelleted by spinning in a Beckman J6-B 
centrifuge at 3000rpm for lOmin at 4°C. 4pl of DNAse 1 (lmg/ml) and 0.4pl 
of RNAseA (lOmg/ml) was added to the supernatant which was then incubated 
at 37°C for 30min. An equal volume of 20%PEG/2M NaCl in SM buffer was 
added and the DNA precipitated on ice for 1 hour. The DNA was pelleted by 
centrifugation in a Beckman J6-B at 3000rpm for 20min at 4°C. The pellet 
was resuspended in 0.5ml of SM buffer and extracted with chloroform xl. 
Following centrifugation at Rill speed in Anderman (5415C) microfuge for 
5min, the aqueous phase was transferred to a fresh eppendorf. 5pl of 10% 
SDS, 5pl of 0.5M EDTA and 0.5pl ProteinaseK (lOmg/ml) was added to the
62
DNA followed by incubation at 68°C for 1 hour. Any contaminating proteins 
were removed by lx  phenol/chloroform and lx  chloroform extraction and the 
DNA then ethanol precipitated and resuspended in lx  TE (made with SM 
buffer).
3.1.10 DNA Extraction from Paraffin Sections
Sections were cut 4-5 microns thick using a microtome and put into 
eppendorfs. Three sections of normal bovine tissue were cut in between each 
tumour sample to prevent cross-contamination. 400pl of xylene was added to 
each sample, vortexed and left for lmin. The section was pelleted by 
centrifugation for 2min at full speed in a microfuge Anderman (5415C) and the 
waste xylene removed. The samples were dried on a heat block at 50°C for 
approximately 3 hours and lOOpl of sample buffer (SPB) was added to the 
dried section. lOpl was removed and made up to lOOpl with SPB and 
proteinase K at 0.5mg/ml (made fresh) and sonicated in a 50°C water bath for 
lOmin. The samples were then boiled for lOmin and the denatured proteins 
pelleted by centrifugation for 5min at full speed in a EC5415 microfuge. The 
supernatant was removed and 5pi was used in each PCR reaction.
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3.1.11 Polymerase Chain Reaction (PCR)
All PCR reactions were carried out an 9600 Perkin Elmer Cetus PCR 
machine.
DNA-PCR was carried out using lpg  of genomic DNA, lxPCR buffer 
as provided by the manufacturer, 1.5mM MgCl2, 200pM dNTP's, 0.5pM 
primers and 2.5u of Taq polymerase in a lOOpl PCR reaction. The primers 
used in the PCR are described in table 3.1.11 A. The standard programme used 
throughout these experiments was;
94°C for 5min / (94°C 15sec, 54°C 15sec, 72°C 30sec) x35 cycles / 
72°C for 5min / (extension cycle) and then 4°C hold. Samples were 
maintained at 4°C or -20°C until required.
3.1.12 Sequencing
Sequencing of DNA was carried out using either the dideoxy 
termination method of manual sequencing with a sequenase version 2.0 kit, or 
by using the ABI 373A automated sequencer. Dideoxy reactions were carried 
out according to the manufacturers instructions. Manual sequencing reactions 
were run on a prewarmed 6% denaturing polyacrylamide gel for 1.75 hours at 
55W. The gel was then dried at 80°C for 2 hours and autoradiographed.
Automated cycle sequencing was carried out as follows. The region to 
be sequenced was amplified by a 20pl PCR reaction and the PCR products 
purified on a miniprep column (Pharmacia Biotech). 7pi of the 50pl purified 
product was mixed with 32ng of primer in a total volume of 12pl and 8pl of 
premix (dye terminator cycle sequence ready reaction) added. The method of 
Taq terminator sequencing was as follows;
96°C 2min, (96°C 15sec, 50°C lsec, 60°C 4min) x25 cycles. The 
samples were then cooled to 4°C. The products were precipitated with 2pl 
3M NaAc pH4.5 and 50pl EtOH at -70°C for 15min. The samples were then 
spun and the DNA pellet washed in 250pl 70% EtOH. The pellet was dried in
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a speedivac for 5min then processed for loading in ABI373A according to the 
manufacturers protocols.
3.1.13 SSCP-PCR Analysis
A 50pl PCR reaction was prepared as follows: lx  PCR buffer, 2.5mM 
MgClz, lOOng genomic DNA, 40pM dNTP’s, 0.1 pi a-[32p]-dCTP 
(l.llM B q), lOOng of each primer and 2.5u of Taq polymerase. PCR with 
LS7A and LS7B (see table 3.1.1 IB) was used for DNA purified from tumour 
tissue using the programme:
94°C 2min, /(94°C 30secs, 65°C 30secs, 72°C 30secs) x30 cycles/ 4°C 
until required. A nested PCR reaction was used for DNA purified from cells 
and paraffin embedded sections. For the nested PCR, the first round was 
carried out using the above programme with an annealing temperature of 55°C 
and primers LS7A' and LS7B' as described in table 3.1.1 IB. lOpl of this 
reaction was used in the second round at an annealing temperature of 65°C, 
using primers LS7A and LS7B.
SSCP gels were run using Gibco BRL S2 sequencing appararus. 3pl of 
50pl PCR products were mixed with 7pl of stop buffer (95% formamide, 
20mM EDTA, 0.05% bromophenol blue, 0/05% xylene cyanol FF). The 
samples were denatured at 80°C for 4min and snap cooled immediately in an 
ice water bath to prevent reannealing of DNA strands. 4pl was loaded onto a 6 
and 10% polyacrylamide or 0.5x and lx  MDE SSCP gels and run overnight at 
4°C or room temperature. Gels were run with lx TBE buffer and the room 
temperature gels contained 5% glycerol.
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Gel mixes were as follows:
6% /10%
15mls/25mls acrylamide (30%, 0.8%w/v)
7.5mls lOxTBE
52.5mls/42.1mls dH20  to 75mls then add 150(xl freshly made 25% APS 
and 75pl TEMED.
I x M D E
37.5mls MDE mix 
4.5mls lOxTBE
29.78mls dH20  to 75mls then as APS and TEMED added as above.
The gels were then dried and autoradiographed as described in 3.1.12.
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3.2 Cell Culture and Analysis
3.2.1 Growth of PalF cells
Cells derived from the palate of a bovine foetus were cultured in 
1XDMEM. They were seeded at approximately 10^ cells per 80cm^ (T80) 
flask and grown at 37°C with air containing 5% (v/v) CO2 until almost 
confluent. At this stage the cells were washed with PBS and trypsinised with 
10% (v/v) trypsin diluted in PE. 10ml of SLM containing 10% FCS was added 
to the flask to inactivate the trypsin and cells then centrifuged at lOOOrpm for 
5min in a MSE (Centaur 2), resuspended in fresh medium and reseeded.
Stocks of cells were kept frozen in liquid nitrogen. The cells were 
trypsinised as described above and resuspended in ice cold lxDMEM 
containing 25% FCS and 10%DMSO, at a concentration of 10^ cells per ml. 
Cells were aliquoted into cryotubes and placed in a polystyrene box. Cells 
were frozen at -70°C overnight before transfer to liquid nitrogen. Gradual 
freezing of the cells ensures viability on thawing. Cells were quickly thawed at 
37°C and then transferred to a universal containing prewarmed lxDMEM, 
centrifuged at lOOOrpm for 5min in a MSE (Centaur 2) then resuspended in 
lxDMEM and supplements as described above and replated as required.
3.2.2 Growth of p53 null mouse fibroblasts
Fibroblast cells were derived from 2 week old p53 knockout mice by 
dissecting skin tissue which was macerated and grown in lx  DMEM containing 
5% penicillin, 5% streptomycin and 10% FCS. These skins were cultured until 
sufficient cells had grown out from the tissue to be trypsinised and expanded. 
Cells were grown and subcultured as described above for the PalF cells.
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3.23 Transfection of cultured cells
All cells were transfected by the CaPC>4 method as described by 
Gorman (1985) using a total of 20pg of DNA including 2pg of pZIPneo or 
pBabehygro encoding geneticin and hygromycin resistance respectively, for 
selection.
5x10^ PalF cells were plated into a T80 flask on day 1. On day 2, the 
DNA to be transfected was made up to 20|il and added to a tube containing 
lOOpd 2M CaCl2, lOOpl O.lxTE and 280pl of distilled water. This was mixed 
by adding slowly, dropwise to a separate tube containing 500pl 2xHBS. The 
DNA mixture was incubated at room temperature for 30min to allow a 
precipitate to form, and then 1ml added to a T80 flask containing 15ml medium 
(or 500pl total to a T25 containing 5ml medium for p53 null cells). On day 3, 
the cells were washed lx in PBS and refed with fresh lxDMEM and 
supplements. On day 4, the cells were trypsinised as described above and 
reseeded in a T175 flask. PalF cells were then selected for resistant colonies 
for a period of 3-5 weeks with 500pg/ml of Geneticin (G418), p53 null 
fibroblasts were selected for resistance for 2-3 weeks with 125pg/ml of 
Hygromycin B. After this period the colonies were then counted and either 
ring cloned or fixed with methanol for lOmin and then stained with 10% 
Giemsa for lOmin and photographed. Ring cloning was carried out as follows. 
The flask was cut open, the medium aspirated out and the cells washed in PBS. 
A 10mm cloning ring coated with silicon grease at the base was then placed 
over the colony and 200pl of trypsin prewarmed to 37°C was added for 
approximately 5min. The trypsinised cells were then transferred to a 24-well 
plate along with 2ml of medium and returned to the 37°C incubator. Cells 
were expanded and stocks frozen down in 10% DMSO, 25% FCS in lx 
DMEM as described above. The PalF cells were continually passaged at 
identical cell densities for about 4-6 months to determine if the cell lines
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established were immortal, cells were also grown in Methocel to determine 
anchorage independent growth and assayed for their growth rates (see M IT  
assay as described below). All solutions were filter sterilised and the plasmids 
sterilised by ethanol precipitation.
3.2.4 RNA extraction from Cell lines
Cells were grown in a 175 cm2 (T175) flask until confluent and washed 
twice with ice cold PBS. 10ml of RNAzol was added to the flask which was 
then left on ice for 15min. The lysate was pipetted into a Falcon 2059 tube and 
lml of chloroform added, vortexed and then left on ice for 15min. The tubes 
were centrifuged in a Sorvall RC5B (HB6 rotor) at 10,000rpm for 15min at 
4°C. The upper, aqueous phase was transferred to a fresh tube and an 
equivalent volume of isopropanol added. The samples were mixed and left at 
-20°C overnight and the RNA pelleted by centrifugation in a Sorvall RC5B 
(HB6 rotor) at 10,000rpm for 15min at 4°C. The pellet was partially 
resuspended in 75% ethanol (made with DEPC H2O), transferred to an 
eppendorf and kept at -70°C until required. Before use the RNA was pelleted 
in a microfuge at full speed at 4°C for 30min, dried on a speedivac and then 
resuspended in 50-100pl of DEPC H2O.
3.2.5 Transformation assays
3.2.5.1 Anchorage independent growth
Cells were tested for viability by the addition of 20pl of trypan blue stain 
(0.4% in 0.85% saline) to 80pl of cells suspended in lxDMEM. Only the 
green (viable) cells were counted and 2x10^ cells added to 15ml Methocel 
medium. The cells and Methocel were poured to bacterial petri dishes and left 
for 10-14 days before colonies were counted and photographed with PanF 50 
technical film.
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Methocel medium was made up as follows:
3g of Methocel agar and 200ml of distilled water was autoclaved and 
stirred at 4°C overnight to dissolve agar. 22ml lOx F10-HAM, 100ml 
FCS, 2.5ml 200mM glutamine, 5ml 7.5% sodium bicarbonate, 4ml 
sodium pyruvate, 4ml MEM-amino acids and 2% penicillin and 
streptomycin was added.
3.2.5.2 Analysis of cell growth rates (MTT assay)
5x10^ viable cells were plated out in quadruplicate, in ten 96-well plates 
for each cell line established. Samples for each cell line were assayed at 24 
hour intervals as follows: 20pl of MTT was added to the well and incubated at 
37°C for 3 hours. The medium was then aspirated off and 100p.l of DMSO 
was added to each well. The plate was shaken at room temperature for 10min. 
The absorbance was read at 590nm, against a medium only blank. This was 
carried out over a period of ten days. A calibration curve for untransfected 
cells was determined to confirm that O.D increased proportionally with cell 
number. Figures 3.2.4.2 A and B illustrate these standard curves.
3.2.53  Tumourigenicity in nude mice
Four 175cm^ flasks of cells were trypsinised to yield 3x10^ viable cells 
which were resuspended in 300^1 of PBS. lOOpl of the cell suspension was 
inoculated into an athymic nude mice at a single injection site. A minimum of 
three mice were used to analyse individual clones for each cell line. The mice 
were then checked weekly until tumours arose. Tumours were scored as 
positive if remaining after 12 weeks. Mice were kept for 20-30 weeks or until 
they had to be sacrificed as a result of tumour load. The tumours were then 
excised and either placed in formalin for paraffin embedding or frozen 
immediately in liquid nitrogen.
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Standard growth curve for p53 null fibroblasts
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Figure 3.2.5.2 MTT assay standard curves
33  Immunocytochemistry
Tissue from cattle that were infected with BPV-4 was excised, placed 
in formalin and then embedded in paraffin. Sections were then cut 4-5 microns 
thick using a microtome and floated onto 3-aminopropyltriethoxysilane (APES) 
(Sigma-Aldrich Co.,U.K) coated slides (Diagnostic Pathology Lab 5, 
Veterinary Pathology, University of Glasgow). Sections were stained using the 
Vectastain ABC peroxidase kit according to the manufacturers instructions 
with the following modifications. After sections had been taken to water they 
were immersed in Lugols iodine for 2.5min then cleared in 5% sodium 
thiosulphate. Antigen retrieval by trypsinising in 0.1% (w/v) trypsin, 0.1% 
(w/v) CaCl2 in TBS or by microwaving the sections in citrate buffer (0.01M 
Citric acid pH6.0) was carried out before blocking the sections with normal 
goat serum. Sections were incubated overnight at 4°C with the primary 
antibody. Diaminobenzidine (DAB) was used to visualise the reaction and 
resulted in a brown stain. Sections were then counterstained with the blue 
nuclear stain haemotoxylin. The cells were then photographed using E6 
tungsten slide film.
CM-1 antibody was used at the concentration supplied by the 
manufacturer. Anti-BPV-4 E7 and Anti-BPV-4 E8 were used at 1/200 and 
1/2000 respectively. Antibodies were diluted in 0.1% BSA in PBS, pH7.6.
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3.4 In-situ hybridisation
The whole BPV-4 genomic insert was excised from the vector pAT153 
using BamHI and 500ng labelled with digoxigenin-ll-dUTP according to the 
manufacturers instructions for in-situ hybridisation. 2|xl of doubling dilutions 
of the labelling reaction were spotted onto Hybond-N membrane and 
immunological detection used to check the success of the labelling reaction 
using a DIG nucleic acid detection kit (Boeringher Mannheim) as instructed by 
the manufacturer. The paraffin sections were dewaxed in xylene and hydrated 
through graded alcohols to water as follows: lOmin xylene, 5min 100% EtOH, 
5min 70% EtOH, 5min 50% EtOH, 5min tap water. The sections were then 
rehydrated in PBS, pH7.2 for 5min, immersed in 0.1M glycine/PBS for 5min 
and immersed in 0.3% Triton X-100 for 15min and finally washed twice with 
PBS for 3min. The sections were then incubated with proteinase K (lOpg/ml) 
in 0.1M Tris.Cl pH8.0, 50mM EDTA at 37°C for 30min. The sections were 
then fixed with 4% paraformaldehyde/PBS for 5min and washed twice with 
PBS for 3min. The sections were immersed in 0.25% acetic anhydride/0.1M 
triethanolamine pH8.0 for lOmin and prehybridised with 50% formamide, 
2xSSC at 37°C for 2 hours. The slides were then drained and 20pl in-situ 
hybridisation mix added containing a 1/10 dilution of the BPV-4 DNA probe. 
The sections were covered with glass coverslips, heated at 80°C for lOmin, 
and then incubated in a moist chamber overnight at 42°C. The coverslips were 
removed by immersion in 4xSSC and the sections washed for lOmin in 4xSSC, 
2xSSC for lOmin and O.lxSSC at 37°C for 30min. The DIG detection 
reaction was carried out according to the manufacturers instructions with a 
1/200 dilution of the anti-DIG antibody. The sections were then counterstained 
with 5% aqueous eosin and mounted in a permanent water mountant. The 
above method was adapted from Hamid et al (1987).
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3.5 Fluorescence In-Situ hybridisation (FISH)
Metaphase chromosomes were prepared with standard methods from 
peripheral blood lymphocytes obtained from cattle. The bovine p53 lambda 
clone and the cosmids ETH3, ETH1 and MAP IB, were labelled by the 
incorporation of biotin-14-dATP using the BioNick nick translation kit. In- 
situ hybridisation, stringency washes and detection of the biotinylated probes 
with fluorescein-avidin DCS and one round of amplification with biotinylated 
anti-avidin antibody (Vector Laboratories), were carried out as described by 
Toldo et al (1993). Preparations were mounted in Vectorsheild antifade 
medium (Vector Laboratories) and were viewed with a BioRad MRC600 
confocal laser scanning microscope.
3.6 Production of antibody against bovine p53
The bovine p53 peptide sequence CSDYSDGERRGLWMG was chosen 
based on the human and mouse epitopes mapped by Yewdell et al (1986). This 
peptide was synthesised and conjugated onto the large antigenic peptide KLH 
(Keyhole Limpet Haemocyanin) by Thistle Peptide Services (Dept, of 
Biochemistry, University of Glasgow). Two rabbits were inoculated with 
lOOpg of KLH-bp53 immunogen at weekly intervals. The peptide was mixed 
with 600pl of adjuvant and syringed with a 24 gauge needle to produce an 
emulsion. The first injection was mixed with Freunds complete adjuvant and 
the second and third injections with Freunds incomplete adjuvant. After the 
third injection (preboost) a test bleed was taken to ensure antibodies were 
being produced. After 8-10 weeks a fourth injection (boost) of immunogen 
was given and 10 days after the fourth injection the rabbits were euthanased 
and bled out. The blood was incubated at 37°C for 30min and the clots ’ringed' 
with a glass pasteur pipette. The blood was then stored overnight at 4°C and 
centrifuge at 2000rpm for 5min in a Beckman J6-B. The serum supernatant 
was then aliquoted and stored at -70°C until use. Figure 3.6 illustrates the
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antibody titre achieved after the 3rd injection (preboost) and after the 4th 
injection (boost). This antibody was also tested on paraffin sections and 
staining compared with that of CM-1.
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Figure 3.6 Antibody titre for rabbit 1 inoculated with KLH-bp53.
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I-  preboost (3rd injection) 
boost (4th injection)
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Introduction
BPV-4 lacks an E6 ORF, as do other members of the subgroup B 
papillomaviruses. All other known papillomaviruses encode an £6  oncoprotein 
and E6 has been demonstrated to contibute to cell transformation in 
cooperation with the E7 oncoprotein (Storey et al, 1994; Munger et al, 1992; 
Sedman et al, 1991, Hawley-Nelson et al, 1989). One function of the E6 
oncoprotein from the high risk papillomaviruses is to bind and degrade the 
tumour suppressor p53 (Scheffner et al, 1993; Scheffner et al, 1992b; Wemess 
et al, 1990; Scheffner et al, 1990 ). As BPV-4 lacks an E6, it was unclear if 
and how p53 functions were abrogated during papilloma formation by BPV-4 
and progression of these lesions to carcinoma. It was suggested that p53 was 
altered or that other factors were involved in these processes (Jackson et al, 
1991). These observations raised several questions which have been addressed 
in this thesis.
1) What is the status of the bovine p53 gene in BPV-4 associated 
papillomas and carcinomas?
2) Does BPV-4 lack E6 associated functions?
3) Can the addition of an exogeneous HPV-16E6 confer additional 
functions in vitrol
Chapters Four and Five will deal with the isolation and characterisation of 
the wild type bovine p53 gene and the p53 status in BPV-4 associated 
papillomas and carcinomas. Chapter Six describes the in vitro transformation 
of primary foetal bovine fibroblasts (PalF) and p53 deficient mouse fibroblasts 
by BPV-4 and HPV-16E6. The effect of the addition of an exogeneous human 
mutant p53 to PalF cells in the presence of BPV-4 will also be described. 
Transfection of p53 deficient fibroblasts with BPV-4 and HPV-16E6 will 
determine if any additional functions provided by HPV-16E6 are p53 
independent.
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CH APTER 4
Characterisation o f  bovine p53
4.1 p 53 isolation
To determine the bovine p53 status, the wild type p53  gene was isolated for 
comparitive studies.
A human wild type p53 cDNA probe was prepared as described (materials 
and methods section 3.1.7) and used to screen a bovine liver genomic DNA 
library. Positive plaques were visualised by southern hybridisation and 
subjected to four rounds of plaque purification until all of the plaques were 
positive as illustrated in figure 4.1.1. Four of the positive plaques were picked 
for further characterisation and the phage DNA isolated as described (materials 
and methods section 3.1.9), one isolate was selected for further analysis. The 
phage DNA was digested with several restriction enzymes and the size of the 
resulting fragments estimated according to the molecular weight markers. 
Figure 4.1.2A illustrates the ethidium bromide stained restriction fragments and 
the subsequent southern hybridisation (Figure 4.1.2B) to confirm the presence 
of p53 DNA sequences.
Digestion of the isolated phage DNA with the restriction enzyme BamHI 
released an insert of 14kb from the lambda vector DNA (Figure 4.1.2A, lane
2). EcoRI cut lambda DNA yielded a fragment of 8kb and two bands of 3kb 
and 2.5kb respectively (Figure 4.1.2A, lane 3), SstI digests resulted in only two 
fragments suggesting that this restriction site may lie within the insert as there 
are no SstI sites within the lambda vector DNA (Figure 4.1.2A, lane 4). The 
Xbal digests yielded fragments at 4.6kb, 4.0kb and a band at about 15kb 
which incorporated the 9kb lambda fragment of the lambda vector DNA 
(Figure 4.1.2A, lane 5). Xhol did not cut the the phage DNA suggesting that
80
Figure 4.1.1 Fourth round screening of selected positive plaques and Southern 
hybridisation with the human p53  cDNA fragment probe (CR345) to plaque 
lift filter. The dark spots on the autorad indicate positive plaques which 
corresponded exactly to the plaques on the agar plate (data not shown). Four 
of these plaques were picked and phage DNA isolated as described (materials 
and methods section 3.1.9).
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B
1 2 3 4 5 6
nCOCOCVJ ►
9.4kb ►
6.5kb ►
4.3kb ►
2.3kb ►
2.0kb ►
Figure 4.1.2 Restriction digests of isolated lambda phage 
A) stained with ethidium bromide and B) southern 
hybridisation using CR345 of human p53 as probe. The 
phage DNA was digested with the following enzymes:
Lane 1: undigested X phage DNA, 2: BamHI cut,
3: EcoRI cut, 4: SstI cut, 5: Xbal cut, 6: Xhol cut.
Positions of the X Hindlll cut markers are indicated on the left.
there are no Xhol sites within the insert (Figure 4.1.2A, lane 6).
Southern hybridisation with the human p53 cDNA fragment probe 
(materials and methods section 3.1.7) revealed that the region of the bovine 
p53 gene containing the sequences corresponding to conserved regions 3, 4 
and 5 (CR345) of the human cDNA probe were present in the 14kb, 8kb, 29kb 
and 4.0kb for digests BamHI, EcoRI, SstI and Xbal respectively (figure 
4.1.2B).
Oligonucleotide primers designed to match the conserved regions of human 
p53 (materials and methods section 3.1.11), were used to generate PCR 
products from both bovine liver genomic DNA and DNA from the isolated 
lambda phage clone. Figure 4.1.3 illustrates the PCR products generated from 
both the bovine and the human control DNA. The predicted sizes for 
amplification of human p53 conserved regions (CR) 1 to 2, 3 to 4 and 4 to 5, 
are 520bp, 767bp and 470bp respectively (Lamb and Crawford 1986; human 
p53 cDNA Genebank accession number K01399) . The observed bands 
amplified from the human genomic DNA of approximately 500bp (CR1/2), 
750bp (CR3/4) and 500bp (CR4/5) are indicated in figure 4.1.3A and B. The 
amplified product for bovine p53 conserved region 1 to 2 was 800bp, for 
conserved region 3 to 4, 280bp (Figure 4.1.3A) and conserved region 4 to 5 
around 480bp (Figure 4.1.3B). The PCR products generated from bovine p53 
conserved regions 1/2 and 3/4 appear to be larger and smaller than the human 
p53 products respectively (Figure 4.1.3A). This would suggest that the 
intronic sequence between bovine p53  conserved region 1 and 2 (exons 2 to 5) 
and conserved regions 3 and 4 (exons 5 to 7), varies in the bovine p53 gene in 
comparison to the human p53 sequence. The predicted size for amplification of 
the ovine p53 gene conserved regions 3 to 4 is less than 500bp (Dequiedt et al, 
1995a), which is smaller than that of the human p53 gene suggesting that this
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1/2 3 /4
Bv Hu C Bv Hu C
CL.OCOinCO ►
603bp ►
310bp ►
B
6500bp ►
Bv
4/5
Hu
1353bp ►
603bp ^
310bp ^
Figure 4.1.3 PCR products generated from both human and 
bovine genomic DNA. Figure A illustrates the amplification 
of p53 conserved regions 1 to 2 and 3 to 4.
Figure B illustrates amplification of conserved regions 4 to 5. 
Bv - bovine, Hu - human, C - negative control primers only.
difference may be due to species variation as ungulates are several million years 
evolutionarily diverged from man. Amplification of a bovine pseudogene 
appears unlikely as only a single product was amplified.
The PCR products from both bovine genomic DNA and the lambda isolate 
were cloned into PCRscript (Stratagene) (materials and methods 3.1.6) and 
both manual and automated sequencing was used (materials and methods 
3.1.12) to confirm the presence of p53 sequences. Sequencing of the 
fragments representing conserved regions 3/4 and 4/5 generated the sequence 
shown in figure 4.1.4A and B. The data shown here confirms that the amplified 
PCR products did indeed contain sequences of the corresponding bovine p53 
gene as previously suggested by Southern hybridisation. The complete cDNA 
sequence of the bovine p53 cDNA (387 AA) has recently been published by 
Dequiedt et aly (1995b). The sequence obtained from the PCR products was in 
complete agreement with that of Dequiedt et al (1995b), however, additional 
sequences flanking exon7 of bovine p53 were characterised as shown in figure 
4.1.4A.
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4.2 Chromosomal localisation of bovine d53
The phage DNA isolated from the bovine liver genomic DNA library was 
used to localise the bovine p53 gene to its specific bovine chromosome. The 
bovine p53 lambda clone was biotinylated and hybridised to metaphase 
chromosomes isolated from bovine peripheral blood lymphocytes by 
fluorescence in-situ hybridisation (FISH) as described (materials and methods 
section 3.5). Arranging the chromosomes by size indicated that bovine p53 
was present on one of chromosomes 19-22, however the acrocentric nature of 
bovine chromosomes makes them difficult to assign by size alone. 
Chromosomal markers specific for loci on bovine chromosomes 19, 20 and 21 
were available and are indicated in Table 4.2.1 below. To date, there are no 
specific markers available for bovine chromosome 22.
Marker Chromosome
ETH 3 (Barendse et al, 1994) 19
MAP1B (Barendse et al, 1994) 20
ETH 1 (Toldo et al, 1993) 21
Table 4.2.1 Chromosomal markers used to colocalise bovine p53.
The above cosmids were biotinylated and cohybridised with the bovinep53 
lambda clone. In-situ hybridisation of the cloned bovine p53 gave a signal near 
the centromere on one pair of bovine metaphase chromosomes. Neither ETH1 
(figure 4.2.1A), nor MAP1B (data not shown) colocalised with the bovine p53 
clone as a signal was detected on two separate pairs of chromosomes. FISH of
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Figure 4.2.1 Chromosomal localisation of the bovine p53 gene by FISH. 
Chromosome spreads of bovine peripheral blood lymphocytes were stained 
with propidium iodide and hybridised with the fluorescent probes.
Panel A demonstrates that bovine p53 lambda clone does not colocalise with 
the ETH1 (21ql7) probe.
Panel B illustrates that the bovine p53 clone and the chromosome 19qter probe 
ETH3 cohybridise in situ to the same chromosome.
Panel C depicts the bovinep53 gene assignment to 19ql5 according to the 
ISCNDA 1989 (1990).
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the ETH 3 probe alone confirmed that it hybridised near the telomere of 
chromosome 19 (Toldo et al, 1993). Cohybridisation of both ETH3 and the 
bovine p53  lambda clone gave four fluorescent signals on chromosome 19 as 
illustrated in figure 4.2.IB. As previously observed, the bovine p53  probe 
hybridised near the centromere and the ETH3 signal was telomeric. Figure 
4.2.1C, illustrates the position of the bovine p53  with respect to ETH3, with 
p53 located proximal to the centromere on band 19ql5.
Mammalian species genome mapping has proceeded to such a point that 
selected genetic loci can serve as anchored reference markers for the 
comparitive genetic analysis of mammalian and vertebrate species (O’Brien et 
al, 1993). For example, Homeobox region 2 (HOXB), the protein kinase C a  
polypeptide (PRKCA) and the growth hormone (GH) gene are all located on 
bovine chromosome 19 (Fries et al, 1993; Gunawardana and Fries, 1992; 
Hediger et al, 1990). The above genes have been localised to human 
chromosome 17qter (O'Brien et al, 1993; Leach et al, 1989; Benchimol et al, 
1985). Similar genes have also been identified in mouse and are listed in table 
4.2.2. This would suggest that the chromosomal localisation of these genes are 
conserved among species.
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Conclusions and Discussion
To determine the status of the bovine p53 gene in BPV-4 associated 
carcinogenesis, it was necessary to clone and sequence the wild type bovine 
p53 gene. A lambda clone isolated from a bovine liver genomic DNA library 
was shown to contain p53 related sequences by southern hybridisation with a 
human p53 fragment cDNA probe. PCR products from the lambda clone were 
sequenced and found to be homologous to the conserved regions of p53 
identified from other species. The recently isolated bovine p53 cDNA 
sequence (Dequiedt et al, 1995b) was also in agreement with our data.
Chromosomal localisation of the bovine p53 gene to 19ql5 (Coggins et 
al, 1995) confirmed that bovine chromosome 19 was syntenic with both the 
short arm of human chromosome 17 and mouse chromosome 11 suggesting 
that this part of the chromosome is conserved among species.
Thus, bovine p53 gene was found to be homologous to human p53 as 
identified by sequencing of its conserved regions and to be syntenic with both 
human and mouse in its chromosomal localisation.
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CHAPTER 5
Status of bovine p53 in BPV-4 associated 
papillomas and carcinomas
Introduction
BPV-4 infects the mucosa of the alimentary tract and results in the 
formation of benign papillomas. Additional cofactors such as 
immunosuppressants and mutagens found in bracken fern, provide the 
opportunity for a widespread, persistent infection to occur. The result of this 
can be progression to carcinoma of the alimentary canal. The morphogenesis 
of papillomas induced by BPV-4 proceeds through a series of distinct stages 
based on size, appearance and histology (Jarrett, 1985). Raised plaque-like 
lesions or stage I papillomas appear a few weeks post infection with BPV-4 
and productive viral infection is apparent at these stages. Stage II lesions 
possess an archetypal papilloma structure with keratinised fronds and large 
amounts of viral DNA are present in the upper differentiating layers of these 
papillomas. After several months the papillomas progress to the mature stage 
III form which is similar to stage II except that levels of viral replication and 
virion production are reduced. Most papillomas regress spontaneously through 
a cell mediated immune response (stage IV) and recent evidence indicates that 
infiltrating lymphocytes have a role in this process (Knowles et al, 1996). The 
normal bovine alimentary mucosal epithelium consists of i) a cubiodal, 
mitotically active basal cell layer, ii) suprabasal cell layer, iii) spinous layer and 
iv) a squamous layer (illustrated in figure 5.1). In the papilloma,
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apilloma fronds
squames
spinous
suprabasal
basal
Dermis
Figure 5.1 Schematic representation of the 
differentiated layers in a mucosal papilloma.
these layers differentiate and the squamous layer becomes comified on the 
external surface of the papilloma.
5.1 Are p 5 3  levels elevated in BPV-4 induced papillomas?
Introduction
To determine the p53 status in BPV-4 associated papillomas, a panel of 
samples representing the progression described above were removed from 
animals experimentally infected with BPV-4. An oesophageal carcinoma which 
had arisen from a BPV-4 induced papilloma was included to represent the 
advanced state when environmental cofactors are present.
Wild type p53 is undetectable by immunocytochemistry due to the short half 
life of the protein (Oren et al, 1981; Matlashewski et al, 1986). Stabilisation of 
the p53 protein by mutation or complex with other cellular or viral factors 
allows p53 detection with antisera as does upregulation of the wild type p53 
protein by DNA damage (Bartek et al, 1990a, 1990b; Bartek et al, 1991; 
Kastan et al, 1991).
In vitro studies have shown that BPV-4 E7 (4E7) is necessary for 
morphological transformation of primary bovine foetal palate cells (Pennie et 
al, 1993). 4E7 possesses conserved motifs which contribute to the
transforming and immortalising activity of other E7 homologues (Barbosa et al, 
1990; Storey et al, 1990; Watanabe et al, 1990; Phelps et al, 1992; McIntyre et 
al, 1993). Cattle vaccinated with a 4E7 subunit vaccine demonstrated early 
regression of BPV-4 induced papillomas (Campo et al, 1993) confirming that 
4E7 has a role in the progression of BPV-4 infected lesions.
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To determine if the bovine p53 protein was stabilised when viral infection 
was present, we analysed serial sections of experimentally induced BPV-4 
lesions. The presence of viral DNA and expression of the 4E7 oncoprotein 
was also determined.
Results
p53 and 4E7 proteins were detected by immunocytochemistry and viral 
DNA detected by in-situ hybridisation (materials and methods sections 3.3 and 
3.4).
Both normal palatine tissue and the oesophageal carcinoma were examined 
for the presence of viral DNA, 4E7 and p53. Neither E7, nor p53 could be 
detected by immunocytochemistry in normal palate tissue (Figure 5.1.1 A; E7 
antiserum) or in the carcinoma (Figure 5.1. IB; p53 antibody). Viral DNA was 
absent in normal palate tissue and in the oesophageal carcinoma (Figures 
5.1.1C and 5.1.ID). This correlated with previous findings that BPV-4 DNA is 
lost during carcinogenesis and is not required for maintenance of the 
transformed phenotype (Campo et al, 1985).
The absence of 4E7 in normal mucosal palatine tissue was expected as no viral 
infection was present. Lack of 4E7 expression in the carcinoma was attributed 
to the loss of viral DNA at this stage. As mentioned above, wild type p53 is 
virtually undetectable by immunocytochemistry and it is assumed that this is the 
case in the normal palatine tissue sample as no p53 was detected (Figure 
5.1. IB). The absence of p53 staining in the carcinoma may indicate that p53 
expression is unaltered. Alternatively, the p53 antibody, CM-1, may
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Figure 5.1.1 (on facing page).
Immunocytochemistry of normal palatine tissue and oesophageal carcinoma. 
The absence of immunoperoxidase detection of;
A: the BPV-4 transforming protein E7 in normal palatine tissue; compare with 
the positive staining in Figure 5.1.3 A-C;
B: the tumour suppressor protein p53 in an oesophageal carcinoma; compare 
with positive staining shown in Figure 5.1.4A and B. Magnification is X50 in 
A and X100 in B.
Absence of detection of viral DNA by in-situ hybridisation.
Sections of normal (C) and oesophageal carcinoma tissue (D) were incubated 
with a BPV-4 DNA probe in the hybridisation mixture. Compare with positive 
in-situ hybridisation in Figure 5.1.2A, D and E. Magnification is X 25 in both 
C and D.
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not recognise mutated bovine p53, however, this is unlikely, as the antibody 
was raised against the N-terminus of the protein and mutations generally occur 
in the central domain of p53.
Another possibility is that the p53 gene may be deleted resulting in the 
absence of a p53 protein.
Analysis of the papillomas by in-situ hybridisation detected high copy 
numbers of viral DNA in the differentiating spinous and squamous layers of 
papillomas (Figures 5.1.2-5.1.5). Few copies of viral DNA were present in the 
plaque-like lesion (Figure 5.1.2C) although this does not exclude viral DNA 
from other cells. Detection of viral DNA by in-situ hybridisation is limited to 
the presence of greater than 30 viral copies per cell. Viral copy numbers were 
high in stage I papillomas (Figure 5.1.2A) and positive staining was absent in 
the control sections (Figure 5.1.2B). At stage II, higher levels of viral DNA 
were detected (Figure 5.1.2D) and at stage III, viral DNA was present in all 
fronds of the papilloma (Figure 5.1.2E).
Expression of the 4E7 oncoprotein varied depending on the stage of the 
papilloma and was found to be both cytoplasmic and nuclear. A stage I 
hyperplastic papilloma demonstrated that 4E7 was expressed in the cytoplasm 
(Figure 5.1.3A). 4E7 expression was detected from the suprabasal to the 
superficial spinous cell layers. At stage II and El, 4E7 expression was found to 
be both nuclear and cytoplasmic. Cytoplasmic 4E7 was expressed in the 
spinous layers (Figure 5.1.3B) and nuclear 4E7 expressed in the basal and 
suprabasal cell layers (Figure 5.1.3C). As a negative control, a 1 in 10
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Figure 5.1.2 (on facing page)
Detection of viral DNA by in-situ hybridisation.
Sections taken from a stage I papilloma were incubated with 
a BPV-4 genomic probe (A) or without probe (B) in the 
hybridisation mixture. Sections of a plaque-like (C), 
stage II (D) and stage III (E) papillomas incubated with 
BPV-4 genomic probe.
Arrows indicate the positively stained cells.
Magnification X 25 (A,B and D); magnification X 50 (C and E).
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Figure 5.1.3 (on facing page)
Immunoperoxidase detection of the BPV-4 transforming protein E7. 
Stage I, II and El papillomas incubated with 4E7 primary antiserum 
(A, B and C respectively), and competed antiserum (D).
Arrow indicates cells staining positively in the cytoplasm and 
the arrowheads indicate nuclear staining.
Magnification X 20 (A and B), magnification X 100 (C and D).
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dilution of the 4E7 antiserum was competed with 200pg of 4E7 synthetic 
oligopeptides (Chandrachud et aly 1994; McGarvie et al, 1995). No positive 
cells were detected in the control section (Figure 5.1.3D).
Elevated levels of p53 protein were detectable in papillomas at all stages 
(Figure 5.1.4 and 5.1.5). p53 protein expression was consistently nuclear and 
found in the basal and suprabasal cell layers at both early and late stages of 
progression (Figure 5.1.4A and B).
The stage IV lesion was assigned this status on the histological observation 
of the disappearance of virus producing cells and due to the presence of 
infiltrating mononuclear cells in the cores of the two fronds. Sub-epithelial 
dermal tissue was absent from this sample and so it was not possible to confirm 
the heavy lymphocytic infiltration into the derma which typifies regressing 
papillomas (Knowles et aly 1996). Only a few cells were observed to contain 
viral DNA (Figure 5.1.5A). However, no 4E7 expression was detected in this 
lesion (Figure 5.1.5B). On the contrary, the p53 antibody did react in this 
papilloma and incubation of the section with preimmune serum eliminated the 
positive staining (Figures 5.1.5D and 5.1.5C respectively). In agreement with 
previous observations (Bartek et aly 1990a, 1990b; Bartek et al, 1991), this 
suggested that the p53 protein was stabilised in this regressing lesion.
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Figure 5.1.4 (on facing page)
Immunoperoxidase detection of the tumour suppressor p53. 
Stage I and II papillomas incubated with p53 antibody 
CM-1, (A and B respectively) and preimmune antiserum (C). 
Arrows indicate positive cells.
Magnification X 100.
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Figure 5.1.5 (on facing page)
Histochemistry of stage IV papilloma.
Virus detection by in-situ hybridisation with BPV-4 genomic 
probe (A), incubated with E7 antiserum (B), preimmune 
antiserum (C), and p53 antibody CM-1 (D). Arrows indicate 
positive cells.
Magnification X 25 (A), X 50 (C), X 100 (B and D).
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Conclusions and Discussion
The above data are summarised in table 5.1.1 on the following page.
No viral DNA, 4E7 or p53 antigens were detected in the normal palatine 
tissue or in the carcinoma. Viral DNA was detected at all of the papilloma 
stages as was the p53 protein. 4E7 was detected in papillomas from stage I to 
HI but not in the plaque or stage IV lesions.
Demers et al (1994b) showed that after DNA damage, cells expressing 
HPV-16 E7 demonstrated an increase in p53 levels. It was initially thought 
that this may be the case for the BPV-4 induced papillomas, however, in the 
stage IV lesion, p53, but not 4E7, was detected suggesting that there is no 
relationship between these two proteins and that p53 stabilisation has occurred 
via another pathway. p53 is induced by DNA damage (Kastan et al, 1991; 
Bartek et al, 1991; Yonish-Rouach et al, 1991; Kuerbitz et al, 1992) and it 
may be that the experimental injection of a large dose of virus into the palate is 
sufficient to cause p53 induction. However, it is unknown if this state would 
persist through the maturation stages of the papillomas.
It is unclear why 4E7 is differentially detected in the cytoplasm and the nucleus. 
No correlation between 4E7 and p53 could be made and so the presence of 
4E7 in the cytoplasm and in the nucleus may be dependent on other cellular 
factors. Analogous to HPV-16, BPV-4 E7 transport to the nucleus may be 
mediated by conserved residues centred around the putative pRb binding 
domain (Fujikawa et al, 1994). It is possible that expression of E7 in the 
nucleus may be masked due to an association with cellular anti-oncogenes or 
conformational changes as a result of these interactions. This is unlikely as 
trypsinisation of sections was employed to maximise epitope
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detection in combination with polyclonal antiserum which may recognise 
additional immunoreactive regions of 4E7 (Chandrachud et al> 1994). 
Potential interactions between 4E7 and nuclear factors appear to be possible 
only in a particular population of differentiating cells, i.e., the basal and 
suprabasal layers of the papilloma. This specific localisation of 4E7 may be 
sufficient to provide an abnormal proliferative signal in the basal cells to induce 
differentiation into a mature papilloma. The cytoplasmic expression of 4E7 
was closely associated with cells where viral DNA was present in the upper 
epithelial layers of the papilloma. It may be that these cells are differentiated 
enough to allow viral production and E7 functions are no longer required, thus 
E7 may be present in the cytoplasm prior to removal from the cell.
Thus, bovine p53 was elevated in experimentally BPV-4 induced papillomas, 
this was accompanied by the presence of viral DNA and the expression of the 
4E7 oncoprotein.
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5.2 Detection of bovine d53 mutations in exon 7 in vivo
Introduction
Although we had established that p53 protein levels were elevated in the 
papillomas experimentally induced by BPV-4 infection, we did not know if this 
stabilisation was a direct result of a mutation in the p53 gene. As the bovine 
p53 exon 7 had been fully characterised (Chapter 4.1) we used a technique 
known as Single Stranded Conformational Polymorphism, Polymerase Chain 
Reaction (SSCP-PCR) to determine whether mutation had occurred in this 
exon in the experimentally induced papillomas.
SSCP-PCR is used to detect the presence of mutations in DNA and allows 
the analysis of large sample numbers with only the positive samples sequenced 
for mutations. Denatured SSCP-PCR samples are run on a non-denaturing 
polyacrylamide gel and the DNA adopts a single stranded conformation 
dependent on intramolecular interactions. The conformation of the DNA and 
therefore the mobility of the DNA on the gel is dependent on the nucleotide 
sequence. This method is capable of detecting a single point mutation in 99- 
100% of all samples screened (Hayashi, 1991).
SSCP-PCR analysis was also used to determine the status of the bovine p53 
gene from naturally occurring BPV-4 associated carcinomas and other lesions 
taken from experimentally infected cattle.
A normal control bovine DNA was used at all times and run on the gels as a 
denatured and non-denatured standard. Samples were run on 6 or 10% gels at 
room temperature or at at 4°C. Glycerol was added to the room temperature 
gels at a concentration of 5-10% to ensure maximum detection of mutations.
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Primary bovine foetal palate fibroblasts (PalF) transfected in vitro with 
BPV-4 were also analysed. DNA from the experimental papillomas described 
in Chapter 5.1 was prepared from paraffin sections (materials and methods 
section 3.1.10). Oligonucleotide primers were designed and SSCP-PCR 
carried out as described (materials and methods section 3.1.11) to amplify 
bovine p53 exon 7. Sequencing of positive samples was used to confirm the 
presence of p53 exon 7 mutations.
Results
Urinary bladder and alimentary canal cancers were available from a previous 
experiment designed to reproduce the synergism between BPV-4 and bracken 
in vivo (Campo et al, 1992; Campo et al, 1994a). From the above experiment 
DNA samples from animals 30 and 32 were examined. Both of these animals 
had received multiple inoculations of virus in the soft palate and were fed 
bracken fern. None of the cancers removed from animal 30 were found to 
contain BPV-4 DNA. The bladder cancer from animal 32 contained multiple 
copies of episomal BPV-2 DNA (Campo et al, 1992). Table 5.2.1 A lists the 
experimental samples described above. Table 5.2.IB lists the experimental 
papillomas as described in Chapter 5.1 and an experimentally induced 
pharyngeal papilloma from the same BPV-4 and bracken experiment as the 
cancers (Campo et al, 1992).
No mutations in bovine p53 exon 7 could be detected in experimental 
carcinomas. None of the cancer DNA tested in table 5.2.1 A demonstrated any 
change in their mobility on the non-denaturing gel with respect to the normal 
bovine control (Figure 5.2.1 A and B). Heteroduplex analysis was also carried
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Table 5.2.1 (on facing page)
Experimental papillomas and carcinomas examined by SSCP-PCR for the 
presence of p53 mutations in exon 7.
Table A, experimental carcinomas and B, experimental papillomas. The lesions 
described in table A, were previously examined for alterations in the bovine 
ras gene, and none could be detected (Campo et al, 1990).
DNA was isolated from either paraffin embedded sections of BPV-4 derived 
lesions (PE) or tumour tissue (D). The 116088 animals were infected with 
multiple inoculations of BPV-4 in the soft palate and received no other 
treatment. Animals 78529/30 and 32 were fed bracken fern and infected with 
BPV-4, animal 78529/9 was treated with the immunosuppressant azothioprine 
and infected with BPV-4 (Campo et al, 1992). All papillomas were removed 
from the palate with exception of the pharyngeal papilloma from animal 
78529/9. (X) indicates an as yet undetermined p53 mutation.
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ALane Animal no. Type of lesion p53 exon 7
1 78529/32 (134185) bladder carcinoma (D) wild type
2 78529/30(30/85) bladder carcinoma (D) wild type
3 78529/30 (30/85) colon adenoma (D) wild type
4 78529/30 (30/85) colon adenoma (D) wild type
5 78529/30 (30/85) lymph metastasis (D) wild type
6 78529/30 (30/85) small intestine 
adenoma (D)
wild type
B
Lane Animal no. Type of lesion (source) p53 exon 7
1 78529/9 pharyngeal papilloma (D) wild type
2 203 palate plaque (PE) wild type
5 116088/67E Stage I papilloma (PE) mutant (X)
4 116088/241 Stage I/O papilloma (PE) wild type
6 116088/227 Stage II papilloma (PE) wild type
7 116088/227 Stage n/ni papilloma (PE) wild type
8 116088/207 Stage El papilloma (PE) mutant (X)
3 116088/78 Regressing lesion (PE) mutant (X)
n o
Figure 5.2.1 (on facing page)
SSCP-PCR analysis of experimental carcinomas.
Figures A and B: Lanes 1 to 6 correspond to the samples described in table
5.2.1 A  Lane B indicates the normal control bovine genomic DNA Mobility 
of single stranded (ss) DNA and double stranded (ds) DNA are indicated by the 
arrows. Figure B is a close-up of the single stranded bands represented in 
figure A  PCR products labelled with [a-^^P]dCTP were electrophoretically 
separated on a 10% polyacrylamide run at room temperature in the presence of 
5% glycerol with a cooling fan for 16hours, 800V, constant current.
Figure C: Heteroduplex mapping of the above negative samples to confirm that 
no mutations in p53 exon 7 were present. Samples were run on a 0.5 X MDE 
gel with 10% glycerol at 6W constant power for 14hours.
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out on these samples to ensure optimum mutation detection within exon 7. In 
heteroduplex analysis, resolution is based on conformational differences in 
double stranded molecules (Keen et al, 1991) as opposed to single stranded 
molecules as utilised in the SSCP analysis. Analysis of the cancers using the 
heteroduplex technique also suggested that no alterations in the bovine p53 
exon 7 were present (Figure 5.2.1C).
Only the bladder cancer was found to contain BPV-2 viral sequences; the 
colon and small intestine adenomas are not associated with the presence BPV 
sequences (Campo et al, 1992; Campo et al, 1994a) and there appeared to be 
no detectable mutation in p53 exon 7. This does not rule out the possibility 
that mutations in other exons of bovine p53 are present or that inactivation of 
p53 by alternative mechanisms have occurred in these cancers. BPV-2 is a 
member of the subgroup A BPVs and does retain an E6 ORF. There is no 
evidence that BPV-2 E6 is capable of binding and degrading the p53 tumour 
suppressor, however, if this is possible then it would be expected that low 
levels of wild type p53 would be present as described for HPV positive 
carcinomas (Butz et al, 1995). The precursors of the colon and small intestine 
adenomas taken from the experimental animals are as yet unknown. These 
tumours have not been shown to arise as a result of BPV-2 or BPV-4 
associated infection but are often present in animals grazing on bracken fern 
with upper alimentary tract tumours (MS Campo; personal communication). 
They may have arisen as a direct aetiological effect of the cattle feeding on 
bracken fem. Bracken possesses immunosuppressants and cocarcinogens and 
the importance of cofactors in the progression of papillomavirus lesions has 
been reviewed (Jackson and Campo; 1995b) however, the effects from constant 
bracken feeding and absorption in the gut of the animal is unclear. Animals fed 
on bracken alone, are severely immunosuppressed and can suffer from acute
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bracken poisoning (Campo et al, 1992) and as previously demonstrated, these 
animals suffer from cytogenetic abnormalities (Moura et al, 1988). These 
tumours may arise in the gut mucosa as a result of exposure to many, as yet 
unknown, breakdown products of bracken fern.
Three of the experimental papillomas (Table 5.2. IB; figure 5.2.2), all of 
which had arisen as a result of infection with BPV-4, did demonstrate an 
altered mobility on the non-denaturing gels. The papilloma DNA samples in 
lane 1 (Figure 5.2.2A) and lanes 3 and 5 (Figure 5.2.2B) correspond to stage 
III, IV and stage I lesions respectively. Although these samples were 
sequenced, technical difficulties did not allow the mutation in each sample to be 
fully characterised (See figure 5.2.4C and D). Sequencing did however 
indicate that these samples may be heterozygous, suggesting that both a wild 
type and mutant gene were present (Figure 5.2.4D).
In Chapter 5.1, immunocytochemistry showed that the bovine p53 protein 
was stabilised. This stabilisation in the experimental stage I, III and IV 
papillomas, appears to be as a result of a mutation in exon 7 of the bovine p53 
gene. Mutant conformations of p53 proteins are known to be more stable and 
are detectable by immunocytochemistry (Iggo et al, 1990; Bartek et al, 1990a; 
Bartek et al, 1991). Although the other experimental papillomas did not 
appear to possess a mutation in exon 7, they may have as yet unidentified 
mutations in other exons.
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Figure 5.2.2 (on facing page)
SSCP-PCR analysis of experimental papillomas.
In lane 1 of figure 5.2.2A, the arrows (i and ii) indicate the presence of a 
second single stranded (ss) species and a decreased mobility of the double 
stranded (ds) DNA (iii). The sample in lane 1 corresponds to sample number 8, 
in table 5.2. IB. All samples in lanes 2 to 8 demonstrated the same pattern as 
the normal control bovine DNA (lane B) when overexposed.
The lanes in panel A and panel B correspond to papillomas described in table 
5.2.1B.
In lanes 1, 2, 4, 6, and 7, showed the same pattern as the normal control bovine 
DNA (lane B). Lane 7 is overexposed in this autoradiograph, however, a 
decreased exposure time confirmed that the mobility of the ss DNA was 
consistent with the normal control bovine DNA. The DNA sample in lane 3 
demonstrated the loss of the upper ss DNA band (arrow iv), and in lane 5, the 
ss band had an increased mobility (arrow v).
As described in figure 5.2.1, PCR products were labelled with [a-^^P]dCTP 
and were electrophoretically separated on was a 10% polyacrylamide gel, run 
at 4°C with no cooling fan at 800V, constant current for 17hours 
(autoradiograph shown in panel A); in panel B the samples were 
electrophoresed in lxMDE at at 4°C with no cooling fan at 800V, constant 
current for !5hours (autoradiograph shown in panel B).
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To compare the p53 status determined in the experimentally induced lesions, 
naturally occurring BPV-4 associated cancers and papillonas were obtained 
from diseased animals referred to the University of Glasgow Veterinary School 
from bracken infested areas. Table 5.2.2A and B, describe the cancers and 
papillomas examined. Figure 5.2.3A and B, illustrate the altered mobility of 
these samples on the non-denaturing SSCP-PCR gels. The majority of the 
cancers and the two papillomas examined did not possess alterations in the 
bovine p53 exon 7. Two metastases, both isolated from the same animal, were 
found to possess a mutation at bovine p53 codon 243 altering a proline residue 
to a threonine. The nucleotide sequence which encodes codon 243 in bovine 
p53 is altered from CCC to ACC (Figure 5.2.4A, B and C). Figure 5.2.4A 
depicts the wild type sequence 5'>3' for p53 exon 7 at codon 243. Figure 
5.2.4B and C illustrate the forward (5'>3') and reverse (5'<3') priming of p53 
exon 7 from the thyroid metastases DNA. An increase in the number of 
secondary species present in figure 5.2.4C is due to inadequate priming with 
the reverse primer LS7B (Methods Figure 3.1.11; Table 3.1.1 IB). The 
apparent heterozygosity may be as a result of the use of genomic DNA possibly 
contaminated with wild type p53 sequences. It is more likely this is due to self 
annealing by the LS7B primer which leads to repriming further along the DNA 
strand causing an increase in the secondary species present. The primary 
cancer of these metastases was not available for analysis.
30% of mutations in the p53 gene are located in CRIV which 
encompasses exon 7 in human cancers (Hollstein et al, 1991; Levine et al, 
1994; Cho et al, 1994). As previously mentioned in Chapter One, the 
importance of conserved region IV is apparent in that the L3 loop is required 
for DNA binding by p53.
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Table 5.2.2 (on facing page).
Naturally occurring papillomas and carcinomas examined for p53 mutations in 
exon 7.
DNA was isolated from either paraffin embedded sections of BPV-4 derived 
lesions (PE) or from tumour tissue (D). The activation of ras sequences in the 
cancers was previously determined by restriction enzyme and hybridisation 
analysis, and by DNA-mediated transformation of NIH3T3 cells (Campo et al, 
1990). The p53 status is indicated as either wild type or mutated at bovine p53 
residue 343 (P243T). nd - not determined.
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ALane Animal
no.
Type of lesion (source) ras activation p53
status
1 80931 rumen carcinoma (D) yes wild type
2 109594/J oesophageal carcinoma (D) n.d wild type
3 72856 rumen carcinoma (D) no wild type
4 74659 thyroid metastasis (D) no P243T
5 75668 cardia carcinoma (D) yes wild type
6 74659 lymph metastasis (D) no P243T
7 86168 rumen carcinoma (D) yes wild type
8 71078 oesophageal carcinoma (D) yes wild type
9 86168 kidney metastasis (D) yes wild type
10 17585 oesophageal carcinoma (PE) n.d wild type
B
Animal no. Type of lesion p53 status
229 alimentary papilloma (D) wild type
unknown alimentary papilloma (D) wild type
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Figure 5.2.3 (on facing page)
SSCP-PCR analysis of naturally occurring cancers and metastases.
Lanes correspond to samples described in table 5.2.2A.
In panel A, lanes 1,2 and 3,4 represent cancers number 4 and 5 in table 5.2.2A 
respectively. Lanes are alternate non-denatured and denatured samples. Lanes 
5 and 6 are the non-denatured and denatured normal control bovine DNA 
respectively.
In panel A, lane 1, arrow (i) indicates an extra single stranded species with an 
increased mobility. The decreased mobility of a second double stranded (ds) 
speciesis indicated by arrow (ii).
In panel B, lane 1 (sample 6 on table 5.2.2A), the single stranded species is 
absent and arrows (iii) and (iv) indicate two separate ds species in 
comparisonto one seen for the normal bovine genomic DNA control (C).
PCR products were electrophoresed on a 10% polyacrylamide gel at 4°C 
without cooling fan at 800V, constant current for 19hours.
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The adjacent AAs arginine R248 and R249 are critical in the contact with the 
minor groove of DNA bound by the core domain of the p53 protein (Cho et al, 
1994). Mutation of R248 results in the loss of critical DNA contacts which 
may destabilise the p53 DNA interaction (Cho et al, 1994). The p53 exon 7 
mutation found in the bovine metastases changed AA 243 from a proline (P) to 
a threonine (T). This corresponds to AA 250 in human p53 which is known to 
be altered in cancers (Hollstein et al, 1991) and is located in the L3 loop as 
determined by the crystal structure of human p53 (figure 1.4; Cho et al, 1994).
Proline is an aliphatic imino acid and has a secondary amine group, in 
contrast to the aliphatic hydroxyl group of the amino acid threonine (T). 
Proline leads to bending of the polypeptide chain and the substitution of P with 
T could result in an altered protein conformation disrupting the DNA binding 
domain. Although this mutation has not been tested in vitro, it could be 
suggested that the DNA binding function of bovine p53 could be abrogated by 
this alteration.
These data suggest that p53 mutations occur in exon 7 under certain 
experimental conditions and are more prevalent in papillomas than in 
carcinomas. Of the field cases analysed, only two mutations could be detected 
and these were isolated from a thyroid and a lymph node metastases taken from 
the same animal. Unfortunately, no normal tissue or material from the primary 
carcinoma of this animal was available for analysis, therefore it cannot be 
determined if this alteration is a polymorphism or a true mutation although 
alteration at this amino acid has been shown to occur in human cancer 
(Hollstein et al, 1991).
All samples that did not demonstrate any band shifts by SSCP-PCR 
analysis (Figure 5.2.1 A, B and C) possessed wild type p53  exon 7 sequence as 
determined by random sequencing of negative samples.
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Figure 5.2.4 (on facing page).
Electropherograms from ABI automated sequencer.
Panel A illustrates the wild type sequence (5*>3r) for bovine p53 exon 7 from 
nucleotides 725-733 (Dequiedt et al, 1995b). The arrow indicates the 
nucleotide which is altered in panel B.
Panel B illustrates the altered nucleotide sequence (5'>3') of bovine p53 exon 7 
found in the thyroid metastases as described in Table 5.2.2. The nucleotide 
which is altered from C to A causes a change from a proline to a threonine at 
bovine p53 residue 243 (Dequiedt et al, 1995b).
Panel C depicts the opposite strand (5'<3') of that indicated in panel B (see text 
page 117).
Panel D indicates sequence 'noise' and weak signals generated from DNA 
isolated from the cell line QOF24 (Table 5.2.3). This pattern was observed for 
the majority of sequences analysed when amplified from DNA purified from 
cell lines.
Panel E indicates the sequence generated from DNA isolated from the Stage III 
experimental papilloma (Table 5.2.1) which was positive for p53 exon 7 
mutation by SSCP-PCR. This pattern of sequence is indicative of 
heterozygous DNA, i.e., two p53 exon 7 DNA sequences are present. The 
arrowhead indicates the presence of a possible C to T transversion in the 
papilloma DNA sequence. This would suggest that a mutation is indeed 
present but the number of undetermined nucleotides (N) are too numerous to 
confirm the exact location of the mutation.
Maximum scale deflection is 1200 in all cases.
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Detection of bovine t>53 mutations in exon 7 in vitro
In vitro transfected PalF cell lines which had been previously characterised, 
(M Caimey, PhD thesis) were also analysed for the presence of a mutation in 
p53  exon 7. These cell lines are described in table 5.2.3. The role of bracken 
fern in alimentary canal cancer in cattle has been previously described (Jackson 
and Campo, 1995b; Campo and Jarrett, 1986; Jarrett et al, 1978) and the 
mutagenic component quercetin is known to confer tumourigenicicty to 
primary bovine fibroblasts in vitro (Pennie and Campo, 1992; Caimey and 
Campo, 1995). PalF cells transfected in vitro with BPV-4 whole genome or 
sub-genomic fragments and treated with the mutagen quercetin, known to be a 
component of bracken fem, a cofactor in BPV-4 associated carcinogenesis 
(Pennie and Campo, 1993; Caimey and Campo, 1995) were examined for 
mutations in p53  exon 7. Due to the absence of an E6 protein, it was possible 
that environmental cofactors may influence the status of the bovine p53  gene, 
and there may be a correlation, with respect to the p53 status, between lesions 
in vivo and transformed bovine cells in vitro.
In lanes 1, 8 and 10, the upper single stranded band (indicated by arrow (i) 
on figure 5.2.5) appeared to have a reduced mobility in comparison to the wild 
type pattern. The sample in lane 1 also appeared to have a double stranded 
doublet (indicated by arrow (ii) in figure 5.2.5) as opposed to a single double 
stranded band as observed for the wild type p53 exon 7 pattern. The samples 
in lane 5 and lane 12 (Figure 5.2.5) were considered positive as additional 
bands were present in lane 5 and on increased exposure only the lower single 
stranded band was evident in lane 12. Five out of the thirteen cell lines 
examined were found to contain a putativep53 exon 7 mutation (Figure 5.2.5), 
these data were not confirmed by sequencing analysis again due to technical
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difficulties (see Figure 5.2.4). However, the quercetin treated PalF cell lines 
examined for p53 mutation in exon 7, were found to possess a pattern similar 
to that illustrated in figure 5.2.4D suggesting that the samples may be 
heterozygous. No correlation could be drawn between the suspected exon 7 
mutations and quercetin treatment. An interesting observation is that p53 exon 
7 mutations did not appear in the cell line that was tumourigenic in nude mice. 
p53 exon 7 mutations in the in vitro transformed cell lines may have arisen 
spontaneously through continuous passage in culture. The cumulative effects 
due to the presence of cofactors in the progression of papillomas to cancers in 
vivo occurs over long periods of time. The ability of a single mutagenic 
component (quercetin) in bracken fern to mimic this function in vitro, is 
unlikely as quercetin exposure in the PalF cells is limited to 48 hours and would 
be insufficient to induce genetic changes over this short time period.
Cytogenetic analysis of quercetin treated PalF cells and screening with 
minisatellite probes did not detect any gross chromosomal changes (M Caimey; 
PhD thesis). The generation of p53 gene mutations in cell culture has been 
observed previously (Harvey and Levine, 1991; Rittling and Denhardt, 1992). 
Rat embryo fibroblasts transfected with HPV16E7 and ras occasionally 
sustained a recessive p53 mutation and acquired a selective growth advantage 
in culture (Peacock et al, 1990; Peacock and Benchimol, 1994).
No correlation could be found between treatment with quercetin, 
immortality or tumourigenicity of the PalF cells and the presence of a putative 
mutation in p53 exon 7. However, p53 mutations did seem to occur when 
subgenomic fragments of BPV-4 were expressed in the presence of quercetin. 
Since several of the cell lines did not possess p53 exon 7 mutations, it is possible 
that mutations are present in additional exons or that some other aspect of the 
pathway has been interrupted.
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Figure 5.2.5 SSCP-PCR of bovine p53 exon 7 from DNA extracted from 
BPV-4 transfected PalF cell lines described in table 5.2.3.
Lanes 1-13 correspond to sample numbers indicated in table 5.2.3, B 
indicates the normal bovine genomic DNA control.
Samples were electrophoresed on a lxMDE gel containing 5% glycerol, 
with cooling fan at 800V for 16hours at room temperature.
Conclusions and Discussion
Mutations were found in exon 7 of bovine p53 both in vitro  and in vivo. 
p53 mutations which result in the production of a disrupted protein are usually 
accompanied by a loss of heterozygosity (LOH), i.e, loss of the remaining wild 
type p53 allele (Levine et aly 1991). The technical difficulties encountered in 
sequencing p53 exon 7 for some of the samples may be attributed to the 
presence of both wild type and mutant p53 sequences. Mutation P243T in the 
bovine metastases was easily detected and may indicate that only a mutant p53 
sequence was present. It could be suggested that perhaps the remaining wild 
type p53 allele has been lost from these metastases. This p53  mutation may 
encode a disrupted p53 protein and as mentioned, this mutation may abrogate 
the ability of p53 to bind DNA, however, this mutation has not yet been tested 
in vitro.
All of the non-BPV-4 associated lesions possessed a wild type p53 
exon 7 as did normal palate, control PalF cells and liver DNA. Two of the 
metastatic tumours from the group of field cases of alimentary tract cancers 
were found to have an alteration in p53 exon 7. Of the experimental 
carcinomas which were not associated with BPV-4, none were mutated in 
exon 7.
A summary of the data on exon 7 p53 mutations from the previous tables is 
given in table 5.2.4.
None of the experimental carcinomas indicated the presence of a mutation in 
p53 exon 7, however, 38% of the experimental papillomas, which had been 
subjected to high titres of virus only, demonstrated mutations in exon 7 as 
determined by SSCP-PCR. Overexpression of the bovine p53 protein had been 
previously detected at all papilloma stages as described in Chapter 5.1. This
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overexpression correlated with a mutation in p53 exon 7 for the stage I, HI and 
IV papillomas. Although no mutations were detected in the remaining 
experimental papillomas, a strong correlation has been observed between high 
level expression of the p53 protein and point missense mutations in the p53 
gene in other systems (Iggo et al, 1990; Bartek et al, 1990a, 1990b; Bartek et 
al, 1991). This would suggest that mutations may be present in other exons of 
the bovine p53 gene not identified in this study.
p53 mutations could not be detected in naturally occurring papillomas, 
however, 20% of the naturally occurring carcinomas examined were positive 
for mutation in p53 exon 7. The absence of mutations in the experimental 
carcinomas may be a result of contamination with residual wild type p53 arising 
from normal tissue which was excised with the tumour, or that mutations may 
exist in other exons. This could also explain the inability to detect p53 
mutations in the majority of field cases. The fact that p53 mutations are 
prevalent in exon 7 in experimental cases of papillomas may reflect the 
difference between animals which receive high doses of virus experimentally 
and persistent infection over many years in naturally occurring cancers. 
Alterations in the ras gene appear to be more prevalent than p53 mutation in 
the field carcinomas although the exact exon in which bovine ras is mutated has 
not been determined.
The data accumulated suggests that mutations in p53 exon 7 are not a result 
of the cocarcinogens and mutagens present in bracken fern. The animals from 
which the experimental papillomas came, had not been fed bracken fern, yet 
high levels of p53 protein were detected. In the case of the transfected cell 
lines, there appeared to be no correlation between exon 7 mutation and 
treatment with the mutagen quercetin. Although the presence of cofactors is a 
requirement for progression, it could be suggested that these p53 mutations
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have not arisen as a result of a single specific mechanism, i.e., the presence of 
environmental cofactors, but as a spontaneous event.
No.tested No.positive p53 exon 7 mutation
Experimental
papillomas
8 3 Unidentified
Experimental
carcinomas
6 0 None
Field cases of 
papillomas
2 0 None
Field cases of 
carcinoma
10 2 P243T
Cell lines 13 5 Unidentified
Table 5.2.4 Summary of the p53 exon 7 mutations present in various BPV 
derived lesions as determined by SSCP-PCR analysis.
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5.3 Cellular amplification
Introduction
As described in Chapter One, the B subgroup of the BPVs lack an E6 ORF, 
the product of which is responsible for p53 binding and degradation in the 
HPVs. In the previous chapter, we demonstrated that some BPV-4 induced 
papillomas and cancers had a p53 mutation in exon 7, although we did not 
know if p53 gene was altered in other exons. Most of the tumours possessed a 
wild type p53 exon 7 sequence. It is possible that the p53 gene may be 
mutated in other exons or that alternative mechanisms of p53 inactivation may 
have occurred in tumours as a result of the lack of an E6 protein. BPV-4 has 
been found to induce cellular amplification of ARS sequences (Smith et al, 
1993; Smith and Campo, 1989), and abrogation of wild type p53 is known to 
be accompanied by cellular amplification of mdm-2 in many human sarcomas 
(Oliner et al, 1992; Ladanyi et al, 1993). The human mdm-2 is a single copy 
gene which is amplified in human tumours, therefore, the genomic copy number 
of the bovine mdm-2 gene in several BPV induced lesions was evaluated.
Several papillomas and cancers which have been characterised in Chapter 
5.2, were chosen for analysis of the bovine mdm-2 gene. The samples were as 
follows; the thyroid and lymph node metastases (Table 5.2.2A), two 
experimentally induced lesions (a cancer of the bladder and a colon adenoma; 
Table 5.2.1 A), and two naturally occurring oesophageal papillomas (Table 
5.2.2B). The mdm-2 status in an adenomatous plaque and normal control 
bovine liver DNA was also determined.
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Results
DNA samples from BPV associated papillomas and carcinomas were 
examined and the DNA was digested overnight with either of the restriction 
enzymes Hindm or EcoRI. Southern hybridisation was carried out using a 
human mdm-2 fragment cDNA probe (nt 161-1283) (Figure 5.3.1a). 
Fakarazedeh et al (1991) showed that the mdm-2 gene is conserved across 
species. The Southern blot was stripped by washing in boiling 0.1% SDS and 
reprobed with a 500bp fragment of the c-Ha-ras-3 pseudogene isolated from a 
3.1kb BamHI fragment of bovine genomic DNA (McCaffrey et al, 1989) 
(Figure 5.3. IB). The bovine Ha-ras-3 sequence contains no introns and is 
believed to be a non-fiinctional processed pseudogene (McCaffrey et al, 1989). 
Bovine Ha-ras-1 is altered in bovine cancers of the alimentary canal as 
previously mentioned (Campo et al, 1990). c-Ha-ros-3 hybridised to two 
fragments in the EcoRI digested bovine genomic DNA of 4.3kb and 2.3kb 
(Figure 5.3.IB) as described by McCaffrey et al, (1989). The human mdm-2 
cDNA probe hybridised to three fragments at approximately 8kb, 4kb and 
2.1kb respectively (Figure 5.3.1 A). The fragment indicated at 1.3kb (Figure 
5.3.IB) coincided with a satellite DNA band in the ethidium bromide stained 
gel suggesting that satellite-like repetitive sequences were present in the probe 
(Figure 5.3.1 A). The mdm-2 gene is known to possess highly repetitive Alu 
sequences at the 3' end of the gene (B. Vogelstein; personal communication) 
and although the cDNA probe was digested to avoid this region, incomplete 
digestion of the DNA may have resulted in carryover of these sequences during 
purification of the insert.
The above experiment was repeated using the Hindlll restricted DNA which 
was hybridised with the human mdm-2 fragment cDNA probe (Figure 5.3.2A),
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Figure 5.3.1 Southern hybridisation of EcoRI digested bovine tumour DNA 
with the human mdm-2 gene and the bovine pseudo-ras-3 gene.
In lanel: EcoRI digested DNA from thymus tumour, lane 2: adenomatous 
plaque, 3: irregular lymph node, 4: adenoma, 5: bladder carcinoma,
6: alimentary papilloma, 7: alimentary oesophageal papilloma.
Bov: normal bovine liver genomic DNA.
In panel A, the arrow indicates the minisatellite band present at 1.3kb in the 
ethidium bromide stained gel. Panel B illustrates the three bands 
for EcoRI digested bovine DNA southern hybridised with the mdm-2 
gene, panel C shows the 4.3kb and the 2.3kb fragments of the bovine 
pseudo-ras-3 gene.
no satellite sequences were present on the ethidium stained gel. The Southern 
blot was stripped and reprobed using a cDNA encoding exon 2 of the mouse 
glyceraldehyde-3-phosphate dehydrogenase gene (gapdh) (Figure 5.3.2B).
The bovine mdm-2 gene appears to be about 13-14kb in size as determined 
by the size of the fragments resulting from the restriction digests (Figure
5.3.1 A and figure 5.3.2A). The human mdm-2 gene is approximately 16kb in 
size (Oliner et al, 1992).
No amplification of the bovine mdm-2 gene was apparent in either the 
EcoRI cut (Figure 5.3.1) or the Hindlll cut (Figure 5.3.2) bovine DNA with 
respect to the loading control. To confirm this, densitometry was carried out on 
the original autoradiographs as shown in figure 5.3.2. The autoradiographs 
were scanned using an ARCUS II (420oe) scanner and analysed by the 
Quantity One gel analysis program (PDI, Inc.). The O.D of three equivalent 
regions with a scanning width of 5mm on the autoradiograph, were analysed 
for each lane and the peak O.D calculated. The tracing of the bands analysed in 
lane 6 on both figures 5.3.2 A and B, were twelve-fold greater than those 
bands in lanes 1, 5 and 7 (Figures 5.3.2A and B).
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Figure 5.3,2 Southern hybridisation of Hindlll digested bovine tumour DNA 
with the human mdm-2 an d  the mouse gapdh gene.
Panel A a n d  B illustrate the bands  (indicated by the arrows) after southern 
hybridisation with mdm-2 cDNA probe (A), a n d  the mouse g a p d h  cDNA 
probe  (B).
Lane 1, bovine liver genomic DNA; lane 2, DNA from thymus tumour; 
lane 3, a d e n o m a to u s  plaque; lane 4, irregular lymph node; lane 5, a d e n o m a ;  
lane 6, b ladder  carcinoma;  lane 7, alimentary papilloma; Iane8, alimentary 
o eso p h ag ea l  papilloma,
Conclusions and Discussion
The mdm-2 gene is known to be amplified and act as an oncogene in human 
sarcomas (Oliner et al, 1992; Ladanyi et al, 1993). This amplification lead to 
the mdm-2 protein binding the tumour suppressor p53 (Oliner et al, 1992), 
preventing the p53 DNA binding activity (Zauberman et al, 1993) and p53 
mediated transactivation (Momand et al, 1992). It was not clear what the 
status of the bovine mdm-2 gene would be, and the copy number of the mdm-2 
gene was analysed in BPV associated papillomas and carcinomas by southern 
hybridisation using the human mdm-2 fragment cDNA probe. Of the lesions 
tested, in both BPV-4 related and non-BPV associated, the mdm-2 gene was 
not amplified. Amplification at the transcriptional level cannot be ruled out, as 
in some leukaemias mdm-2 mRNA levels were increased (Buesos-Ramos et al, 
1993) although expression of the bovine mdm-2 mRNA was not assessed. In 
tumours expressing high levels of mdm-2, p53 is generally found to be wild 
type. Our data suggest that in the lesions examined, only the thyroid metastases 
was previously shown to possess a mutation in exon 7, the remaining lesions 
had a wild type p53 gene, at least in exon 7.
It was concluded that in vivo, both the BPV-4 and non-BPV related 
tumours did not possess any alteration in the copy number of the bovine mdm-2 
gene. Further investigation of the mdm-2 status in other BPV-4 associated 
lesions is required in order to confirm these observations. If p53 mutations are 
present in other exons, it would be expected that no amplification of the bovine 
mdm-2 gene would be detected.
138
CHAPTER 6
In vitro analysis of the effect of an exogeneous m utant p 5 3  and HPV-16E6 
Introduction
BPV-4 does not possess an E6 oncoprotein (Jackson et al, 1991), and one 
of the original questions asked was, does BPV-4 lack E6 associated functions 
and can an exogeneous HPV-16E6 (16E6) confer additional functions in vitrol 
Previous experiments have demonstrated that the addition of 16E6 to 
BPV-4 transfected PalF cells in vitro confers immortality (M Caimey, PhD 
thesis, Pennie et al> 1993). This also raises the question as to whether these 
functions are a result of p53 inactivation or are there other functions of 16E6 
involved. Two approaches were taken to investigate whether mutant p53 
could enhance transformation by BPV-4; to cotransfect an exogeneous mutant 
p53 with BPV-4 into PalF cells (Chapter 6.1), and to cotransfect BPV-4 and 
16E6 into cells from p53 deficient mice to determine if additional 16E6 
functions were p53 independent (Chapter 6.2).
The following experiments were carried out in parallel with the analysis of 
the p53 status and so a human mutant p53 cDNA was used due to the lack of a 
bovine mutant cDNA.
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6.1 In vitro transfection of primary bovine foetal palate fibroblasts fPalFl
The p53 gene is commonly mutated in human carcinogenesis and p53 
protein inactivation appears to be involved in tumourigenesis associated with 
the high risk HPVs 16 and 18 (reviewed in Vousden, 1993), but does it play a 
part in BPV-4 associated carcinogenesis?
BPV-4 DNA transfected in the presence of an activated human Ha -ras, is 
capable of partially transforming PalF cells in vitro. On addition of an 
exogeneous 16E6 these cells become immortal.
The p53-SCX3 mutant human p53 cDNA from colorectal tumour CX-3, 
(Baker et al, 1990) is altered in exon 5 at codon 143 and valine is substituted 
by alanine (V143A). Table 6.1.1 lists the known functions of this mutant 
p53(V143A).
This construct was cotransfected into PalF cells in combination with BPV-4, 
ras and HPV-16E6(16E6) to determine the effect of adding an exogeneous 
mutant p53. HPV-16E6 was included in the transfection as previous 
experiments demonstrated a requirement for 16E6 to confer immortality to 
PalF cells.
It may be that mutant p53 can substitute for 16E6 functions in PalF cells in 
vitro and perhaps provide them in vivo.
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p53 (V143A) Reference
Found in human colon cancer Baker et al, 1990
Decreased ability to bind DNA Kern et al, 1991b
Can substitute for 16E6 in the immortalisation of 
human keratinocytes
Sedman et al, 1992
Stimulates expression of the MDR1 gene Dittmer et al, 1993
Tumourigenic in murine fibroblast cell line (10)3 Dittmer et al, 1993
Did not affect the growth of the non-tumourigenic 
adenoma derived cell line AA/C1
Williams et al, 1994
Table 6.1.1 Characterised features of the human mutant cDNA p53 SCX-3 
(VI43 A).
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Results
PalF cells were cotransfected with BPV-4, ras, 16E6 and mutant p53 
(V143A) as described (materials and methods section 3.2.3), the cells were 
selected with 500pg/ml G418 and the resulting colonies picked and analysed 
for transformation. The data for the PalF transfections are indicated in table 
6.1.2.
No colonies were established from cells transfected with pZipneo alone, nor in 
the cells transfected with wild type human p53 regardless of the other 
oncogenes present (PFG; Table 6.1.2). Wild type p53 has been previously 
shown to suppress transformation by oncogenes in primary rat embro 
fibroblasts and human foreskin keratinocytes (Eliyahu et al, 1989; Finlay et al, 
1989; Sedman et al, 1992). It is unclear whether the lack of colony formation 
in the presence of wild type p53 is a result of apoptosis or a toxic effect due to 
overexpression of wild type p53. Expression of an exogeneous wild type p53 
can induce apoptosis in p53 negative myeloid leukemia cells (Yonish-Rouach et 
al, 1991), human colon carcinoma cells (Shaw et al, 1992) and murine 
erythroleukemia cells (Ryan et al, 1993). It is possible that this apoptotic 
response results in the inhibition of colony formation in PalF cells.
When mutant p53 was included in the transfection (Table 6.1.2; PFD and 
PFF), two-three times as many colonies were produced in comparison to cells 
transfected without mutant p53 (Table 6.1.2; PFA and PFB) suggesting that 
mutant p53 enhances cell transformation. Sedman et al (1992) demonstrated 
that the cotransfection of p53(V143A) with 16E7 stimulated proliferation in 
human foreskin keratinocytes, whereas cotransfection of wild type p53 with 
16E6 or 16E7 did not induce proliferation.
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The extent of transformation was measured as four separate parameters; 
morphological transformation, anchorage independent growth, immortality and 
tumourigenicity in nude mice. Figure 6.1.1 illustrates the morphological 
transformation of the transfected PalF cells. Cells which were morphologically 
transformed grew as raised clusters (Figure 6.1.1B-D), whereas untransformed 
cells continued to grow as a monolayer on the surface of the flask (Figure
6.1.1 A). Six clones were picked from each flask containing transformed 
colonies for further analysis. Only a few colonies grew in the flasks containing 
PalF cells transfected with neomycin resistant plasmid pZipneo. The pZipneo 
colonies remained flat and it was not possible to expand these colonies for 
more than several passages. No colonies formed in any of the transfections 
containing an exogeneous wild type p53.
Clones were tested for the ability to grow in 1% methocel. Figure 6.1.2 
illustrates those clones which were capable of anchorage independent growth.
Untransfected PalF cells and those transfected with ras alone, were not 
capable of growth in soft agar. The PFA, PFB, PFC, PFD and PFF cell lines 
were all capable of anchorage independent growth as was the control cell line 
C4Ta2a. When 16E6 was present in addition to BPV-4 and ras (PFB), the 
anchorage independent colonies appeared to be larger in size in comparison to 
PFA To determine if this difference in colony size was a function of an 
increased rate growth, these transformed cell lines were analysed using the 
M IT  assay (materials and methods section 3.2.4.2), in which the O.D 
measurement is proportional to the number of cells present. Figure 6.1.3 
shows the MTT assay data and the rates of growth of the transformed cell 
lines.
When 16E6 was present in the transfection (Table 6.1.2; PFB and PFF), the 
growth rates were significantly higher than in the other transfected cell lines
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Figure 6.1.1 Examples of morphological transformation of transfected 
PalF cells.
Cells were stained with 10% Giemsa and photographed using PanF50 film. 
Panel A; untransfected PalF cells, panel B; PalF cells transfected with 
mutant p53(V143A) and ras, panel C; PalF cells transfected with mutant 
p53(V143A), BPV-4 and ras , and panel D; PalF cells transfected with 
mutant p53(V143A), BPV-4, ras and HPV-16E6.
Magnification X 125.
Figure 6.1.2 (on facing page)
Anchorage independent growth of transfected PalF cells.
1x10^ cells from each cell line was added to 1% methocel and grown for 14 
days at 37°C. Untransfected PalF cells or cells transfected with ras alone were 
not capable of growth in soft agar (A and B). PalF cells transfected with 
BPV-4 and additional oncogenes were capable of growth in soft agar (C-G). 
C4Ta2a is the tumourigenic cell line used a a positive control (H).
The bar in panel G indicates lOOnm. Magnification X 60.
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PFA and PFD (Figure 61.3). Mutant p53 did mo t appear to substitute for this 
16E6 function (PFD)orto enhance the growth iraite as no significant difference 
was observed between tie PFB and the PFF celll llines. It may be possible that 
this increase in growtl provided by 16E6 cdo»es not function via a p53 
dependent pathway.
All of the clones teSed were immortal witlh the exception of PFA which 
confirmed previous obsevations that an additiomall function can be provided by 
16E6 and is a requiremeit for immortalising PallF cells (M Caimey, PhD thesis; 
Pennie et al, 1993). Hovever, in the absence o>f 16E6, mutant p53 could also 
immortalise PalF cells wien cotransfected with E3PV-4 and ras (PFD).
The transfected PalF cell lines were foundl tto be capable of anchorage 
independent growth as siown in figure 6.1.2, however, only the PFF cell lines 
were tumourigenic in nule mice (Table 6.1.2; Fijguire 6.1.4).
Subcutaneous injectioi of nude mice with celll liines PFC and PFD resulted in 
the appearance of small lodules which disappeared after three to four weeks. 
This is indicative of a naction at the site of imjection and not as a result of 
tumour formation. The JFF clones tested howewe;r, were tumourigenic and the 
tumours persisted for loiger than 12 weeks. Tuimours arose in the nude mice 
within 3 weeks and reacled a maximum size of 7-<8mm in diameter at 8 weeks 
then regressed slightly renaming at approximately 5mm in diameter. Animals 
displaying no tumours ater 12 weeks were considered tumour free. Thus, in 
the absence of 16E6 Pal7 cells were not tumouirigenic in nude mice and 16E6 
was still providing additbnal functions that BPW-4 lacked in vitro even in the 
presence of mutant hum;n p53. The tumours which had arisen as a result of 
inoculation of the mice vith the PFF cell line, w ere  excised from the mice and 
embedded in parafin wax for immnnnohistochemical analysis.
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Figure 6.1.3 (on facing page)
Growth rates of transfected PalF cells as determined by M IT assay. 
Graph A PalF cells transfected with BPV-4, ras and HPV-16E6. 
Graph B as for graph A with the addition of mutant p53 (V143A). 
Control PalF cells were analysed at passage 3.
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Figure 6.1.4 (on facing page)
Tumourigenicity of transformed PalF cell lines in nude mice.
No tumours were present after 12 weeks in mice inoculated with untransfected 
PalF cells or the non-tumourigenic cell lines (A). The PFF cell line was 
transfected with BPV-4, ras, 16E6 and mutant p53 was positive after 12 weeks 
(B). The tumourigenic cell line C4Ta2a was used as a positive control (C). 
Arrows indicate tumours, bar indicates 1cm.
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The transfected cell lines were analysed by Northern hybridisation for the 
expression of the viral E7 and E8 mRNAs. Expression of p53 and the bovine 
cellular ductin transcripts were also examined. Ductin is a 16kd proteolipid of 
the vacuolar H+-ATPase and is also a constituent of the connexon channel of 
gap junctions. PalF cells transformed with BPV-4 E8 show a reduction in 
cell-cell communication and ductin is known to bind to BPV-4 E8 in vitro 
(Faccini et al, 1996). Ductin interactions are thought to play a role in gap 
junctional intercellular communication (GJIC) and it is possible that in 
tumourigenic cell lines, the cells have lost the ability to communicate and ductin 
expression may be altered.
E8 mRNA was expressed only in the PFF cell lines which were 
tumourigenic (Figure 6.1.5A). No E8 mRNA could be detected in any other 
cell lines. E7 mRNA could be detected in all of the cell lines but not in 
untransfected PalF cells (Figure 6.1.5B). All of the cell lines expressing E7 
and E8 were transfected with whole genome BPV-4 DNA.
p53 transcripts were only detected in those cell lines which had been 
transfected with p53 (VI43A) suggesting that only mutant p53 was expressed 
at detectable levels and not the endogeneous wild type p53 (Figure 6.1.6A). 
Figure 6.1.6A illustrates three cell lines transfected with p53(V143A) which do 
not appear to express mutant p53, however, a longer exposure of the 
autoradiograph revealed that p53 transcripts were indeed present and these cell 
lines were also positive.
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Figure 6.1.5 Northern blot analysis of transfected PalF 
cell lines. Panel A E8 mRNA, panel B E7, and panel C 
7s RNA loading control.
- + + + + + + + + p53 (V143A)
- - + + + + + + + BPV-4
+ + + HPV-16E6
_ + + + + + + + + ras
p53 
(V143A)
B
4  28s
18s 
•4 ductin
<4  7s
Figure 6.1.6 Northern blot analysis of transfected PalF cell lines. 
Panel A depicts RNA hybridised with the mutant p53 (V143A) probe, 
panel B illustrates RNA hybridised to the bovine ductin cDNA probe 
1.3kb fragment, 18s and 28s indicate the rRNA fragments, and 
panel C 7s RNA loading control.
The 1.3kb ductin mRNA was unaltered (figure 6.1.6B) with respect to the 7s 
RNA loading control, however, another mRNA of 2.1kb in size was observed. 
This mRNA was apparent in cell lines which had been previously found to be 
expressing the E8 mRNA (tumourigenic cell line PFF). The 2.1kb mRNA was 
also present in the cell line PFC transfected with mutant p53 and Ha-ras 
(Figure 6.1.6B). It is possible that this may be a connexin/ductin homologue or 
a splice variant of the ductin message. As the 2.1kb mRNA was detected in 
certain cell lines, including those expressing £ 8, it is possible that this 
unidentified mRNA may be involved in the loss of GJIC in cells and possibly be 
induced as a result of E8 expression. Another possibility is that mutant p53 
and not E8 may induce the 2.1kb mRNA as it was observed in cell line PFC 
albeit at a lower level than PFF. The 2.1 kb mRNA was not apparent in any of 
the other cell lines transfected with mutant p53, i.e, PFD, however, it is 
possible that the 2.1kb mRNA is present in all cell lines but expressed at 
different levels. Budunova et al (1995) showed that three gap junction 
proteins, connexins 26, 43 and 31.1 are differentially expressed during mouse 
skin carcinogenesis. Connexin 26 mRNA was not expressed in untreated 
mouse epidermis but was found to be increased 45-50 fold in the hyperplastic 
epidermis of TPA treated mice and in papillomas of DMBA/TPA treated mice. 
Budunova et al (1995) suggested that gap junctions composed of different 
connexins may work as selective filters for growth factors and secondary 
messengers of different signal transduction pathways.
This 2.1kb mRNA may provide evidence of novel expression during loss of 
cell-cell communication in PalF cells and may be important in BPV-4 
associated carcinogenesis. Other components of gap junctions may be altered
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Figure 6.1.7 (on facing page)
Detection of the BPV-4 and cellular transforming proteins in PFF induced 
tumours.
Nude mouse tumour section incubated with BPV-4 genomic probe (A) by in- 
situ hybridisation. Immunoperoxidase detection of p53 (B), E8 (C) and E7 (D) 
with primary antiserum and competed antiserum (E).
Magnification X 100.
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in these cell lines which have not yet been characterised and this unidentified 
mRNA is currently being investigated by a research group in the Beatson 
Institute for Cancer Research.
Therefore, although E8 mRNA levels are increased, ductin RNA is not 
altered, thus ductin transcript levels do not vary in tumourigenic cell lines and 
ductin may be altered post-translationally.
As viral transcripts were detected in the tumourigenic cell lines, PFF, the 
excised tumours from the mice were analysed for the presence of viral E7 and 
E8 proteins, viral DNA and p53 protein (Figure 6.1.7). E7, E8 and p53 were 
detected by immunocytochemistry (Figure 6.1.7D, C and B respectively), but 
no viral DNA was detected by in-situ hybridisation (Figure 6.1.7A). As 
mentioned in Chapter Four, in-situ hybridisation is limited to the detection of 
greater than 30 copies of viral DNA per cell, therefore, viral copy number may 
be below the limits of detection in these tumours. Immunoperoxidase detection 
(Figure 6.1.7B-E) confirmed that the viral proteins are continuously expressed 
after inoculation into the nude mouse.
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Conclusions and Discussion
In parallel with the analysis of naturally occurring and experimental 
tumours in cattle, experiments were carried out to test the role of mutant p53 
and HPV-16E6 in in vitro transformation by BPV-4. At this time, the bovine 
cDNA had not yet been cloned and the human mutant p53 cDNA (V143A) was 
available. In the presence of ras and HPV-16E6 (16E6), cells transfected with 
BPV-4 and mutant p53 became tumourigenic in nude mice. Without 16E6 
these cells were not tumourigenic, however, in the absence of mutant p53 the 
cells were not tumourigenic either. The BPV-4 and ras transfected PalF cells 
were immortal in the presence of either mutant p53 or 16E6. Previous data 
demonstrated that 16E6 is required to confer immortality to PalF cells 
transformed with BPV-4 and ras (Pennie et al, 1993; M Caimey, PhD thesis). 
16E6 cooperates with E7 to immortalise primary human foreskin keratinocytes 
in vitro (Sedman et al, 1991). Sedman et al (1992) have also shown that 
transfection of human keratinocytes with 16E7 and the mutant p53 (V143A), 
can substitute for 16E6 in an immortalisation assay. Mutant p53 substituted for 
this E6 function lacking in BPV-4 in vitro and could replace the lack of an E6 
ORF in vivo. Storey et al (1995) have demonstrated that the expression of an 
inducible 18E6 and EJ-ras results in the immortalisation of baby mouse kidney 
cells (BMK). In the absence of dexamethasone-induced 18E6, the cells 
arrested at the G0/G1 point of the cell cycle. This may explain the requirement 
for 16E6 to immortalise PalF cells. Storey et al (1995) also showed that those 
18E6 dependent clones which reverted to dexamethasone independent growth, 
possessed a mutation in one of the p53 allelles supporting previous reports that 
mutations in the p53 gene can substitute for E6 functions in BMK cells (Storey 
and Banks, 1993). Mutant p53 has been implicated in the immortalisation
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process in cell culture (Harvey and Levine, 1991; Rittling and Denhardt, 1992). 
Ulrich et al (1992) showed that the loss or mutation of p53 correlated with the 
immortalisation of v-src transformed chick embryo fibroblasts and the 
expression of a foreign mutant p53 promoted the immortalisation of rodent 
fibroblasts (Jenkins et al, 1984; Rovinski and Benchimol, 1988). Thus 16E6 
and mutant p53 appear to have distinct pathways by which they can both 
immortalise cells. Both of these pathways are functional in BPV-4 transformed 
cells in vitro, therefore although BPV-4 lacks an E6 protein in vivo, the 
presence of a mutant p53 could replace this missing function. This is supported 
by the findings that BPV-4 induced papillomas and carcinomas possess p53 
mutations in exon 7 although these mutants have not been tested in vitro.
The requirement of both 16E6 and mutant p53 for tumourigenicity in vitro 
suggested that BPV-4 lacks more than one function required for cellular 
transformation. Certain p53 mutants are thought to inhibit the growth 
suppressive properties of wild type p53 by forming inactive hetero-oligomers 
(Eliyahu et al, 1988; Finlay et al, 1989; Rovinski and Benchimol, 1988) and it 
may be that the formation of heterocomplexes of mutant and wild type p53 are 
necessary for tumorigenicity of BPV-4 transfected PalF cells in vitro. 
p53(V143A) is no longer capable of binding DNA (Kern et al, 1991b) 
however, the mutant protein may still retain the ability to bind other cellular 
factors to form active complexes which can affect the transcription of target 
genes. Desaintes et al (1995) showed that wild type p53 could repress 
transcription of HPV, the mutant p53(V143A) exhibited no repression of HPV 
transcription. This would suggest that p53(V143A) may not affect the 
transcription of BPV-4 genes in vitro and contributes to transformation via 
other mechanisms. Thus, although p53 and 16E6 appear to have independent 
pathways which lead to immortality, the requirement for both p53 and 16E6 to
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confer tumourigenicity to PalF cells in the presence of BPV-4 suggests that 
these pathways are complementary. Possible mechanisms by which mutant p53 
and HPV-16E6 contribute to both immortality and tumourigenicity will be 
discussed in Chapter Seven.
Analysis of the growth rates of the BPV-4 transformed cell lines showed 
that 16E6 contributed a growth advantage regardless of the presence of mutant 
p53. This function may be p53 independent, as Ishiwatari et cd (1994) showed 
that degradation of p53 is not sufficient for a growth stimulatory effect in 
human embryonic fibroblasts.
Both E8 and E7 mRNAs were found to be expressed in the tumourigenic 
cell lines, and E8 and E7 proteins were detected in the tumours.
Liu et al (1995) have shown that levels of E7 expression in baby rat kidney 
cells correlate with its transforming potential. The presence of mutant p53 or 
16E6 may induce an increase in BPV-4 E7 levels leading to enhanced 
transformation. Crook et al (1991c) showed that mutant p53 potentiated the 
transforming functions of E7 in baby rat kidney cells. Their data suggested that 
E7 and p53 function in separate yet complementary pathways. Coexpression 
of E6 is known to increase levels of E7 (Halbert et al, 1991) and 
transformation appears to depend on enhanced expression of viral genomes. 
This has been demonstrated with the use of glucocorticoids (Pater et al, 1988) 
and strong heterologous promoters (Kanda et al, 1988). Thus increased levels 
of E7 mRNA and hence protein, can lead to accelerated transformation.
Expression of E8 and the loss of gap junctional communication may 
contribute to tumourigenicity. Initiated cells which have lost their ability to 
communicate with the surrounding normal cells are important for the clonal 
expansion of a population of cells capable of progressing. Although no direct
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interaction between ductin and E8 has been observed in PalF cells, expression 
of E8 protein in the tumours extracted from the nude mice may indicate that 
these cells have lost their ability to communicate.
The presence of viral DNA is not required for maintenance of the 
transformed phenotype and is not detected in BPV-4 associated cancers 
(Campo et al, 1985). Viral proteins were detected in the nude mouse tumours 
confirming the presence of viral DNA, although no DNA was detected by the 
in-situ technique used. The short term culture of PalF cells in vitro may not 
mimic latent BPV-4 infection in vivo, and the presence of viral DNA may still 
be required to maintain the cell phenotype. These tumours may represent an 
intermediate stage of transformation which supports viral replication and viral 
protein production. Loss of viral DNA may be a consequence of long term 
transformation in combination with an accumulation of genetic alterations in 
vivo.
Thus, BPV-4 appears to lack several functions in vitro which can be 
provided by HPV-16E6 and mutant p53. These functions appear to be 
separate but can interact to enhance transformation.
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fb l Additional functions provided bv 16E6 in transformation bv
BPV-4 in vitro.
The addition of an exogeneous 16E6 is required to confer immortality 
to BPV-4 transfected PalF cells in vitro and this function can be substituted by 
the addition of mutant p53. It is apparent that p53 mutations may be present in 
vivo, and BPV-4 is still lacking functions in vitro which can be provided by 
16E6. PalF cells only become tumourigenic when both 16E6 and mutant p53 
are present suggesting that the additional 16E6 functions are independent of 
the p53 growth suppressive pathway. To establish if 16E6 was capable of 
cooperating with BPV-4 in the absence of a functional p53 gene, p53 deficient 
mouse fibroblasts were transfected with BPV-4, ras and 16E6 as described 
(materials and methods section 3.2.3). p53-deficient mice were derived by the 
introduction of a null mutation into the p53 gene by homologous recombination 
(Donehower et al, 1992). Fibroblast cultures were derived from the skins of 
these homozygous p53 null mice as described (materials and methods section 
3.2.2).
Bgsults
In all transfections, the cells were morphologically transformed (Figure 6.2.1 
B-H) in comparison to the untransfected p53 deficient fibroblasts (Figure
6.2.1 A) and as described in table 6.2.1 A. However, in cells transfected with 
16E6 alone, the colonies had a much flatter appearance than the other 
transformed cells (Figure 6.2. IB). BPV-4 and 16E6 cooperated to produce
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Figure 6.2.1 (on facing page)
Morphological transformation of transfected p53 deficient fibroblasts. 
The cells were transformed when transfected with plasmids (B-H) 
in comparison to the untransfected p53 deficient fibroblasts (A). 
Magnification X 60.
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A p53 null fibroblasts B 16E6
ras D BPV-4
E 16E6+ras
G BPV-4+16E6
B P V -4 + r a s
H BPV-4+ras+16E6
A
Morphological
Transformation
(+hygro)
pBabeHygro -
BPV-4 +
ras +
16E6 +
BPV-4+ras +
ras+16E6 +
BPV-4+16E6 +
BPV-4+ras+16E6 +
B No. of colonies / Experiment
1 2 3 Aver
pbabehygro 0 0 0 0
BPV-4 3 4 3 3
ras 1 7 1 3
16E6 3 2 1 2
BPV-4+ras 4 12 9 8
ras+16E6 10 9 9 9
BPV-4+16E6 10 12 14 12
BP V-4+ros+16E6 6 16 11 11
Table 6.2.1 Transformation efficiency of BPV-4, ras and HPV-16E6 constructs 
in primary p53 deficient mouse fibroblasts. Table A, shows if cells were 
transformed and table B, indicates the number of colonies formed for three 
separate transfections.
168
four to six fold as many colonies as when BPV-4 and 16E6 were transfected 
on their own (Table 6.2.IB). This effect appears to be synergistic as BPV-4 
and 16E6 together produced two fold more colonies than the added number of 
colonies (five) of BPV-4 and 16E6. The significance of this observation 
cannot be determined as the colony numbers counted for the transfections were 
very small.
The additional presence of ras in the transfection did not appear to create a 
significant difference to the resulting number of colonies.
Six separate colonies were picked from each transfection and analysed for 
the ability to grow in 1% methocel. Untransfected p53 deficient fibroblasts and 
those transfectants containing BPV-4, ras or 16E6 on their own were not 
capable of anchorage independent growth as illustrated in figure 6.2.2A-D. 
However, in combination, as indicated in table 6.2.2, the transfected p53 
deficient fibroblasts grew in 1% methocel (Figure 6.2.2E-H). The numbers of 
colonies per dish was constant regardless of the transfected plasmids as 
described in table 6.2.2.
The growth rates of these transfectants was analysed by the M i l  assay 
(Figure 6.2.3). The rates of growth for untransfected p53 deficient fibroblasts 
and a cell line derived from a facial tumour excised from a p53 homozygous 
null mouse were also determined as controls. Those cells transfected with 
BPV-4 alone grew at a rate equivalent to that of the untransfected p53 
deficient fibroblasts (Figure 6.2.3A). p53 deficient fibroblasts transfected with 
ras or 16E6, appeared to have a reduced rate of growth in comparison to the 
other cell lines (Figure 6.2.3A).
Overexpression of an activated ras gene in the rat embryo fibroblast line 
REF52 results in a growth arrest at the Gl/S or G2/M boundary of the cell 
cycle (Hicks et al, 1991). The reduction in the growth rate of p53 deficient
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Figure 6.2.2 (on facing page)
Anchorage Independent growth of transfected p53 deficient fibroblasts. 
Untransfected cells and those transfected with BPV-4, ras or 16E6 alone were 
not capable of growth in soft agar (A-D). Cotransfection of the above did 
allow the cells to grow in soft agar (E-H).
Magnification X 60. Bar on panel G indicates 100pm.
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A p53 null fibroblasts B 16E6
ras
16E6+ras
D BPV-4
%
- *
F B P V -4 + r a s  
i • ♦
•  •
.  # » .  
«
BPV-4+16E6 H BPV-4+rss+16E6
Anchorage Independent 
Growth
Average no.* 
Anchorage Independent 
Colonies /cm^
(+hygro)
pBabeHygro _ 0
BPV-4 _ 0
ras - 0
16E6 _ 0
BPV-4+ras + 96
ras+16E6 + 96
BPV-4+16E6 + 94
BP V -4+ras+16E6 + 97
Table 6.2.2 Anchorage independent growth of transfected p53 deficient fibroblasts. 
The number of colonies determined for the clones analysed was not significantly 
different. + - indicates cell line positive for anchorage independent growth.
* Six separate clones from each transfection were assayed for anchorage 
independent growth and the average number of colonies counted on six separate 
sites on each dish.
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fibroblasts transfected with activated ras, and the low number of colonies 
generated as a result of transfection (Table 6.2. IB) may be due to a negative 
growth regulation induced by ras; however, it is unclear what negative growth 
regulatory mechanisms, if any, 16E6 is exerting in these cells. p53 deficient 
fibroblasts are known to grow at a high rate during continuous passage 
(Harvey et al, 1993).
The additional presence of 16E6 and ras with BPV-4 did not appear to 
significantly increase or decrease the growth rate of the p53 deficient mouse 
fibroblasts (Figure 6.2.3B) in comparison to BPV-4 alone (Figure 6.2.3A). 
BPV-4 did however, overcome the negative growth regulation which was 
previously demonstrated in the presence of ras alone (Figure 6.2.3A) when 
both were transfected into the p53 deficient fibroblasts (Figure 6.2.3B). The 
negative effect of 16E6 however, was not released by the addition of BPV-4 
(Figure 6.2.3B).
Thus, 16E6 appeared to slow the growth of the cells except when both 
BPV-4 and ras were present.
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Figure 6.2.3 (on facing page)
Growth rates of transfected p53 deficient fibroblasts as determined by MTT 
assay.
Graph A illustrates the growth rates of p53 deficient fibroblasts transfected 
with BPV-4, ras or 16E6 alone (in the presence of pbabehygro).
2914FT is a cell line derived from a facial tumour explant taken from a p53 
deficient mouse.
Graph B illustrates the growth rates of p53 deficient fibroblasts transfected 
with a combination of the above plasmids. The p53 untransfected deficient 
fibroblasts were assayed at passage #10.
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Conclusions and Discussion
As BPV-4 lacked transformation functions provided by 16E6 in vitro, 
further analysis of the BPV-4/16E6 interaction was carried out. Cells lacking 
an endogeneous p53 protein were transfected with BPV-4 and 16E6 to 
establish if the additional functions were indeed p53 dependent. 16E6 was 
found to provide transforming functions, i.e., anchorage independent growth, 
for p53 deficient cells transformed by BPV-4 in vitro suggesting that the 
additional functions of 16E6 were indeed p53 independent. Although it is 
apparent that BPV-4 and 16E6 can cooperate to transform p53 deficient mouse 
fibroblasts in the absence of rasy there is not a significant effect on the growth 
of the cells except in the presence of BPV-4, 16E6 and ras. The presence of 
16E6 conferred a growth advantage to transfected PalF cells (Figure 6.1.3). It 
may be that the growth advantage provided by 16E6 in PalF cells is a p53 
dependent function as it is absent in the p53 deficient fibroblasts. The growth 
advantage seen in the PalF cells may also be a function of ras as BPV-4 and ras 
cooperate to increase the growth rate of the p53 deficient fibroblasts. This 
cooperation may occur in the PalF cells as an activated ras is an absolute 
requirement for transformation, no colony formation occurs in the absence of 
an activated H-ras. This seems a more likely explanation as E6 is known to 
cooperate with EJ-ras in murine cells independent of its ability to associate 
with p53 (Pirn et al, 1994). This would suggest that 16E6 cooperates with ras 
in both PalF cells and p53 deficient mouse fibroblasts to enhance the growth 
rates of these cells, ras activation may be an early event in BPV-4 
transformation although activation of ras has only been observed in cancers 
(Campo et aly 1990).
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BPV-4 and 16E6 synergised to transform p53 deficient cells in vitro. 
These cells were capable of anchorage independent growth, but it is not known 
if they are tumourigenic in nude mice. The initial observation was that ras was 
no longer required for transformation in the absence of p53, suggesting that 
loss of p53 can replace activation of ras. Alternatively, it may be that the ras 
gene has already been inactivated in these cells, as in p53 deficient cells only 
about a third of the cells contain the normal number of chromosomes and the 
rest of the cells are aneuploid after only three passages (Harvey et al, 1993).
Other functions of 16E6 may contribute to transformation in p53 deficient 
cells as 16E6 has been shown to repress AdE2 promoter activity independent 
of p53 (Etscheid et aly 1994). Keen et al (1994) have demonstrated that 16E6 
binds other cellular proteins in addition to p53. The functions of these proteins 
have not yet been characterised and may be important in p53 independent 
pathways of transformation.
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6.3 Further analysis of the HPV16-E6 transforming functions independent
Of P53.
To further characterise these apparent p53 independent functions and to 
further define the region of the £6 oncoprotein which could cooperate with 
BPV-4, a panel of 16E6 mutants (Crook et al, 1991a) as described in table 
6.3.1, were cotransfected into p53 deficient fibroblasts together with BPV-4 
DNA.
E6 is an oncoprotein of 151 amino acids (Figure 1.6). As discussed 
previously, the E6 protein has functions which vary according to the relative 
risk of the papillomavirus infection. Certain amino acids have been found to be 
conserved between those E6 oncoproteins of the oncogenic or high risk HPVs. 
Point mutations were targeted to the conserved Cys-x-x-Cys motifs (Gly 103 
and Gly 136) and the amino acids conserved among E6 oncoproteins encoded 
by the oncogenic HPV types (YYH, A ll 1-115 and A123-127) (Figure 6.3.1A). 
The latter mutations were designed to result in the substitution with those 
residues found in the benign (low risk) HPV types. A premature termination 
mutation which resulted in the expression of a truncated E6 protein (A 110) 
(Figure 6.3.1 A), and chimaeric proteins consisting of the N and C-terminal 
regions of HPV-16 and HPV-6 E6 as well as the wild type HPV16 and HPV6 
E6 proteins were also examined for their ability to cooperate with BPV-4 
(Figure 6.3.IB and C). The mutants described above are illustrated in figure
6.3.1 and table 6.3.1.
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A 110
N
Y Y H
tt  t t
G L Y  1 0 3  A l l l - 1 1 5  A 1 2 3 -1 2 7  G L Y 1 3 6
W T 1 6 E 6
1 5 1
B
n  16E6 c  n  6E6 c
1  6 0  5 9  1 5 1
c
N  6E6 c  N  16E6 c
1  5 9  6 1  1 5 1
Figure 6.3.1 Location of the mutations in HFV-16E6 and the structure of the 
chlmaerlc proteins.
Construct Alteration p53 binding p53
degradation
Transactivation
wt 16E6 none + + +
wt 6E6 none + +
YYH AA45Y,46Y,47H + . +
A110 Deletion
AA111-151
- nd -
Al 11-115 Deletion
AA111-115
- - +
A123-127 Deletion
AA123-127
+ + -
GLY103 Cysl03Gly + nd* nd*
GLY136 Cysl36Gly + nd nd
6/16 N6E6, C16E6 + . +
16/6 N16E6, C6E6 + + +
Table 6.3.1 Summary of the wild type and mutant HPV-16E6 plasmids and their 
functions (Crook et al, 1991a). nd - not determined.
* - Although not determined for HPV16E6, a similar mutation in HPV-18E6 demonstrated 
reduced ability (less than 50%) to degrade p53 but was still capable of transactivating the 
adenovirus E2 promoter (Pirn et al, 1994).
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Results
All of the mutants described above were transfected singly and in the 
presence of BPV-4 into p53 deficient mouse fibroblasts. Figures 6.3.2 to 6.3.5 
are a representation of the extent of colony formation observed when the 
transfectants were stained with 10% Geimsa after two to three weeks.
All of the mutants retained the ability to morphologically transform the p53 
deficient fibroblasts and to form colonies both when transfected on their own 
or with BPV-4. Table 6.3.2 summarises the average number of colonies 
obtained as a result of five separate transfection experiments.
In comparison to the synergy of BPV-4 and 16E6, none of the mutants or 6E6 
cooperated with BPV-4 to transform the p53 deficient fibroblasts as efficiently 
as wild type 16E6, although all of the mutants were capable of morphologically 
transforming the cells (Figure 6.3.6). The numbers of colonies obtained for 
each experiment varied, however the appearance of the stained flasks was 
similar throughout the separate experiments. It is possible that due to the small 
flasks used colonies were not counted consistently, as it is obvious in figures
6.3.2 to 6.3.5 that colonies merged into one another and it was difficult to 
determine the boundary of one colony and that of the next.
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NO PLASMID WT 16E6 B P V - 4  W T 1 6 E 6  + B P V -4
l
Figure 6.3.2 Wild type 16E6 plasmid transfected into p53 deficient fibroblasts 
with and without BPV-4 DNA followed by selection with hygromycin (125ng/ml) 
for 2-3 weeks. Cells in T25 flasks were then stained with 10% Giemsa and 
photographed. All transfection mixes contained pbabehygro plasmid for selection 
and 'no plasmid' indicates the control transfection with pbabehygro alone.
WT16E6 M TYYII MT GLY 103 MTGLY136
WTI6E6 MTYYII MT GLY 103 MT GLY 136
+  B P V - 4  +  B P V - 4  +  B P V - 4  +  I I P V - 4
Figure 6.3.3 Mutant E6 plasmids transfected into p53 deficient fibroblasts
with and without BPV-4 DNA. Other details as for figure 6.3.2.
M l  A I K )  M T  A l l  1 - 1 1 5  M T  A 1 2 3 - 1 2 7
M T  A110 M T A l l  1-115 M TA123-127
+ BPV-4 + BPV-4 + BPV-4
Figure 6.3.4 Mutant E6 plasmids transfected into p53 deficent fibroblasts
with and without BPV-4 DNA. Other details as for figure 6.3.2.
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Figure 6.3.5 HPV6E6 and 6E6/16E6 chimaeric plasmids transfected
into p53 deficient fibroblasts with and without BPV-4 DNA. Other details
as for figure 6.3.2.
Table 6.3.2 Summary of the number of transformed colonies (^average of five 
separate experiments) and the % of the transformed colonies picked per flask 
that were positive for growth in 1% methocel. pbabehygro was present in all 
transfections. Figures in brackets indicate the standard error.
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Transfection Average no. of colonies / 
T25 flask* (S.E)
% clones anchorage 
independent (colonies 
positive/colonies tested)
BPV-4 4 (0.9) 0
16E6 5 (0.9) 0
BPV-4+16E6 20 (1.4) 100
6E6 8(1.0) 0
BPV-4+6E6 6 (1.6) 50
A110 8 (1.8) 0
BPV-4+A110 9 (2.0) 0
YYH 8(1.6) 0
BPV-4+YYH 8 (1.9) 50
GLY103 8 (1.0) 0
BP V-4+GLY103 4 (1.0) 25
GLY136 5 (0.8) 0
BPV-4+GLY136 5 (0.9) 50
6/16 8 (1.0) 0
BPV-4+6/16 8 (1.4) 50
16/6 5 (1.3) 0
BPV-4+16/6 5 (1.6) 75
Al 11-115 6 (1.3) 0
BPV-4+A111-115 4 (0.9) 75
A123-127 4 (0.9) 0
BPV-4+A123-127 4 (0.8) 75
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Control
'vV 'kV I
A110 D A123-127
Figure 6.3.6 Examples o f morphological transformation of p53 
deficient fibroblasts transfected with mutant 16E6.
Panel A, untransfected p53 null fibroblasts, panel B, 
cells transfected with chimaeric mutant 16/6, panel C, 
cells transfected with deletion mutant A110, and panel 
D, cells transfected with A123-127.
Magnification X125 (A), X 60 (B-D). Bar in panel D indicates 100pm.
The transfectants were analysed for the ability to grow in 1% methocel (Table 
6.3.2; figure 6.3.7) and their growth rates determined (Figure 6.3.8). None of 
the transfectants containing mutant 16E6 plasmids alone were capable of 
anchorage independent growth (Table 6.3.2). However, in cooperation with 
BPV-4, only mutant A110 lost the ability to confer anchorage independent 
growth. Mutants Gly 103 and Gly 136 were diminished in their ability to 
cooperate with BPV-4 and alteration of Cysl03 to Glyl03 reduced the 
percentage of colonies positive for anchorage independent growth to only 25%. 
The presence of intact cysteine residues in both zinc finger motifs of 16E6 
appears to be required for cooperation with BPV-4 and anchorage independent 
growth of the p53 deficient cells. The alteration and deletion of residues 
conserved among the oncogenic HPVs also led to a reduction in the number of 
colonies capable of anchorage independent growth. This may suggest that the 
ability of 16E6 to induce anchorage independent growth in the presence of 
BPV-4 in p53 deficient cells is considerably reduced in the low risk HPVs and a 
function of the oncogenic HPVs. From the data shown, anchorage 
independent growth did not appear to correlate with the mapped p53 binding 
and degradation functions or transactivation which would suggest that the 
ability to confer anchorage independent growth in the absence of p53 may be 
an as yet unidentified function of 16E6.
The MTT assay as shown in figure 6.3.8, demonstrated that although there 
was no significant difference in the growth rates of either 16E6 or 6E6 in 
conjunction with BPV-4 or the chimaeric constructs (figure 6.3.8A and B), 
mutant YYH (Figure 6.3.8C), Gly 136 (Figure 6.3.8D), and A ll  1-115 (Figure 
6.3.8E) demonstrated increased rates of growth in cooperation with BPV-4. 
It is unclear how this cooperation is occurring as the wild type E6 constructs 
do not increase the rate of growth confirming the previous observations that 
the growth advantage in the presence of BPV-4 is possibly ras dependent.
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A 16E6A110+BPV-4 B 16/6E6+BPV-4
Figure 6.3.7 Anchorage independent growth of p53 deficient fibroblasts 
transfected with mutant 16E6 and BPV-4. Panel A; cells transfected 
with A110 and BPV-4 are negative for A.I growth and panel B; 
cells transfected with chimaeric 16/6 and BPV-4 which were positive 
for A. I growth.
Magnification X 60. Bar in panel B indicates 100pm.
Figure 6.3.8 MTT assay of growth rates for transfected p53 deficient fibroblasts. 
Graphs A-D illustrate the average growth rates from two separate experiments.
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These mutants may demonstrate the interactions of 16E6 with other proteins 
which allow cooperation with BPV-4 to increase the growth rate of the p53 
deficient fibroblasts. It may be necessary to further dissect BPV-4 and look at 
the sub-genomic components in cooperation with the mutant £6 constructs to 
accurately define the functions BPV-4 lacks.
Conclusions and Discussion
The use of 16E6 mutants to further characterise the BPV-4/16E6 
interaction demonstrated that the cysteine residues in the zinc finger motifs of 
16E6 are required for the interaction with BPV-4 to confer anchorage 
independent growth. Crook et al (1991a) showed that all of the HPV-16E6 
mutants except for A110 could efficiently transactivate the adenovirus E2 
promoter. This suggests that they are expressed as functional proteins and 
differences in their abilities observed here and their previously characterised 
functions are not attributable to a lack of expression or instability of the mutant 
proteins. Analysis of both HPV-16 and HPV-18 E6 mutants has led to the 
observation that p53 degradation and the transactivation activities of E6 are 
separable (Crook et al, 1991a; Pim et al, 1994) and p53 independent functions 
of E6 are apparent in these cells. In the absence of p53 other proteins may be 
targeted for degradation as has already been demonstrated (Scheffner et al, 
1992a).
The anchorage independent functions provided by 16E6 in the presence of 
BPV-4 appear to be p53 independent and so may the cooperation between 
BPV-4 E7 and E8 oncoproteins to induce anchorage independent growth of 
PalF cells (Pennie et al, 1993; M Caimey, PhD thesis). Thus, although p53 
inactivation is important in BPV-4 transformation it may not be involved in 
anchorage independent growth of cells. It is necessary to confirm which
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BPV-4 oncoprotein interacts or cooperates with 16E6 to enable the cells to 
grow in soft agar.
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Summary
p53 protein levels were found to be elevated in experimentally induced 
papillomas from animals inoculated in the palate with purified BPV-4. 38% of 
these experimental papillomas were found to possess putative mutations in 
bovine p53 exon 7. The naturally occurring papillomas and carcinomas had a 
lower incidence of mutation in p53 exon 7, but this does not rule out the 
presence of other mutations. The cell lines were also shown to possess 
putative mutations. Previous data suggest that spontaneous mutations arise in 
cell culture on transfection with the HPV viral oncogenes and the nature of the 
mutations suggest that they are not attributable to a single mechanism.
Addition of an exogeneous mutant p53 to PalF cells in the presence of 
BPV-4, ras and HPV-16E6 (16E6) led to tumourigenicity. BPV-4 was indeed 
found to be lacking in functions which could be provided by 16E6, some of 
which appeared to be independent of the p53 binding and degradation pathway. 
The presence of mutant p53 in vitro was not required for morphological 
transformation or anchorage independent growth in PalF cells transformed 
BPV-4, however, mutant p53 was capable of substituting for 16E6 to confer 
immortality to PalF cells and was required for tumourigenicity in nude mice. 
Partial transformation by BPV-4 in vitro does not appear to require a mutant 
p53 but the progression to carcinoma may involve p53 mutations which give 
the cells a selective advantage and make them targets for further alteration.
In cervical cancer, p53 status is varied depending on the presence of 
HPV DNA. Generally, if HPV DNA is present then p53 is wild type and 
appears to possess its normal cell regulatory functions (Butz et al> 1995), albeit 
at very low levels due to the presence of E6. Absence of HPV DNA usually 
results in the mutation of the p53 gene. As viral DNA is lost in BPV-4
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associated cancers in vivo, the presence of mutant p53 may be an important 
step in progression to carcinoma.
Complementation of BPV-4 with 16E6 in both PalF and p53 deficient 
cells demonstrated that BPV-4 did not encode E6-like functions. Although 
BPV-4 lacks the p53 binding and degradation functions of the E6 oncoprotein, 
this does not appear to affect the ability of BPV-4 to transform cells both in 
vivo and in vitro. The E6 functions lacking in BPV-4 can be partially replaced 
by the addition of a mutant p53 and p53 mutations found in BPV-4 induced 
lesions would suggest that p53 dysfunction does indeed appear to have a role in 
BPV-4 transformation. The absence of an E6 ORF is not detrimental to cell 
transformation by BPV-4, however progression to tumourigenicity does 
require additional functions.
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GENERAL DISCUSSION
CHAPTER 7
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General Discussion
Introduction
The natural progression to carcinoma in vivo as a result of BPV-4 infection 
and the presence of cofactors is summarised in figure 7.1
Infection by BPV-4 results in benign papillomas of the alimentary canal 
which progress to squamous cell carcinoma in cattle feeding on bracken fern. 
Bracken fern has been shown to contain immunosuppressants and 
cocarcinogens which contribute to this process (reviewed in Jackson and 
Campo, 1995b).
The action of immunosuppressants present in bracken creates a widespread 
papillomatosis which is susceptible to further transformation. Activation of ras 
(Campo et al, 1990) and an increase in the numbers of EGF receptors (Smith et 
al, 1987) are also known to occur during tumour progression. The loss of viral 
DNA at this stage may reflect the advanced stages of progression and that the 
presence of virus is no longer required or that the cells are no longer suitable 
for viral replication.
BPV-4 lacks an E6 ORF as do the other subgroup B bovine 
papillomaviruses (Jackson et al, 1991). The E6 proteins of the oncogenic 
HPVs 16 and 18 bind to and degrade the p53 protein and this event is thought 
to contribute to transformation by these viruses (Scheffner et aly 1990; Werness 
et al, 1990). It is obvious that in the presence of cofactors, BPV-4 is capable 
of full malignant transformation in vivo and in vitro (Campo and Jarrett, 1986; 
Pennie and Campo, 1992; Campo et al, 1994b; Caimey and Campo, 1995). 
This does not appear to be hindered in any way by the lack of an E6 
oncoprotein and raises the question whether E6 functions are necessary for 
BPV-4 transformation.
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The absence of an E6 ORF suggests the hypothesis that the p53 protein 
would be unaltered in papillomas but that p53 mutations may occur during the 
progression of benign papillomas to carcinomas. Alternatively BPV-4 may 
have evolved another mechanism of evading p53 growth suppression.
The work in this thesis examines the status of the bovine p53 in both 
naturally occuring and experimentally BPV-4 induced papillomas and 
carcinomas. We have also studied the significance of the absence of the E6 
ORF by investigating the roles of an exogenous 16E6 and p53 in BPV-4 cell 
transformation.
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p53 mutations in vivo and in vitro.
p53 protein levels were found to be elevated in experimentally BPV-4 
induced papillomas, however, no p53 protein could be detected in an 
oesophageal carcinoma. Analysis of these papillomas by SSCP-PCR suggested 
that mutations were present in bovine p53 exon 7 in several of these 
papillomas. Technical difficulties arose in the sequencing of the DNA from 
these papillomas and so we were unable to confirm the exact nature of the exon 
7 mutation present. The samples did appear heterozygous and evidence of a C 
to T transversion was identified in one of the papillomas. This could not be 
confirmed due to the number of unidentified nucleotides in the sequence 
analysis (Figure 5.2.4). It could be suggested that the mutation present in these 
experimentally induced BPV-4 papillomas is different from that identified in the 
naturally occurring metastases.
No mutations in p53 exon 7 were found in experimentally induced urinary 
bladder carcinomas although these were identified as non-BPV related. 
Naturally occuring papillomas were examined for the presence of mutations in 
p53 exon 7 and none were detected although it is not known if the p53 protein 
is stabilised in these papillomas. Two naturally occuring metastases harboured 
p53 mutations in exon 7 altering a proline residue to a threonine at codon 243. 
No other p53 exons were analysed and so it cannot be ruled out that mutations 
may be present in other exons.
Only two naturally occurring papillomas were analysed and found to possess 
a wild type p53. It is possible that mutations are present elsewhere in the p53 
gene and that analysis of a larger number of papillomas may also reveal 
mutations in exon 7. One aspect of the naturally occurring papillomas which 
was not investigated was that of the p53 status by immunocytochemistry. We 
do not know if p53 is also stabilised in these papillomas, as was the case for the 
experimental papillomas which demonstrated a stabilisation of the p53 gene and
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a mutation in exon 7. Further characterisation of the other p53 exons as 
discussed above would confirm if mutations were indeed present. Mutations 
have also been identified outside the highly conserved exons 5-8 (Hartmann et 
al, 1995) and these regions may harbour potential BPV-4 induced mutations.
PalF cells which had been transformed by whole genome and sub-genomic 
fragments of BPV-4 and treated with quercetin (M. Caimey; PhD thesis) were 
also analysed by SSCP-PCR. Quercetin is one of the mutagens present in 
bracken fern (Evans, I.C et al, 1982; Evans, W.C et al, 1982). The action of 
quercetin both in vitro and in vivo has been widely studied (reviewed in 
Jackson et al, 1993; Jackson and Campo, 1995b). Quercetin also synergises 
with BPV-4 in vitro to fully transform PalF cells (Pennie and Campo, 1992; 
Caimey and Campo, 1995). Although treatment of BPV-4 transformed PalF 
cells lead to a more aggressively transformed phenotype and tumourigenicity in 
nude mice, no quercetin-induced mutagenic effects were detected (M. Caimey, 
PhD thesis). Several putative p53 exon 7 mutations were detected in both the 
quercetin and non-quercetin treated cell lines, and there appeared to be no 
correlation between the presence of p53 mutation and quercetin treatment. 
The initial studies provided in this thesis suggest that p53 exon 7 mutations 
may not be directly related to environmental cofactors. The animals from 
which the experimental papillomas were obtained did not receive any bracken 
fern and were only exposed to BPV-4.
We know from this thesis, that at the papilloma stage the production of viral 
proteins takes place and possible mutation of the p53 gene occurs. p53 
mutation may be one of the deciding factors in conjuction with cofactors which 
determine whether the papilloma remains benign and regresses via an immune 
response (Knowles et al, 1996) or if it transforms and progresses to a 
carcinoma.
Demers et al (1994a) showed that wild type p53 levels were elevated in 
primary foreskin epithelial cells immortalised by the HPV-16 E7 (16E7) gene.
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p53 is known to function as a cellular checkpoint and high levels of p53 protein 
associated with DNA damage, are accompanied by a growth arrest (Kastan et 
al, 1991). Demers et al (1994b) demonstrated that this growth arrest can be 
bypassed by expression of 16E7 in DNA damaged keratinocytes. Expression 
of the BPV-4 E7 (4E7) oncoprotein was detected at all papilloma stages but 
not in the regressing lesion. The p53 protein was detected in all of the 
papillomas examined. The stabilisation of p53 was initially thought to be a 
consequence of 4E7 expression, however, the absence of E7 protein in the 
regressing lesion suggested that this may not be the case. The lack of 4E7 
expression in this lesion may represent the difference between a papilloma 
which is capable of further progression and one which follows the typical 
regression pathway. 4E7 has sequence similarity to and functional homology 
with 16E7 (Campo et al, 1994b). If 4E7, like 16E7, can bypass a p53 induced 
growth arrest this may result in the accumulation of genetic alterations which 
could contribute to the BPV-4 transformation pathway.
Transformation by papillomaviruses appears to depend on the targeting and 
inactivation of both the Retinoblastoma (Rb) and p53 tumour suppressor genes 
(Vousden et al, 1991; Munger et al, 1992). The HPV E7 proteins complex 
with the Rb tumour suppressor gene product (Munger et al, 1989). SV40 
large T antigen and adenovirus E l a also complex with Rb and functional 
similarities have been demonstrated between these viral proteins and HPV- 
16E7 (Vousden and Jat, 1989). Although binding studies have not yet been 
carried out, BPV-4 E7 possesses a putative pl05Rb binding domain and 
deletion or mutation of this region abolish transformation (Jaggar et al, 1990; 
GJ Grindlay, personal communication). The expression of both 4E7 and 
mutant p53 would be required to inactivate these tumour suppressor pathways 
and result in the deregulation of cellular control.
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The bovine p53 gene was localised to chromosome 19ql5 (Coggins et al, 
1995). The availabilty of a bovine p53 genomic clone and the recently 
published bovine p53 sequence (Dequiedt et al, 1995b) will allow further 
characterisation of p53 mutations in exons 5, 6 and 8 where the major 
mutational hotspots have been located in human cancer (Hollstein et al, 1991). 
This would confirm the proportion of BPV-4 associated papillomas and 
carcinomas which do indeed possess mutations in the p53 gene and further 
characterisation of the effects of these mutations by their analysis in vitro.
BPV-4 lacks a 16E6 associated function in vitro which can be substituted 
bv mutant p 5 3 .
It has been demonstrated that the addition of an exogeneous 
HPV-16E6 to BPV-4 genes can confer immortality to PalF cells in vitro, 
however, these cells are not tumourigenic (Pennie et al, 1993; M. Caimey, PhD 
thesis). Morphological transformation of PalF cells by BPV-4 is dependent on 
the presence of an activated ras gene. The presence of ras is a requirement for 
the transformation of primary cells by other papillomaviruses including HPV-16 
and 18 (Matlashewski et al, 1988; Storey et al, 1988; Storey and Banks, 1993).
This thesis confirms that the addition of an exogeneous 16E6 conferred 
immortality to BPV-4 transformed cells and showed that this function can be 
substituted by the presence of an exogeneous mutant p53. Other studies have 
demonstrated the substitution of E6 activities by p53 mutations in vitro 
(Sedman et al, 1992; Storey and Banks, 1993; Storey et al, 1995). This 
would suggest that inactivation of wild type p53 is required for BPV-4 induced 
immortalisation in vitro and that in this system 16E6 and mutant p53 disrupt a 
common pathway.
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16E6 does possess functions in addition to immortalisation as both mutant 
p53 and 16E6 were required for PalF cells to become tumourigenic in the 
presence of BPV-4. It appears that p53 inactivation is not the only E6 activity 
required for tumourigenicity in vitro and that other p53 independent E6 
functions may contribute.
The E6 oncoprotein has been demonstrated to possess other functions and 
more recently has been shown to bind many other cellular proteins other than 
p53 (Keen et al, 1994).
The E6 oncoproteins of the oncogenic HPVs type 16 an 18 are known to 
interact with two cellular proteins, the tumour suppresssor p53 (Wemess et al, 
1990) and the lOOkDa protein E6-AP (plOO) (Huibregtse et al, 1991; 
Huibregste et al, 1993a). The interaction of 16E6 with E6-AP is necessary for 
the interaction with p53. Keen et al (1994) described an additional five cellular 
proteins pp212, ppl82, p87, p75, p33 which were bound by a biologically 
active 16E6 protein. The proteins pp212 and ppl82 were found to be highly 
phosphorylated and Keen et al (1994) showed that both p i00 and p33 interact 
directly with 16E6. E6 from HPVs 6, 11, 16 and 18 also demonstrated the 
ability to bind a cellular protein kinase which phosphorylated Histone HI. This 
HI kinase activity was not associated with the E6 of the cutaneous HPVs 5 and 
8 (Keen et al, 1994). The functions of these proteins have yet to be identified 
and so it is difficult to postulate what mechanisms may be involved, although 
this confirms that E6 has a role in addition to p53 binding and degradation by 
its ability to complex other cellular proteins.
The recently identified E6 binding protein, E6-BP (Chen et al, 1995), was 
found to contain four potential calcium binding motifs and a putative 
endoplasmic reticulum retention signal. E6-BP was identical in sequence to 
ERC-55 an EF-hand calcium binding protein which is localised to the 
endoplasmic reticulum. Only E6 from the high risk anogenital HPVs 16, 31
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and 18 bound E6-BP, as did BPV-1 E6. Interestingly, although BPV-1 E6 
does not bind and degrade p53 in vitro (Wemess et al, 1990), BPV-1 E6 was 
still capable of binding E6-AP suggesting that this interaction is insufficient for 
the interaction with p53 or that E6-AP has other functions which play a role in 
BPV-1 induced transformation. Chen et al (1995) also demonstrated that 
16E6, E6-AP and E6-BP could associate in a complex with no detectable p53, 
which suggests that this complex may possess p53 independent functions.
Other calcium binding proteins, such as Trichohyalin which is found in the 
granular cells of the epidermis, target keratins and are involved in the 
regulation of cell structure (Lee et al, 1993). Calcium ions are important 
second messengers in the control of many biological processes such as cell 
growth and differentiation (reviewed in Schafer and Heizmann, 1996). The 
interaction of 16E6 with E6-BP may prevent the terminal differentiation of 
epithelial cells providing the necessary environment for viral DNA replication. 
McCance et al (1988) showed that E6 alters the differentiation of 
keratinocytes, and keratinocytes immortalised by HPV-16 E6 and E7 are 
resistant to calcium induced differentiation (Schlegel et al, 1988). The 
inhibition of cell differentiation is an important feature of transformation, 
although it is possible that E6 is not the only viral oncoprotein which can 
influence cellular calcium levels. Members of the calcium binding S100 protein 
family CAPL and SI00b have been demonstrated to target p53. These 
interactions have been suggested to be involved in the depolymerisation of the 
cytoskeleton and the inhibition of protein kinase C (PKC) mediated 
phosphorylation (Parker et al, 1994; Baudier et al, 1992). In the case of 
BPV-4 transformed cells, the interactions of 16E6 with other cellular proteins 
may depend on as yet unidentified factors which in vivo may be substituted by 
the presence of cofactors or even mutant p53 leading to the disruption of 
cellular calcium flux.
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In this thesis, we found that PalF cells transfected with BPV-4 and mutant 
p53 were immortal but only became tumourigenic when 16E6 was present. 
Evidence of the ability of 16E6 to immortalise cells was discussed in Chapter 
6.1, however, no mechanisms by which this may occur were proposed. It has 
been shown that one function of wild type p53 may be to signal growth arrest 
in response to telomere shortening in senescent human cells and that mutant 
p53 can overcome this senescence in human fibroblasts (Bond et al, 1994). 
Wynford-Thomas et al (1995) have proposed a hypothesis that when a cell 
reaches a critical number of divisions, the telomere is sufficiently shortened to 
trigger activation of wild type p53. If p53 function is eliminated, i.e, by 
mutation, no growth arrest will occur which would account for the resulting 
immortal phenotype.
Klingelhutz et al (1996) showed that 16E6 is capable of telomerase 
activation in human keratinocytes and mammary epithelial cells. This function 
was also shown to have no correlation with p53 binding and degradation and 
may be p53 independent. However, the keratinocytes expressing E6 alone 
possessed an extended lifespan but were not immortal (Klingelhutz et al,
1994). This would suggest that the p53 binding and degradation function and 
telomerase activation by E6 are insufficient for immortalisation. It would be 
expected that this telomerase activation would be sufficient for immortality, 
however, as discussed above, p53 elimination by mutation appears to induce 
the immortal phenotype (Bond et al, 1994). Butz et al (1995) demonstrated 
that residual wild type p53 activity exists in cells expressing 16E6. This would 
possibly account for the inability of the keratinocytes to become immortal in 
this assay if the model (Wynford-Thomas et al, 1995) discussed above is 
correct. Klingelhutz et al (1996) could not detect telomerase activity in E6 
expressing early passage human fibroblasts. It is possible that this activity is 
due to differences in the proliferative capacity of keratinocytes and fibroblasts, 
i.e, epithelial cells have a lower proliferative capacity than fibroblasts, and that
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the E6 expressing fibroblasts have not reached their threshold for telomerase 
activation.
The addition of an exogeneous 16E6 to BPV-4 transfected PalF cells was 
shown to be required for their immortalisation in vitro suggesting that BPV-4 
lacked 16E6 functions, however, this function was substituted for by the 
addition of an exogeneous mutant p53. This may account for the ability of 
BPV-4 transfected PalF cells to become immortal with the expression of either 
mutant p53 or 16E6, it does not however, explain why in the presence of both 
mutant p53 and 16E6, BPV-4 transfected PalF cells become tumourigenic. It 
could be suggested that telomerase has been activated in BPV-4 transfected 
PalF cells which express an exogenous 16E6. The additional presence of 
mutant p53 may provide a selective growth advantage allowing the cells to 
become tumourigenic.
Infection by BPV-4 may be enough to generate the clonal expansion of cells 
which results in a benign tumour growth (papilloma) before growth is arrested 
by p53 activation. Elimination of p53 by mutation would allow further 
proliferation and in the presence of cofactors, such as those contained in 
bracken fem, progression to a squamous cell carcinoma could occur.
BPV-4 does indeed lack more than one function which can be provided by 
the addition of an exogeneous HPV-16E6 as shown in this thesis, however it is 
also apparent that some of these functions can be substituted by other factors. 
The ability of 16E6 to associate with many cellular proteins illustrates the 
requirement for many different steps in the transformation process. The lack of 
an E6 protein in the BPV-4 genome does not have any detrimental effects on 
its ability to transform bovine cells and induce papillomas. The use of 16E6 as 
a tool to identify mechanisms of transformation by BPV-4 may reveal 
important aspects of viral transformation which have not yet been identified.
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Expression of viral proteins in tumourigenic cell lines.
The transforming functions of BPV-4 have been mapped to the E7 and E8 
ORFs. The E7 ORF is involved in morphological transformation (Jaggar et al, 
1990) and the E8 ORF is responsible for anchorage independent growth 
(Pennies al, 1993).
BPV-4 E7 (4E7) mRNA was expressed in all of the cell lines transfected 
with BPV-4, however only those cell lines which were tumourigenic in nude 
mice expressed BPV-4 E8 (4E8) mRNA. Immunohistochemical analysis of the 
tumours excised from the nude mice demonstrated expression of both 4E7 and 
4E8 transforming proteins. High levels of p53 protein were also detected and 
accompanied expression of 4E7 as was observed in the experimentally BPV-4 
induced papillomas. 4E8 protein was also detected in the experimentally 
BPV-4 induced papillomas (Anderson et al, 1996).
The similarity of 4E7 to the E7 proteins of other papillomaviruses suggest 
that it acts in the same way in transformation. The ability of E7 to bind Rb is 
essential for the transforming and immortalising properties in rodent cells 
(Barbosa et al, 1990) and as mentioned deletion of the potential pl05Rb 
binding site abolishes 4E7 transformation functions. Crook et al (1989) 
demonstrated that continued expression of E7 was required for the 
maintenance of the transformed phenotype in baby rat kidney cells transformed 
with HPV-16 and EJ-ros. Expression of 4E7 in BPV-4 transfected cells in 
vitro may contribute to transformation by disruption of the Rb dependent 
pathway and the biological significance of 4E7 in vivo has been demonstrated 
by its expression in the nude mouse tumours and in the experimentally BPV-4 
induced papillomas.
The 4E8 protein is similar to the BPV-1 E5 protein (Jackson et al, 1991) 
and both BPV-1 E5 and 4E8 have been demonstrated to bind ductin, a 16kD 
cellular component of both the vacuolar H+-ATPase and gap junctions
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(Goldstein et al, 1991; Finbow et al, 1991; Faccini et al, 1996) although no 
direct interaction between ductin and 4E8 has been observed in transfected 
PalF cells. Other viral oncoproteins such as HPV-16 E5 and HPV-6 E5 also 
bind to ductin (Goldstein etal, 1991).
E5 alone will transform cells (Schiller et al, 1986; Yang et al, 1985), 
however, overexpression of E8 in PalF cells in the presence of ras results in 
accelerated senescence and cell death (Pennie et al, 1993; Caimey and Campo,
1995). In PalF cells transformed by BPV-4 and an activated ras, expression 
of BPV-4 E8 is associated with the loss of gap junctional intercellular 
communication (GJIC) (M Caimey, PhD thesis; Faccini et al, 1996). This is 
supported by the study of Oelze et al (1995) who found that HPV-16 E5 
expressed in a human keratinocyte cell line inhibited GJIC. It has also been 
shown that BPV-1 transformed primary bovine conjunctival fibroblasts have 
disrupted GJIC (W.D Pennie, PhD thesis).
This disruption of cell-cell interactions appears to be a consequence of E8 
expression and lead to a population of cells isolated from the surrounding 
normal cells and factors which may negatively regulate cell growth. Thus 
both BPV-4 E7 and E8 contribute to BPV-4 induced cellular progression.
16E6 cooperates with BPV-4 to confer transformation functions 
independent of p 5 3 .
BPV-4 and 16E6 were found to cooperate in the transformation of p53 
deficient mouse fibroblasts suggesting that not all 16E6 functions are mediated 
via a p53 dependent pathway. Transformation of the p53 deficient mouse 
fibroblasts with BPV-4 and 16E6, unlike PalF cells, did not require the 
presence of an activated ras.
BPV-4 and 16E6 transformed p53 deficient fibroblasts were capable of 
anchorage independent growth, but it is not known if these cells are
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tumourigenic in nude mice. Activated ras is not a requirement for 
morphological transformation of the p53 deficient fibroblasts by BPV-4 (as it is 
in the PalF cells) but it is still required for anchorage independent growth in the 
absence of 16E6. These cells were not tested for tumourigenicity. Activation 
of ras is seen at the later stages of BPV-4 progression in cancers (Campo et al, 
1990) and at the earlier stages of transformation all papillomas examined to 
date appear to possess a normal ras gene. The requirement for ras for in vitro 
transformation of PalF cells may suggest that it is an early event and from data 
in this thesis, ras may provide a selective advantage for the enhanced growth of 
PalF cells in culture. This would suggest that although ras is not necessary for 
transformation by BPV-4 and 16E6 in p53 deficient fibroblasts, it may be a 
requirement for tumourigenicity.
The ability of 16E6 and BPV-4 to confer anchorage independence to the 
p53 deficient mouse fibroblasts required intact Cys-X-X-Cys motifs and the 
presence of the C-terminal domain. It has been demonstrated that for the 
HPV-18 E7 protein intact Cys-X-X-Cys motifs are necessary for zinc binding, 
dimerisation and transformation (McIntyre et al, 1993). Crook et al (1991a) 
suggested that disruption of one residue in the Cys-X-X-Cys motifs was 
insufficient to destabilise the 16E6 protein as these mutants retained wild type 
functions. Mutants of 18E6 which fail to bind and degrade p53 were found to 
still cooperate with EJ-ras in the immortalisation of primary baby mouse kidney 
cells (Pirn et al, 1994) yet transforming activity localised to the C-terminal 
region including the second Cys-X-X-Cys motif. Band et al (1993) also 
suggested a transforming function of E6 which is independent of a direct 
association with p53 in human mammary epithelial cells. The HPV E6 proteins 
have been shown to bind zinc and the highly conserved Cys-X-X-Cys motifs 
are predicted to play a role in forming this complex comparable to that 
predicted for zinc finger proteins (Barbosa et al, 1989). This 16E6 region is
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important in the cooperation with BPV-4 and may suggest that zinc binding by 
16E6 has a role in transformation. Our data also confirms that a p53 
independent transforming activity of 16E6 localises to the C-terminal half of 
the protein.
This is supported by the previous observations that both mutant p53 and 
16E6 were required for tumourigenicity of PalFs suggesting that p53 
inactivation is not the only mechanism by which E6 transforms cells. These in 
vitro experiments demonstrating that the additional functions conferred by 
16E6 may be p53 independent, could be further confirmed by the 
cotransfection of BPV-4 with one of the 16E6 mutants defective for p53 
binding and degradation. It would be expected that if this is indeed a p53 
independent function, then the immortalisation and tumourigenicity functions 
provided by 16E6 would not be altered in PalF cells.
The data in this thesis suggests that p53 inactivation does indeed play a role 
in BPV-4 induced cellular transformation. It is known that quercetin, a 
mutagenic component of bracken fern, can bypass both mutant p53 and 16E6 
requirements in vitro and cause BPV-4 transformed PalF cells to become 
tumourigenic in nude mice (Caimey and Campo, 1995; Pennie and Campo, 
1992) confirming the role of cofactors in BPV-4 induced transformation.
p53 mutation may be an early event in the transformation of BPV-4 induced 
papillomas as high levels of p53 protein and mutations were detected in 
papillomas. In the absence of 4E7 expression these papillomas may regress, 
however, the expression of both mutant p53 and 4E7 could provide a 
proliferative stimulus. The presence of immunosuppresants in bracken fem 
would suppress any immune response which may induce regression. 
Expression of 4E8 resulting in a loss of cell-cell communication would lead to 
the isolation of virally transformed cells from the growth inhibitory effects of 
surrounding untransformed cells. The contributions of these viral proteins and
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the disruption of p53 regulatory functions would create a situation which, in 
the presence of environmental cofactors, would allow further progression to 
carcinoma in vivo.
Future Work
Further experiments have already been suggested in the general discussion 
however, there are some aspects which have not yet been addressed.
Bovine papillomavirus type-4 (BPV-4) does not require an E6 ORF for a 
successful infection cycle and papillomas induced by BPV-4 progress to 
carcinoma in the absence of E6. It is still unclear if other viral or host proteins 
provide E6 functions. 16E6 immortalises PalF cells transformed by BPV-4 E7 
and ras +/- E8 suggesting that E6 does indeed provide functions not supplied 
by E7 and E8 (Pennie et al, 1993). In the presence of the mutagen quercetin, 
E7 is the only BPV-4 oncogene required for full transformation substituting E8 
in conferring anchorage independence and 16E6 in inducing immortalisation. 
16E6 is known to inhibit apoptosis by binding oligomeric and monomeric forms 
of p53 (Marston et al, 1994). It would be interesting to determine if 16E6 
confers immortality by the inhibition of apoptosis and if other E6 proteins from 
the low risk papillomaviruses HPV-6 and 11 or BPV-1 E6 can provide the 
same functions. Expression of cell death/survival genes such as bcl-2 and box 
and the p53 induced wafl/cipl could be determined at various stages of cell 
transformation. This would raise the question as to whether the expression of 
these genes is altered when the cells are treated with quercetin in the presence 
of viral oncogenes. The status of p53 protein expression in transformed cell 
lines is also unclear and differences in p53 expression between quercetin and 
non-quercetin treated cells could be determined by immunohistochemistry.
213
REFERENCES
214
Agoff, SN;Hou, J;Linzer, DIH;Wu, B (1993)
Regulation of the human hsp70 promoter by p53. Science. 259 (5091):84-87
Anderson, R.A., Scobie, L., O'Neil, B.W., Grindlay, G.J and Campo, M.S (1996)
Viral proteins of bovine papillomavirus type-4 during the development of alimentary canal 
tumours. British Veterinary Journal., in press.
Band, V; Dalai, S; Demolino, L; Androphy, E.J (1993)
Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalised human 
mammary epithelial cells. Embo Journal. 12:1847-1852
Barak Y. Juven T. Haffner R. Oren M. (1993)
mdm2 expression is induced by wild type p53 activity. EMBO Journal. 12(2):461-8
Barbosa, MS;Edmonds, C;Fisher, C;Schiller, JT;Lowy, DR;Vousden, KH (1990)
The region of the HPV E7 oncoprotein homologous to adenovirus Ela and SV40 large T 
antigen contains separate domains for Rb binding and casein kinase II phosphorylation 
EMBO Journal. 9(1):153-160
Barbosa, MS;Lowy, DR;Schiller, JT (1989)
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. Journal of Virology.
63(3): 1404-1407
Barbosa, MS;Vass, WC;Lowy, DR;Schiller, JT (1991)
In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of 
different oncogenic potential. Journal of Virology. 65(l):292-298
Barendse, W., Armitage, S.M., Kossarek, L.M., et al. (1994)
A genetic linkage map of the bovine genome. Nature Genetics. 6:227-235
Bargonetti, J;Friedman, PN;Kern, SE;Vogelstein, B;Prives, C (1991)
Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the 
SV40 origin of replication. Cell. 65 (6); 1083-1091
Bargonetti, J., Reynisdottir, I., Friedman, P.N., Prives, C. (1992)
Site-specific binding of wild type p53 to cellular DNA is inhibited by S V40 T antigen and 
mutant p53. Genes and Development. 6:1886-1898
Bartek, J;Iggo, R;Gannon, J;Lane, DP (1990a)
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. 
Oncogene. 5(6):893-899
Bartek, J;Bartkova, J;Vojtesek, B;Staskova, Z;Rejthar, A;Kovarik, J;Lane, DP (1990b) 
Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in 
situ and in vitro. International Journal of Cancer. 46(5):839-844
Bartek, J., Bartkova, J., Vojtesek, B., Staskova, Z., Lukas, J., Rejthar, A., Kovarik, J., 
Midgeley, C.A., Gannon, J.V., Lane, D.P (1991)
Abberant expression of the p53 oncoprotein is a common feature of a wide spectrum of 
human malignancies. Oncogene. 6:1699-1703
Baker, SJ;Markowitz, S;Fearon, ER;Willson, JKV;Vogelstein, B (1990)
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 249
(4971); 912-915
215
Baudier, J., Delphin, C., Grunwald, D., Khochbin, S and Lawrence, J.J. (1992) 
Characterisation of the tumour suppressor protein p53 as a protein kinase C substrate and 
SlOOb-binding protein. Proceedings of the National Academy of Sciences of the United 
States of America. 89:11627-11631
Benchimol, S., Lamb, P., Crawford, L.V., Sheer, D., Shows, T.B., Bruns, G.A.P., Peacock, J. 
(1985)
Transformation associated p53 protein is encoded by a gene on human chromosome 17. 
Somatic Cell and Molecular Genetics. 11 (5):505-509
Bischoff, J.R., Friedman, P.N., Marsh, D.R., Prives, C., Beach, D. (1990)
Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proceedings of the National 
Academy of Sciences of the United States of America. 87:4766-4770
Bjieldanes, L.F., and Chang, G.W. (1977)
Mutagenic activity of quercetin and related compounds. Science. 197:577-578 
Bond, J.A., Wyllie, F.S., Wynford-Thomas, D. (1994)
Escape from senescence in human diploid fibroblasts induced directly by mutant p53. 
Oncogene. 9:1885-1889
Brietburd, F., Croissant, O., Orth, G. (1987)
Expression of human papillomavirus type 1 E4 gene product in warts. Cancer Cells. 5:115- 
122
Buckwalter, M.S., Katz, R.W., Camper, S.A (1991)
Localisation of the panhypopituitary dwarf mutant (df) on mouse chromosome 11 in an 
intersubspecific backcross. Genomics. 10:515-526
Budunova, I.V., Carbajal, S., Slaga, T.J. (1995)
The expression of gap junctional proteins during different stages of mouse skin 
carcinogenesis. 2717-2724
Buesos-Ramos, C., Yang, Y., deLeon, E., McCown, P., Stass, S.A., Albitar, M. (1993)
The human mdm2 oncogene is overexpressed in leukemias. Blood. 82(9):2617-2623
Butz, K; Shahabeddin, L; Geisan, C; Spitovsky, D; Ullmann A.HS (1995)
Functional p53 protein in human-papillomavirus positive cancer cells. Oncogene. 10:927- 
936
Caimey, M. PhD Thesis, (1995), University of Glasgow.
Cairney M. and Campo MS. (1995)
The synergism between bovine papillomavirus type 4 and quercetin is dependent on the 
timing of exposure. Carcinogenesis. 16(8): 1997-2001
Campo, MS;Moar, MH;Jarrett, WFH;Laird, HM (1980)
A new papillomavirus associated with alimentary cancer in cattle. Nature. 286 (5769);ISO- 
182
Campo, MS and Spandidos, DA (1983)
Molecularly cloned bovine papillomavirus DNA transforms mouse fibroblasts in vitro 
Journal of General Virology. 64 (3);549-557
Campo, M.S., Moar, M.H., Sartirana, M.L., Kennedy, I.M., Jarret, W.F.H (1985)
The presence of bovine papillomavirus type 4 DNA is not required for the progression to and 
the maintenance of the malignant state in cancers of the alimentary canal in cattle. EMBO 
Journal. 4: 1819-1825
216
Campo, M.S and Jarrett, W.F.H. (1986)
Papillomavirus infection in cattle: viral and chemical cofactors in naturally occurring and 
experimentally induced tumours. CIBA Foundation Symposium. 120:117-131
Campo, MS;McCaffery, RE;Doherty, I;Kennedy, IM;Jarrett, WFH (1990)
The Harvey ras 1 gene is activated in papillomavirus-associated carcinomas of the upper 
alimentary canal in cattle. Oncogene. 5(3);303-308
Campo MS. Jarrett WF. Barron R. O'Neil BW. Smith KT. (1992)
Association of bovine papillomavirus type 2 and bracken fern with bladder cancer in cattle. 
Cancer Research. 52(24):6898-904
Campo MS. Grindlay GJ. O'Neil BW. Chandrachud LM. McGarvie GM. Jarrett WF.
(1993)
Prophylactic and therapeutic vaccination against a mucosal papillomavirus. Journal of 
General Virology.
74 ( Pt 6):945-53
Campo MS. O'Neil BW. Barron RJ. Jarrett WF. (1994a)
Experimental reproduction of the papilloma-carcinoma complex of the alimentary canal in 
cattle. Carcinogenesis. 15(8): 1597-601
Campo, M.S., Anderson, R.A., Caimey, M., Jackson, M.E. (1994b)
Bovine papillomavirus type 4: from transcriptional control to control of disease. In, Viruses 
and Cancer (eds, A.C Minson, J.C Neil, M.A McRae) Society for General Microbiology 
Symposium 51, p47-122. Published by Cambridge University Press.
Chandrachud LM. O'Neil BW. Jarrett WF. Grindlay GJ. McGarvie GM. Campo MS.
(1994)
Humoral immune response to the E7 protein of bovine papillomavirus type 4 and 
identification of B-cell epitopes. Virology. 200(1):98-104
Chen, E.Y., Howley, P.M., Levinson, A.D., Seeburg, P.H. (1982)
The primary structure and genetic organisation of bovine papillomavirus type 1. Nature. 
299:529-534
Chen, J.J; McNealy, D.J; Dalai, S; Androphy, E.J (1995)
Interaction of papillomavirus E6 oncoproteins with a putative calcium binding protein. 
Science. 269:529-531
Clarke, AR;Purdie, CA;Harrison, DJ;Morris, RG;Bird, CC;Hooper, ML; Wyllie, AH (1993) 
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362 
(6423):849-852
Clore, GM;Omichinski, JG;Sakaguchi, K;Zambrano, N;Sakamoto, H; Appella, 
E;Gronenborn, AM (1994)
High-resolution structure of the oligomerization domain of p53 by multidimensional NMR 
Science. 265 (5170):386-391
Cho, Y;Gorina, S;Jeffrey, PD;Pavletich, NP (1994)
Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic 
mutations. Science. 265 (5170):346-355
Ciccolini, F;Di Pasquale, G;Carlotti, F;Crawford, L;Tommasino, M (1994)
Functional studies of E7 proteins from different HPV types. Oncogene. 9 (9): 2633-2638
217
Counter, C.M (1992)
Telomere shortening associated with chromosomal instability is arrested in immortal cells 
which express telomere activity. EMBO Journal. 11:1921-1929
Crook,T., Storey, A., Almond, N., Osborn, K., Crawford, L. (1988)
Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the 
hormone-dependent transformation of primary mouse cells. Proceedings of the National 
Academy of Sciences of the United States of America. 85:8820-8824
Crook, T; Morganstem, J.P., Crawford, L., Banks, L (1989)
Continued expression of HPV-16 E7 protein is required for the maintenance of the 
transformed phenotype of cells cotransformed by HPV-16 plus EJ-ras. EMBO Journal. 
8:513-519
Crook, T;Tidy, JA;Vousden, KH (1991a)
Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for 
p53 binding and trans-activation. Cell. 67 (3):547-556
Crook, T;Wrede, D;Vousden, KH (1991b)
p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene. 6 
(5):873-875
Crook, T., Fisher, C., Vousden, K.H (1991c)
Modulation of immortalising properties of human papillomavirus type 16 E7 by p53 
expression. Journal of Virology. 65(1):505-510
Crook, T;Farthing, A;Vousden, K (1992)
HPV-16 and cervical intraepithelial neoplasia . Lancet. 339:8803- 1231 
Crook, T and Vousden, K.H (1992)
Properties of p53 mutations detected in primary and secondary cervical cancers suggest 
mechanisms of metastasis and involvement of environmental carcinogens. Embo Journal. 
11:3935-3940
Coggins LW. ScobieL. Jackson ME. Campo MS. (1995)
Assignment of the bovine p53 gene (TP53) to chromosome 19ql5 by fluorescence in situ 
hybridization. Mammalian Genome. 6(9):687-8
Coutourier, J., Sastre-Garau, X., Scneider-Maunoury, S., Labib, A., Orth, G. (1991) 
Integration of papillomavirus DNA near myc genes in genital carcinomas and its 
consequences for proto-oncogene expression. Journal of Virology. 65:4534-4538
Croissant, O., Brietburd, F., Orth, G. (1985)
Specificity of cytopathic effect of cutaneous human papillomaviruses. Clinical Dermatology. 
3:43
Debbas, M and White, E (1993)
Wild-type p53 mediates apoptosis by El A, which is inhibited by E1B. Genes and 
Development. 7 (4); 546-554
Defeo-Jones, D., Vuocola, G., Haskell, K.M., Hanobik, M.G., Kiefer, D.M., McAvoy, E.M., 
Ivey-Hoyle, M., Brandsma, J., Oliff, A., Jones, R.E. (1993)
Papillomavirus E7 protein binding to the retinoblastoma protein is not required for viral 
induction of warts. Journal of Virology. 67(2):716-725
Deffie, A., Wu, H., Reinke, V., Lozano, G. (1993)
The tumour suppressor p53 regulates its own transcription. Molecular and Cellular Biology. 
13(6):3415-3423
218
Demers, G.W; Halbert, C.L; Galloway, D.A (1994a)
Elevated wild type p53 protein levels in human epithelial cell lines immortalised by the 
human papillomavirus type 16 E7 gene. Virology. 198:169-174
Demers, G.W; Foster, S.A; Halbert, C.L; Galloway, D.A (1994b)
Growth arrest induction of p53 in DNA damaged keratinocytes is bypassed by human 
papillomavirus 16 E7. Proceedings of the National Academy of Sciences of the United States 
of America. 91:4382-4386
Deppert.W. (1994)
The yin and yang of p53 in cellular proliferation. Seminars in Cancer Biology. 5:187-202 
Desaintes, C; Hallez, S; Detremmerie, O; Bumy, A (1995)
Wild-type p53 downregulates transcription from oncogenic human papillomavirus promoters 
through the epithelial specific enhancer. Oncogene. 10:2155-2161
Desaintes, C; Hallez, S; Van Alphen, P; Bumy, A (1992)
Transcriptional activation of several heterologous promoters by the E6 protein of human 
papillomavirus type 16. Journal of Virology. 66:325-333
DequiedtF. KettmannR. Bumy A. Willems L. (1995a)
Nucleotide sequence of the ovine P53 tumor-suppressor cDNA and its genomic organization. 
DNA Sequence. 5(4):255-9
Dequiedt F. Willems L. Bumy A. Kettmann R. (1995b)
Nucleotide sequence of the bovine P53 tumor-suppressor cDNA. DNA Sequence. 5(4):261-4 
de Villiers, E.M. (1989)
Heterogeneity of the human papillomavirus group. [Minireview] Journal of Virology. 63 
(ll):4898-4903
Dittmer, D;Pati, S;Zambetti, G;Chu, S;Teresky, AK;Moore, M;Finlay, C; Levine, AJ (1993) 
Gain of function mutations in p53. Nature Genetics. 4(l):42-46
Donehower, LA;Harvey, M;Slagle, BL;McArthur, MJ;Montgomery CA, Jr; Butel,
JS;Bradley, AT (1992)
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours 
Nature. 356(6366):215-221
Doorbar, J., Campbell, D., Grand, R.J.A, Gallimore, P.H (1986)
Identification of the human papillomavirus la E4 gene product. EMBO Journal. 5:355-362 
Doorbar, J;Ely, S;Sterling, J;McLean, C;Crawford, L (1991)
Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the 
epithelial cell intermediate filament network. Nature. 352 (6338): 824-827
Dutta, A., Ruppert, J.M., Aster, J.C., Winchester, E. (1993)
Inhibition of DNA replication factor RPA by p53. Nature. 365:79-82
ElDeiry, WS;Tokino, T;Velculescu, VE;Levy, DB;Parsons, R;Trent, JM; Lin, D;Mercer, 
WE;Kinzler, KW;Vogelstein, B (1993)
WAF1, a potential mediator of p53 tumor suppression. Cell. 75 (4); 817-825
ElDiery, W.S., Kem, S., Pietenpol, J.A., Kinzler, K.W., Vogelstein, B. (1992)
Definition of a consensus binding site for p53. Nature Genetics. 1:45-49
219
Eliyahu, D;Michalovitz, D;Eliyahu, S;PinhasiKimhi, 0;0ren, M (1989)
Wild-type p53 can inhibit oncogene-mediated focus formation. Proceedings of the National 
Academy of Sciences of the United States of America. 86(22):8763-8767
Eliyahu, D., Goldfinger, N., Pinhasi-Kimhi, O., Shaulsky, G., Skumik, Y., Arai, N., Rotter, 
V., Oren M. (1988)
MethA fibrosarcoma cells express two transforming mutant p53 species. Oncogene. 3:313- 
321
Etscheid, B.G, Foster, S.A., Galloway, D.A (1994)
The E6 protein of humna papillomavirus type 16 functions as a transcriptional repressor in a 
mechanism independent of the tumour suppressor protein p53. Virology. 205:583-585
Evans, I.A., Prorok, J.H., Cole, R.C., Al-Samani, M.H., Al-Sammarai, A.M., Patel, M.C., 
Smith, R.M.N (1982)
The carcinogenic, mutagenic and teratogenic toxicity of bracken. Proceedings of the Royal 
Society of Edinburgh. 81:65-78
Evans, W.C., Patel, M.C., Koohy, Y. (1982)
Acute bracken poisoning in homogastric and ruminant animals. Proceedings of the Royal 
Society of Edinburgh. 81:29-64
Ewen, M.E., Sluss, H.K., Sherr, C.J., Matsushime, H., Kato, J.Y., Livingstone, D.M. (1993) 
Functional interaction of the retinoblastoma protein with mammalian D-type cyclins. Cell. 
73:487-497
Ewen, M.E., faha, B., Harlow, E., Livingstone, D.M. (1992)
Interaction of p i07 with cyclin A independent of complex formation with viral oncoproteins. 
Science, 255:85-87
Faccini, A.M., Caimey, M., Ashrafi, G.H., Finbow, M.E., Campo, M.S., and Pitts, J.P. 
(1996)
The bovine papilomavirus type-4 E8 protein binds to ductin and causes loss of gap junctional 
intercellular communication in primary fibroblasts. Journal of Virology. 70 (12): in press.
Fakarazedeh, S.S., Trusko, S.P., George, D.L. (1991)
Tumourigenic potential associated with enhanced expression of a gene that is amplified in a 
mouse tumour cell line. EMBO Journal. 10:1565-1569
Fields, S and Jang, SK (1990)
Presence of a potent transcription activating sequence in the p53 protein. Science. 249
(4972); 1046-1049
Finbow, M.E., Pitts, J.D., Goldstein, J.D., Schlegel, R., Findlay, J.B.C (1991)
The E5 oncoprotein target: a 16kD channel-forming protein with diverse functions. 
Molecular Carcinogenesis. 4:441 -444
Finlay, CA;Hinds, PW;Levine, AJ (1989)
The p53 proto-oncogene can act as a suppressor of transformation. Cell. 57(7): 1083-1093 
Finlay, C.A. (1993)
The mdm2 oncogene can overcome wild type p53 suppression of transformed cell growth. 
Molecular and Cellular Biology. 13(1 ):301 -306
Fries,R., Eggen, A., Womack, J.E. (1993)
The bovine genome map. Mammalian Genome. 4:405-428
220
Fritsche, M., Haessler, C., Brandner, G (1993)
Induction of nuclear accumulation of the tumour suppressor protein p53 by DNA damaging 
agents [published erratum appears in Oncogene 1993 Sep; 8 (9):2605] Oncogene. 8:307- 
318
Fujikawa, K., Furuse, M., Uwabe, K.I., Maki, H., Yoshie, O. (1994)
Nuclear localisation and transactivation of HPV-16 E7 b-galactosidase fusion protein: 
characterisation of the nuclear localisation signal. Virology. 204(2):789-793
Funk, W.D., Pak, D.T., Karas, R.H., Wright, W.E., Shay, J.W. (1992)
A transcriptionally active DNA-binding site for human p53 protein complexes. Molecular 
and Cellular Biology. 12:2866-2871
Gaukroger, JM;Bradley, A;Chandrachud, L;Jarrett, WFH;Campo, MS (1993)
Interaction between bovine papillomavirus type 4 and cocarcinogens in the production of 
malignant tumours. Journal of General Virology. 74 (10);2275-2280
Gaukroger, J;Chandrachud, L'.Jarrett, WFH;McGarvie, GE;Yeudall, WA;
McCaffery, RE;Smith, KT;Campo, MS (1991)
Malignant tranformation of a papilloma induced by bovine papillomavirus type 4 in the nude 
mouse renal capsule. Journal of General Virology. 72 (5); 1165-1168
Ginsberg, D;Mechta, F;Yaniv, M;Oren, M (1991a)
Wild-type p53 can down-modulate the activity of various promoters. Proceedings of the 
National Academy of Sciences of the United States of America. 88 (22); 9979-9983
Ginsberg, D;MichaelMichalovitz, D;Ginsberg, D;Oren, M (1991b)
Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased 
nuclear localization and decreased stability of the protein. Molecular and Cellular Biology.
11 (l);582-585
Giri, I and Danos, O (1986)
Papillomavirus genomes: From sequence data to biological properties. Trends in Genetics. 2 
(9):227-232
Goodrich, DW;Nan Ping, Wang;Qian, YW;Lee, EYHP;Lee, WH (1991)
The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle 
Cell. 67 (2); 293-302
Goodrich, DW and Lee, WH (1993)
Molecular characterization of the retinoblastoma susceptibility gene. Biochimica et 
Biophysica Acta - Reviews on Cancer. 1155 (1); 43-61
Goldstein, D.J., Finbow, M.E., Andresson, T., McLean, P., Smith, K., Bubb, V., and 
Schlegel, R. (1991)
Bovine papillomavirus E5 binds to the 16k component of the vacuolar H+ -ATPases. Nature. 
352 (6333):347-349
Gorman, C. (1985)
High efficiency gene transfer into mammalian cells. In, DNA cloning Volume II; a practical 
approach, ed, D.M Glover, IRL Press Ltd.
Greenfield, I., Nickerson, J., Penman, S., Stanley, M. (1991)
Human papillomavirus 16 E7 protein is associated with the nuclear matrix. Proceedings of 
the National Academy of Sciences of the United States of America. 88; 1217-1221
221
Gunawardana, A and Fries, R. (1992)
Assignment of the HOX2 and HOX3 gene clusters to the bovine chromosome regions 19ql7- 
q23 and 5ql3-22. Animal Genetics. 23:161-165
Hainaut, P., and Milner. J. (1993)
A structural role for metal ions in the wild type p53 conformation of the tumour suppressor 
protein p53. Cancer Research. 53:1739-1742
Halbert, C.L., Demers, G.W., Galloway, D.A. (1991)
The E7 gene of HPV-16 is sufficient for immortalisation of human epithelial cells. Journal 
of Virology. 65(l):473-478
Halbert, C.L., Rolley, N., Davies, M., Milner, J. (1992)
The E6 and E7 genes of human papillomavirus type 6 have weak immortalising activity in 
human epithelial cells. Journal of Virology. 66:2125-2134
Ham, J., Dostatni, N., Gauthier, J., Yaniv, M. (1991)
The papillomavirus E2 protein: a factor with many talents. Trends in Biochemical Sciences. 
16:440-444
Hamid, Q., Wharton, J., Terenghi, G., et al. (1987)
Localisation of atrial natriuretic peptide mRNA and immunoreactivity in the rat heart and 
human atrial appendage. Proceedings of the National Academy of Sciences of the United 
States of America. 84:6760-6764
Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K., Elledge, S.J. (1993)
The p21 Cdk- interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. 
Cell. 75:805-816
Hartmann, A., Blaszyk, H., McGovern, R.M., Schroeder, J.J., Cunningham, J., DeVries, 
E.M.G., Kovach, K.S., Sommer, S.S. (1995)
p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other 
cancers. Oncogene. 10:681-688
Harvey, M;Sands, AT;Weiss, RS;Hegi, ME;Wiseman, RW;Pantazis, P;Giovanella, 
BC;Tainsky, MA;Bradley, A;Donehower, LA (1993)
In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice 
Oncogene. 8 (9):2457-2467
Harvey, D.M. and Levine, A.J. (1991)
p53 alteration is a common event in the spontaneous immortalisation of primary Balb/c 
murine embryo fibroblasts. Genes and Development. 5:2375-2385
Haupt Y. Rowan S. Oren M. (1995)
p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene. 
10(8): 1563-71
HawleyNelson, P;Vousden, KH;Hubbert, NL;Lowy, DR;Schiller, JT (1989)
HPV 16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes 
EMBO Journal. 8 (12):3905-3910
Hayashi.K. (1991)
PCR-SSCP: s simple and sensitive method for detection of mutations in the genomic DNA. 
PCR methods and applications. 1:34-38
He, Z., Brinton, B.T., Greenblatt, J., Hassell, J.A., Ingles, C.J. (1993)
The transactivaor proteins VP16 and Gal4 bind replication factor A. Cell. 73:1223-1232
222
Hediger, R., Johnson, S.E., Barendse, W., Drinkwater, R.D., Moore, S.S., Hetzel, DJ.S 
(1990)
Assignment of the growth hormone gene locus to 19q26-qter in cattle and llq25-qter in 
sheep by in-situ hybridisation. Genomics. 8:171-174
Hicks, GG., Egan, S E., Greenberg, A H., Mowat, M. (1991)
Mutant p53 tumour suppressor alleles release ras-induced cell cycle growth arrest. Molecular 
and Cellular Biology. 11(3): 1344-1352
Hinds, P.W., Finlay, C.A., Quartin, R.S., Baker, S.J., Fearon, E.R., Vogelstien, B., Levine, 
A.J. (1990)
Mutant p53 cDNA clones from human colon carcinomas cooperate with ras in transforming 
primary rat cells: A comparison of the hot spot mutant phenotypes. Cell Growth and 
Differentiation. 1:571-580
Hirano, Y., Yamato, K., Tsuchida, N. (1995)
A temperature sensitive mutant of the human p53, Vell38, arrests rat cell growth without 
induced expression of cipl/wafl/sdil after temperature shift-down. Oncogene. 10:1879- 
1885
Hollstein, M;Sidransky, D;Vogelstein, B;Harris, CC (1991) 
p53 Mutations in human cancers. Science. 253 (5015); 49-53
Huibregtse, JM;Scheffner, M;Howley, PM (1991)
A cellular protein mediates association of p53 with the E6 oncoprotein of human 
papillomavirus types 16 or 18. EMBO Journal. 10 (13); 4129-4135
Huibregtse, JM;Scheffner, M;Howley, PM (1993a)
Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the 
human papillomavirus E6 oncoprotein with p53. Molecular and Cellular Biology. 13 
(2);775-784
Huibregtse, JM;Scheffner, M;Howley, PM (1993b)
Localization of the E6-AP regions that direct human papillomavirus E6 binding, association 
with p53, and ubiquitination of associated proteins. Molecular and Cellular Biology. 13 (8); 
4918-4927
Hupp, T.R., Meek, D.W., Midgeley, CA., Lane, D.P. (1993)
Activation of the cryptic DNA binding formation of mutant forms of p53. Nucleic Acids 
Research. 21:3167-3174
Iggo, R;Gatter, K;Bartek, J;Lane, D;Harris, AL (1990)
Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 
335(8691):675-679
ISCDNA (1989,1990).
International system for cytogenetic nomenclature of domestic animals, D. Diberadino, 
H.Hayes, R.Fries, S.Long, eds. Cytogenetics and Cell Genetics. 53:65-78
Ishidate, M. (1988)
Data book on chromosomal aberration tests in vitro. Elsevier.
Ishikawa, M., Okada, F., Hamada, J., Hosokawa, M., Kobayashi, A. (1987)
Changes in the tumourigenic and metastatic properties of tumour cells treated with quercetin 
or 5-azacytidine. International Journal of Cancer. 39:338-342
223
Ishioka, C., Englert, C., Winge, P., Yan, Y., Engelstein, M., Friend, S.H. (1995)
Mutational analysis of the carboxy terminal portion of p53 using both yeast and mammalian 
cell assays in vivo. Oncogene. 10:1485-1492
Ishiwatara, H., Hayasaka, N., Inoue, H., Yutsudo, M., Hakura, A. (1994)
Degradation of p53 only is not sufficient for the growth stimulatory effect of human 
papillomavirus 16 E6 oncoprotein in human embryonic fibroblasts. Journal of Medical 
Virology. 44:243-249
Jackson, ME;Pennie, WD;McCaffery, RE;Smith, KT;Grindlay, GJ;Campo, MS (1991)
The B subgroup bovine papillomaviruses lack an identifiable E6 open reading frame. 
Molecular Carcinogenesis. 4 (5);382-387
Jackson, ME and Campo, MS (1991)
Positive and negative E2-independent regulatory elements in the long control region of 
bovine papillomavirus type 4. Journal of General Virology. 72(4);877-883
Jackson, ME and Campo, MS (1992)
Bovine papillomaviruses. Papillomavirus Report, ed, C. Lacey, published Royal Society of 
Medicine Services, University of Leeds. 3(4):91-94
Jackson, ME., Campo, MS., Gaukroger, J.M (1993)
Cooperation between papillomavirus and chemical cofactors in oncogenesis. Critical 
Reviews in Oncogenesis. 4(3):277-291
Jackson ME. and Campo MS. (1995a)
Both viral E2 protein and the cellular factor PEBP2 regulate transcription via E2 consensus 
sites within the bovine papillomavirus type 4 long control region. Journal of Virology. 
69(10):6038-46
Jackson ME. and Campo MS. (1995b)
Cooperation between bovine papillomaviruses and dietary carcinogens in cancers of cattle. 
In, DNA tumour viruses: Oncogenic mechanisms, pi 11-122. (eds G. Barbanti-Brodano et 
al). Plenum Press, New York.
Jarrett, W.F.H., McNeal, P.E., Grimshaw, T.R., Selman, I.E., McIntyre, W.I. (1978)
High incidence area of cattle cancer with a possible interaction between an environmental 
carcinogen and a papillomavirus. Nature. 274:215-217
Jarrett, WFH., Campo, MS., ONeil, BW., Laird, H.M., Coggins, L.W (1984)
A novel bovine papillomavirus (BPV-6) causing true epithelial papillomas of the mammary 
gland skin: A member of a proposed new BPV subgroup. Virology. 136 (2);255-264
Jarrett, W.F.H (1985)
The natural history of bovine papillomavirus infection. Advances in Viral Oncology. 
5:83-102
Jaggar, RT;Pennie, WD;Smith, KT;Jackson, ME;Campo, MS (1990)
Cooperation between bovine papillomavirus type 4 and ras in the morphological 
transformation of primary bovine fibroblasts. Journal of General Virology. 71 (12);3041- 
3046
Jeffrey, PD;Gorina, S;Pavletich, NP (1995)
Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms 
Science. 267 (5203): 1498-1502
224
Jenkins, J.R., Rudge, K., Currie, G.A. (1984)
Cellular immortalisation by a cDNA clone encoding the transformation associated 
phosphoprotein p53. Nature. 312:651-654
Jewers, R.J., Hildebrandt, P., Ludlow, W.J., Kell, B., McCance, DJ. (1992)
Regions of human papillomavirus type 16 E7 oncoprotein required for the immortalisation of 
human keratinocytes. Journal of Virology. 66:1329-1335
Juven T. Barak Y. Zauberman A. George DL. Oren M. (1993)
Wild type p53 can mediate sequence-specific transactivation of an internal promoter within 
the mdm2 gene. Oncogene. 8(12):3411-6
Kanda, T., Watanabe, S., Yoshiike, K. (1988)
Immortalisation of primary rat cells by HPV-16 subgenomic DNA fragments controlled by 
the SV40 promoter. Virology. 165(l):321-325
Kastan, MB;Zhan, Q;ElDeiry, WS;Carrier, F;Jacks, T;Walsh, WV; Plunkett, BS;Vogelstein, 
B;Fomace AJ, Jr (1992)
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in 
ataxia-telangiectasia. Cell. 71 (4);587-597
Kastan, MB;Onyekwere, 0;Sidransky, D;Vogelstein, B;Craig, RW (1991)
Participation of p53 protein in the cellular response to DNA damage. Cancer Research. 
51(23); 6304-6311
Kern, SE;Kinzler, KW;Bruskin, A;Jarosz, D;Friedman, P;Prives, C; Vogelstein, B (1991a) 
Identification of p53 as a sequence-specific DNA-binding protein. Science. 252 
(5013);1708-1711
Kern, SE;Kinzler, KW;Baker, SJ;Nigro, JM;Rotter, V;Levine, AJ;Friedman, P;Prives, 
C;Vogelstein, B (1991b)
Mutant p53 proteins bind DNA abnormally in vitro. Oncogene. 6(1);131-136 
Keen, N;Elston, R;Crawford, L (1994)
Interaction of the E6 protein of human papillomavirus with cellular proteins. Oncogene. 9 
(5): 1493-1499
Keen, J., Lester, D., Inglehearn, C., Curtis, A., Bhattacharya, S. (1991)
Rapid detection of single base mismatches as heteroduplexes on Hydrolink gels. Trends in 
Genetics. 7:5
Kessis, T.D., Slebos, R.J., Nelson, W.G., Kastan, M.B., Plunkett, B.S., Han, S.M.L., 
Hedrick.L., Cho, K.R. (1993)
Human papillomavirus 16E6 expression disrupts the p53-mediated cellular response to DNA 
damage. Proceedings of the National Academy of Sciences of the United States of America. 
90:3988-3992
Khare, S., Pater, M.M., Pater, A. (1995)
Role of exogeneous cofactors in HPV infection and oncogenesis. [Review] Papillomavirus 
Report, ed, C. Lacey, published Royal Society of Medicine Services, University of Leeds. 
6(4): 89-93
Klingelhutz, A.J., Barber, S.A., Smith, P.P., Dyer, K., McDougall, J.K. (1994)
Restoration of telomeres in HPV immortalised human anogenital epithelial cells. Molecular 
and Cellular Biology. 14:961-969
225
Klingelhutz, A.J., Foster, S.A., McDougall, J.K. (1996)
Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature. 
380:79-82
Knowles, G., O'Neil, B.W and Campo, M.S. (1996)
Phenotypical characterisation of lymphocytes infiltrating regressing papillomas. Journal of 
Virology, 70, in press.
Kowenz-Leutz, E., Twamley, G., Ansieau, S., Leutz, A. (1994)
Novel mechanism of C/EBPP (NF-M) transcriptional control: activation through 
derepression. Genes and Development. 8:2781-2791
Krek, W., Livingston, D M., Shirodkar, S W., Manidor, G., Peter, M. (1993)
Binding to DNA and the retinoblastoma gene product promoted by the complex formation of 
different E2F family members. Science. 262(5139):1557-1560
Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V., Kastan, M.B (1992)
Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proceedings of 
the National Academy of Sciences of the United States of America. 89:7491-7495
Ladanyi, M., Cha, C., Lewis, R., Jhanwar, S.C., Huvos, A.G., Healey, J.H. (1993)
MDM2 gene amplification in metastatic osteosarcoma. Cancer Research. 53:16-18
Lane, D.P and Crawford, L.V (1979)
T-antigen is bound to host protein in SV40-transformed cells. Nature (London). 278:261- 
263
Lane, D.P (1993)
Cancer:A death in the life of p53 [news comment]. Nature (London). 362:786-787 
Lamb, P and Crawford, L (1986)
Characterization of the human p53 gene. Molecular and Cellular Biology. 6(5): 1379-1385 
Leach, R.J., Thayer, M.J., Schafer, A.J., Fournier, R.E.K. (1989)
Physical mapping of human chromosome 17 using fragment-containing microcell hybrids. 
Genomics. 5:167-176
Lechner, M.S., Mack, D.H., Finicle, A.B., Crook, T., Vousden, K.H., Laimins, L.A. (1992) 
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of 
transcription. EMBO Journal. ll(8):3045-3052
Lechner, M.S and Laimins, L.A. (1994)
Inhibition of p53 DNA binding by human papillomavirus E6 proteins. Journal of Virology. 
68(7):4262-4273
Lee, S.C., Kim, IG., Marekov, LN., OKeefe, EJ., Parry, DAD., Steinert, PM. (1993)
The structure of human trichohyalin. Potential multiple roles as a functional EF-hand-like 
calcium binding protein, a comified cell envelope precursor and an intermediate filament 
associated (cross-linking) protein. Journal of Biological Chemistry. 268(16): 12164-12176
Levine, AJ (1990)
The p53 protein and its interactions with the oncogene products of the small DNA tumour 
viruses. Virology. 177 (2):419-426
Levine, A.J., Momand, J., Finlay, C.A (1991)
The p53 tumour suppressor gene. Nature. 351:453-456
226
Levine, A.J., Perry, M.E., Chang, A., Silver, A., Dittmer, D., Wu, M., Welsh, D. (1994)
The 1993 Walter Hubert Lecture: The role of the p53 tumour suppressor gene in 
tumourigenesis. British Journal of Cancer. 69(3):409-416
Liu, Z., Ghai, J., Ostrow, R.S., Faras, A.J. (1995)
The expression levels of human papillomavirus type 16 E7 correlate with its transforming 
potential. Virology. 207:260-270
Liu, Z., Ghai, J., Ostrow, R.S., McGlennen, R.C., Faras, A.J. (1994)
The E6 gene of human papillomavirus type 16 is sufficient for transformation of baby rat 
kidney cells in cotransfection with activated H-ras. Virology. 201:388-396
Liu, X., Miller, C.W., Loeffler, P.H., Berk, A.J. (1993)
The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFII-D and a 
neighbouring p53 domain inhibits transcription. Molecular and Cellular Biology. 13:3291- 
3300
Liu, M and Pelling, JC (1995)
UV-B/A irradiation of mouse keratinocytes results in p53-mediated WAF1/CIP1 expression 
Oncogene. 10 (10); 1955-1960
Livingstone, L.R., White, A., Sprouse, J., Livanos, E., Jacks, T., Tisty, T.D. (1992)
Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. 
Cell. 70:923-925
Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A., Jacks, T. (1993)
p53 is required for radiation induced apoptosis in mouse thymocytes. Nature. 362:847-849
Lutzner, M.A. (1985)
Papillomavirus lesions in immunodepression and immunosuppression.
Clinical Dermatology. 3:165-169
McBride, A.A., Spalholz, B.A., Lambert, P.F., Howley, P.M. (1989)
Functional domains of papillomavirus E2 proteins. In, Common mechanisms of 
transformation by small DNA tumour viruses (Villareal, L.P., ed), ppl 15-126, American 
Society for Microbiology.
McCaffery, RE;Coggins, LW'.Doherty, I;Kennedy, I;OPrey, M;McColl, L; Campo, MS 
(1989)
Multiple Harvey-ras genes in the bovine genome. Oncogene. 4 (12); 1441-1448 
McCaffrey, R and Jackson, M.E (1994)
An element binding C/EBP related transcription factor contributes to negative regulation of 
the bovine papillomavirus type 4 long control region. Journal of General Virology. 75:3047- 
3056
McCance, D.J., Kopan, R., Fuchs, E., Laimins, L.A. (1988)
Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. 
Proceedings of the National Academy of Sciences of the United States of America. 85:7169- 
7173
McGarvie GM. Grindlay GJ. Chandrachud LM. O'Neil BW. Jarrett WF. Campo MS. 
(1995)
T cell responses to BPV4 E7 during infection and mapping of T cell epitopes. Virology. 
206(1):504-10
227
McIntyre, M.C., Frattini, M.G., Grossman, S.R., Laimins, l.A. (1993)
Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc 
binding, dimerisation, and transformation but not for Rb binding. Journal of Virology. 
67:3142-3150
McVey, D., Brizuela, L., Mohr, I., Marshak, D.R., Gluzman, Y., Beach, D. (1989) 
Phosphorylation of large tumour antigen by cdc2 stimulates SV40 DNA replication. Nature. 
341:503-507
Marsh, J.L., Erfle, M., Wykes, E.J. (1984)
The pIC plasmid and phage vectors with versatile cloning sites for recombinant selection by 
insertional inactivation. Gene. 32:481-485
Marston, NJ., Crook, T., Vousden, KH. (1994)
Interaction of p53 with mdm-2 is independent of E6 and does not mediate wild type 
transformation suppressor function. Oncogene. 9(9):2707-2716
Martin, K., Trouche, D., Hagemeler, C., Sorenson, T.S., La Thangue, N.B., Kouzarides, T. 
(1995)
Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature. 375:691- 
694
Matlashewski, G;Osbom, K;Banks, L;Stanley, M;Crawford, L (1988)
Transformation of primary human fibroblast cells with human papillomavirus type 16 DNA 
and EJ-ras. International Journal of Cancer. 42(2): 232-238
Matlashewski, G;Banks, L;Pim, D;Crawford, L (1986)
Analysis of human p53 proteins and mRNA levels in normal and transformed cells. 
European Journal of Biochemistry. 154 (3):665-672
Meek, D.W. (1994)
Post translational modification of p53 [Review]. Seminars in Cancer Biology. 5:211-219 
Meek, DW and Street, AJ (1992)
Nuclear protein phosphorylation and growth control. Biochemical Journal. 287 (1); 1-15 
Meek, D.W., Simon, S., Kikkawa, U., Eckhart, W. (1990)
The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. 
EMBO Journal. 9:3253-3260
Meyers, C and Laimins, L.A (1992)
In vitro model systems for the study of HPV induced neoplasia. Papillomavirus Report, (ed, 
C. Lacey, Royal Society of Medicine Services, University of Leeds). 3 (l):l-3
Milne, D.M., Palmer, R.H., Meek, D.W. (1992)
Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity 
of p53. Nucleic Acids Research. 20:5565-5570
Milner, J. (1994).
Forms and functions of p53. [Review] Seminars in Cancer Biology. 5:211-219 
Milner, J and Watson, JV (1990)
Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour 
suppressor protein. Oncogene. 5(11); 1683-1690
228
Moll, UM;Riou, G;Levine, AJ (1992)
Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion 
Proceedings of the National Academy of Sciences of the United States of America. 89 
(15):7262-7266
MomandJ. ZambettiGP. Olson DC. George D. Levine AJ. (1992)
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53- 
mediated transactivation. Cell. 69(7): 1237-45
Moura, J.W., Stocco dos Santos, R.C., Dagli, M.L.Z., D'Angelino, J.L., Birgel E.H., Becack, 
W. (1988)
Chromosome abberations in cattle raised on bracken fern pasture. Experientia. 44:785-788
Munger, K., Wemess, B.A., Dyson, N., Phelps, W.C., Harlow, E., Howley, P.M. (1989) 
Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumour 
suppressor gene product. EMBO Journal. 8:4099-4105
Munger, K., Yee, C.L., Phelps, W.C., Peitenpol, J.A., Moses, H.I., Howley, P.M. (1991) 
Biochemical and biological differences between E7 oncoproteins of the high and low risk 
human papillomavirus types are determined by amino-terminal sequences. Journal of 
Virology. 65:3943-3948
Munger, K;Scheffner, M;Huibregtse, JM;Howley, PM (1992)
Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer 
Surveys. 12;197-217
Munger, K and Phelps, WC (1993)
The human papillomavirus E7 protein as a transforming and transactivating factor. 
Biochimica et Biophysica Acta. 1155;111-123
Myashita, T., Krajewski, S., Krajewski, M., Wang, H.G., Lin, H.K., Liebermann, D.A., 
Hoffman, B., Reed, J.C. (1994)
Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. 
Oncogene. 9:1799-1805
Nishitani, H., Ohtsubo, M., Yamashita, K., Iida, H., Pines, J., Yasudo, H. (1991)
Loss of RCC1 a nuclear DNA binding proteinuncouples the completion of DNA replication 
from the activation of cdc2 protein kinase and mitosis. EMBO Journal. 10(6): 1555-1564
Oberosler, P., Hloch, P., Ramsperger, U., Stahl, H. (1993)
p53 catalysed annealing of complementary single strand nucleic acids. EMBO Journal. 12: 
2389-2396
O'Brien, S.J., Womack, J.E., Lyons, L.A., Moore, K.J., Jenkins, N.A., Copeland, N.G (1993) 
Anchored reference loci for comparitive mapping genome mapping in mammals. Nature 
Genetics. 3:103-112
Oelze, I;Kartenbeck, J;Crusius, K;Alonso, A (1995)
Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial 
cell line. Journal of Virology. 69 (7):4489-4494
Oliner, JD;Kinzler, KW;Meltzer, PS;George, DL;Vogelstein, B (1992)
Amplification of a gene encoding a p53-associated protein in human sarcomas 
Nature. 358 (6381); 80-83
Olson DC. Marechal V. Momand J. Chen J. Romocki C. Levine AJ. (1993)
Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein 
complexes. Oncogene. 8(9):2353-60
229
Oltvai, Z.N., Milliman, C.L., Korsmeyer, S.J. (1993)
Bcl-2 heterodimerises in vivo with a conserved homologue, bax, that accelarates 
programmed cell death. Cell. 74:609-619
Oren, M.t Maltzman, W., Levine, A.J. (1981)
Postranslational regulation of the 54K cellular tumour antigen in normal and transformed 
cells. Molecular and Cellular Biology. 1:101-110
Orth, G. (1987)
Epidermodysplasia verruciformis. In, N.P Salzman and P.M Howley (eds), The 
Papovaviridae, Vol 2, pp. 199-243. New York: Plenum Publishing Corporation.
Parker, C., Lakshmi, M.S., Piura, B., Sherbet, G.V. (1994)
Metastasis associated mtsl gene expression correlates with increased p53 detection in the 
B16 murine melanoma. DNA and Cell Biology. 13 (4):343-351
Pater, M.M., Hughes, G.A., Hyslop, D.E., Nakshatri, H., Pater, A. (1988)
Glucocortocoid dependent oncogenic transformation by type 16 not type 11 human papilloma 
virus. Nature. 335:832-835
Pavletich, N.P., Chambers, K.A., Pabo, C.O. (1993)
The DNA binding domain of p53 contains the four conserved regions and the major mutation 
hotspots. Genes and Development. 7:2556-2564
Peauroi, J.R., Mohr, F.C., Fisher, D.J., Misheff, M., Grindlay, G.J., Campo, M.S. (1995) 
Anemia, hematuria and multicentirc urinary neoplasia in a llama (Lama Glama) exposed to 
bracken fern. Journal of Zoo and Wildlife Medicine. 26(2):315-320
Pennie, W.D. PhD Thesis, (1992), University of Glasgow
Pennie WD. and Campo MS. (1992)
Synergism between bovine papillomavirus type 4 and the flavonoid quercetin in cell 
transformation in vitro. Virology. 190(2):861-5
Pennie WD. Grindlay GJ. CaimeyM. Campo MS. (1993)
Analysis of the transforming functions of bovine papillomavirus type 4. Virology. 
193(2):614-20
Peacock, J.W., Matlashewski, G.J., Benchimol, S. (1990)
Synergism between pairs of immortalising genes in transformation assays of rat embryo 
fibroblasts. Oncogene. 5:1769-1774
Peacock, J.W and Benchimol, S. (1994)
Mutation of the endogeneous p53 gene in cells transformed by HPV-16E7 and EJ-ras confers 
a growth advantage involving an autocrine mechanism. EMBO Journal. 13:1084-1092
Perry, ME and Levine, AJ (1993)
Tumor-suppressor p53 and the cell cycle. Current Opinion in Genetics and Development. 3 
(1); 50-54
Pfister, H. (1987)
Papillomaviruses: general description, taxonomy and classification. In, The Papovaviridae, 
Vol 2 (N.P. Salzman and P.M. Howley, Eds) New York: Plenum Press.
Phelps, W.C., Munger, K., Yee, C.L., Barnes, J.A., Howley, P.M. (1992)
Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. Journal of 
Virology. 66:2418-2427
230
Phelps, W.C., Yee, C.L., Munger, K., Howley, P.M. (1988)
The human papillomavirus type 16 E7 gene encodes transactivation and transformation 
functions similar to those of adenovirus E1A. Cell. 53:539-547
Pietenpol, JA;Tokino, T;Thiagalingam, S;ElDeiry, WS;Kinzler, KW;Vogelstein, B (1994) 
Sequence-specific transcriptional activation is essential for growth suppression by p53 
Proceedings of the National Academy of Sciences of the United Slates of America.
91 (6);1998-2002
Phelps, W.C., Munger, K., Yee, C.L., Barnes, J.A., Howley, P.M (1992)
Stucture function analysis of the human papillomavirus type 16 E7 oncoprotein. Journal of 
Virology. 66:2418-2427
Pirn, D;Storey, A;Thomas, M;Massimi, P;Banks, L (1994)
Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, 
abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. 
Oncogene. 9 (7): 1869-1876
Prives, C (1993)
Doing the right thing: Feedback control and p53. Current Opinions in Cell Biology. 5:214- 
218
RagimovN. KrauskopfA. NavotN. Rotter V. OrenM. Aloni Y. (1993)
Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with 
the binding of basal transcription factors to the TATA motif. Oncogene. 8(5): 1183-93
Rahman, A., Shahabuddin, S.M.H., Parish, J.H. (1990)
Complexes involving quercetin, DNA and Cu(II). Carcinogenesis. 11:2001
Raycroft, L., Wu, H., Lozano, G. (1990)
Transcriptional activation by wild type but not transforming mutants of the p53 anti­
oncogene. Science. 249:1049-1051
ReidSW. Smith KT. Jarrett WF. (1994)
Detection, cloning and characterisation of papillomaviral DNA present in sarcoid tumours of 
Equus asinus. Veterinary Record. 135(18):430-2
Reisman, D and Rotter, V (1993)
The helix-loop-helix containing transcription factor USF binds to and transactivates the 
promoter of the p53 tumor suppressor gene. Nucleic Acids Research. 21 (2); 345-350
Rittling, S.R and Denhardt, D.T (1992)
p53 mutations in spontaneously immortalised 3T12 but not 3T3 mouse embryo cells. 
Oncogene. 7(5):935-942
Roberts, S., Ashmole, I., Johnson, G.D., Kreider, J.W., Gallimore, P.H (1993)
Cutaneous and mucosal human papillomavirus E4 proteins form intermediate filament like 
structures in epithelial cells. Virology. 197:176-187
Rotter, V., Wolf, D., Pravtcheva, D., Ruddle, F.H (1984)
Chromosomal assignment of the murine gene encoding the transformation related protein 
p53. Molecular and Cellular Biology. 4:383-385
Rous, P and Freidewald, W.F (1944)
The effect of chemical carcinogens on virus induced rabbit carcinomas. Journal of 
Experimental Medicine. 79:511
231
Rovinski, B and Benchimol, S. (1988)
Immortalisation of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene. 2:445- 
452
Ryan, J.J., Danish, R., Gottleib, C.A., Clarke, M.F (1993)
Cell cycle analysis of p53-induced cell death in murine erythroleukaemia cells. Molecular
and Cellular Biology. 13:711-719
Sambrook, J., Fritsch, E F., Maniatis, T. (1989)
Molecular Cloning: A laboratory manual. 2nd Edition (eds), N. Ford., M. Ferguson., C. 
Nolan, Cold Spring Harbor Laboratory Press.
Sandler, A.B., VandePol, S.B., Spalholz, B.A. (1993)
Repression of bovine papillomavirus type 1 transcription by the El replication protein. 
Journal of Virology. 67(9):5079-5087
Sander, J.L. van den Heuvel., van Laar, T., The, I., van der Eb, A.J. (1993)
Large E1B proteins of adenovirus types 5 and 12 have different effects on p53 and distinct
roles in cell transformation. Journal of Virology. 67(9):5226-5234
Santos, E., Tronick, S.R., Aaronson, S.A., Pulciani, S., Barbacid, M. (1982)
T24 human bladder oncogene is an activated form of the normal homologue of BALB- and 
Harvey-MSV transforming genes. Nature. 298:343-347
Schafer, B.W and Heizmann, C.W (1996)
The S100 family of EF-Hand calcium binding proteins: functions and pathology. Trends in 
Biochemical Sciences. 21:134-140
Scheffner, M;Wemess, BA;Huibregtse, JM;Levine, AJ;Howley, PM (1990)
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the 
degradation of p53. Cell. 63 (6); 1129-1136
Scheffner, M;Munger, K;Huibregtse, JM;Howley, PM (1992a)
Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion 
proteins. EMBO Journal. 11 (7);2425-2431
Scheffner, M;Takahashi, T;Huibregtse, JM;Minna, JD;Howley, PM (1992b)
Interaction-of the human papillomavirus type 16 E6 oncoprotein with wild- type and mutant 
human p53 proteins. Journal of Virology. 66 (8); 5100-5105
Scheffner, M;Huibregtse, JM;Vierstra, RD;Howley, PM (1993)
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the 
ubiquitination of p53. Cell. 75 (3);495-505
Schiller, J.T., Vass, W.C., Vousden, K.H., Lowy, D.R (1986)
E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene.
Journal of Virology. 57:1-6
Schiller, J.T and Roden, R.B.S. (1995)
Papillomavirus-like particles. Papillomavirus Report, (ed, C. Lacey, Royal Society of 
Medicine Services, University of Leeds). 6(5):121-128
Schiller, J.T., Vass, W.C., Lowy, D.R (1984)
Identification of a second transforming region in bovine papillomavirus DNA. Proceedings 
of the National Academy of Sciences of the United States of America. 81:7880-7884
232
Schlegel, R., Phelps, W.C., Zhang, Y.L., Barbosa, M. (1988)
Quantitative keratinocyte assay detects two biological activities of human papillomavirus 
DNA and identifies viral types associated with cervical carcinoma. EMBO Journal. 7:3181- 
3187
Schwarz, E., Freese, U.K., Gissman, L. et al. (1985)
Structure and transcription of humna papillomavirus sequences in cervical carcinoma cells. 
Nature. 314:111-114
Sedman, S.A., Barbosa, M.S., Vass, W.C. (1991)
The full length E6 protein of human papillomavirus type 16 has transforming and trans- 
activating activities and cooperates with E7 to immortalise keratinocytes in culture. Journal 
of Virology. 65:4860-4866
Sedman, S.A., Hubbert, N.L., Vass, W.C., Lowy, D.R., Schiller, J.T (1992)
Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalisation of human 
keratinocytes but does not have E6 associated transactivation or transforming activity.
Journal of Virology. 66:4201-4208
Seto E. Usheva A. Zambetti GP. Momand J. Horikoshi N. Weinmann R. Levine AJ. 
ShenkT. (1992)
Wild-type p53 binds to the TATA-binding protein and represses transcription.
Proceedings of the National Academy of Sciences of the United States of America. 
89(24): 12028-32
Shaulsky, G;Goldfinger, N ;Rotter, V (1991)
Alterations in tumour development in vivo mediated by expression of wild type or mutant 
p53 proteins. Cancer Research. 51:5232-5237
Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., Costa, J. (1992)
Induction of apoptosis by wild type p53 in a human colon tumour derived cell line. 
Proceedings of the National Academy of Sciences of the United States of America. 89:4495- 
4499
Smith KT. Coggins LW. Doherty I. Pennie WD. Caimey M. Campo MS. (1993)
BPV-4 induces amplification and activation of'silent' BPV-1 in a sub-line of C127 cells. 
Oncogene. 8(1): 151-6
Smith, KT and Campo, MS (1989)
Amplification of specific DNA sequences in C127 mouse cells transformed by bovine 
papillomavirus type 4. Oncogene. 4 (4); 409-413
Smith, KT and Campo, MS (1988)
'Hit and run' transformation of mouse C l27 cells by bovine papillomavirus type 4: The viral 
DNA is required for the initation but not for maintenance of the transformed phenotype. 
Virology. 164 (l);39-47
Smith, K.T., Campo, M.S., Bradley, J., Gaukroger, J., Jarrett, W.F.H. (1987)
Cell transformation by bovine papillomavirus cofactors and cellular responses. In, Cancer 
Cells 5, Papillomaviruses, p267-274. Cold Spring Harbor Laboratory.
Smith, KT;Patel, KR;Campo, MS (1986)
Transcriptional organization of bovine papillomavirus type 4. Journal of General Virology 
67 (11); 2381-2393
233
Smotkin, D and Wettstein, F.O (1986)
Transcription of human papilomavirus type 16 early genes in a cervical cancer and a cancer- 
derived cell line and identification of the E7 protein. Proceedings of the National Academy 
of Sciences of the United States of America. 83:4680-4684
Srivastava, S;Wang, S;Tong, YA;Pirollo, K;Chang, EH (1993)
Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome 
exhibit transdominant effects on the biochemical properties of the wild-type p53. Oncogene 
8 (9):2449-2456
Srivastava, S., Tong, Y.A., Devadas, K., Zou, Z., Chen, Y., Pirollo, K.F., Chang, E.H (1992) 
The status of the p53 gene in human papillomavirus positive or negative cervical carcinoma 
cell lines. Carcinogenesis. 13(7): 1273-1275
Srivastava, S;Zou, Z;Pirollo, K;Blattner, W;Chang, EH (1990)
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni 
syndrome. Nature. 348(6303):747-749
Storey, A., Pirn, D., Murray, A., Osborn, K., Banks, L., Crawford, L. (1988)
Comparison of the in vitro transforming activites of human papillomavirus types. EMBO 
Journal. 7(6): 1815-1820
Storey, A;Almond, N;Osbom, K;Crawford, L (1990)
Mutations of the human papillomavirus type 16 E7 gene that affect transformation, 
transactivation and phosphorylation by the E7 protein. Journal of General Virology. 
71(4):965-970
Storey, A and Banks, L (1993)
Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary 
mouse cells. Oncogene. 8 (4):919-924
Storey, A., Sexton, C., Banks, L. (1994)
The keratinocyte handbook, (eds.) Leigh, I., Lane, B., Watt, F. Cambridge University press. 
pp439-457
Storey, A;Massimi, P;Dawson, K;Banks, L (1995)
Conditional immortalization of primary cells by human papillomavirus type 18 E6 and EJ- 
ras defines an E6 activity in G0/G1 phase which can be substituted for mutations in p53. 
Oncogene. 11(4):653-661
Shope, R.E and Hurst, E.W (1933)
Infectious papillomatosis of rabbits: with a note on the histopathology. Journal of 
Experimental Medicine. 58:607
Soussi, T;Caron De Fromentel, C;May, P (1990)
Structural aspects of the p53 protein in relation to gene evolution. Oncogene. 5(7):945-952
Sturzbecher, H.W., Brian, R., Addison, C., Rudge, K., Remm, M., Grimalsi, M., Keenan, E., 
Jenkins, J.R. (1992)
A C-terminal alpha helix plus basic region motif is the major structural determinant of p53 
tetramerisation. Oncogene. 7:1513-1523
Thomas, M; Matlashewski, G; Pirn, D; Banks, L. (1996)
Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by 
HPV-18 E6 through ubiquitin mediated degradation. Oncogene. 13(2);265-273
234
Toldo SS. Fries R. Steffen P. Neibergs HL. Barendse W. Womack JE. Hetzel DJ. 
Stranzinger G. (1993)
Physically mapped, cosmid-derived microsatellite markers as anchor loci on bovine 
chromosomes. Mammalian Genome. 4(12):720-7
Tommasino, M;Adamczewski, JP;Carlotti, F;Barth, CF;Manetti, R; Contomi, M;Cavalieri, 
F;Hunt, T;Crawford, L (1993)
HPV16 E7 protein associates with the protein kinase p33(CDK2) and cyclin A. Oncogene. 8 
(1): 195-202
Tommasino, M., and Crawford, L. (1995)
Human papilomavirus E6 and E7: proteins which deregulate the cell cycle. Bioessays. 
17(6):509-518
Ulrich, E., Boehmelt, G., Bird, A., Beug, H (1992)
Immortalisation of conditionally transformed chicken cells: Loss of normal p53 expression is 
an early step that is independent of cell transformation. Genes and Development. 6(5):876- 
887
Unger, T;Mietz, JA;Scheffner, M;Yee, CL;Howley, PM (1993)
Functional domains of wild-type and mutant p53 proteins involved in transcriptional 
regulation, transdominant inhibition, and transformation suppression. Molecular and 
Cellular Biology. 13 (9);5186-5194
Van Ranst, M.A., Tachezy, R., Delius, H., Burk, R.D (1993)
Taxonomy of the human papillomaviruses. Papillomavirus Report, (ed, C. Lacey, Royal 
Society of Medicine Services, University of Leeds). 4 (3):61-65
Van Ranst, M.A., Tachezy, R., Burk, R.D (1994)
Human papillomavirus nucleotide sequences: What's in stock?. Papillomavirus Report, (ed, 
C. Lacey, Royal Society of Medicine Services, University of Leeds). 5 (3):65-72
Van Wart Hood, J., Linder, M.E., Burr, J.G. (1989)
TPCK and quercetin act synergistically with vanadate to increase protein tyrosine 
phosphorylation in avian cell. Oncogene. 4:1267-1271
Vogelstein, B (1990)
A deadly inheritance. Nature. 348 (6303); 681-682 
Vogelstein, B and Kinzler, KW (1993)
The multistep nature of cancer. Trends in Genetics. 9 (4);138-141 
Vousden, K (1993)
Interactions of human papillomavirus transforming proteins with the products of tumor 
suppressor genes. FASEB Journal. 7(10):872-879
Vousden, KH;Vojtesek, B;Fisher, C;Lane, D (1993)
HPV-16 E7 or adenovirus El A can overcome the growth arrest of cells immortalized with a 
temperature-sensitive p53. Oncogene. 8(6): 1697-1702
Vousden, K H., Wrede, D., Crook, T. (1991)
HPV oncoprotein function: Releasing the brakes on cell growth control. Papillomavirus 
Report, ed, C. Lacey, published Royal Society of Medicine Services, University of Leeds. 
2(1):1-3
Vousden, K.H (1990)
Human papillomavirus oncoproteins. Seminars in Cancer Biology. 1:415-424
235
Vousden, K H and Jat, P S. (1989)
Functional similarity between HPV 16 E7, SV40 large T antigen and adenovirus Ela 
proteins. Oncogene. 4(2): 153-158
Vousden, KH (1989)
Human papillomaviruses and cervical carcinoma. Cancer Cells. 1 (2):43-49 
Vousden, KH;Androphy, EJ;Schiller, JT;Lowy, DR (1989)
Mutational analysis of bovine papillomavirus E6 gene. Journal of Virology. 63(5):2340- 
2342
Wang, Y., Szekely, L., Okan, I., Klein, G., Wiman, G., Wiman, K.L. (1993)
Wild type p53 triggered apoptosis is inhibited by bcl-2 in a v-myc induced T-cell lymphoma 
line. Oncogene. 8:3427-3431
Wang, Y and Eckhart, W (1992)
Phosphorylation sites in the amino-terminal region of mouse p53. Proceedings of the 
National Academy of Sciences of the United States of America. 89 (10); 4231-4235
Watanabe, S., Kanda, T., Sato, H., Furuno, A., Yoshiike, K. (1990)
Mutational analysis of human papillomavirus type 16 E7 functions. Journal of Virology. 
64:207-214
Weinert, TA and Hartwell, LH (1990)
Characterization of RAD9 of Saccharomyces cerevisiae and evidence that its function acts 
posttranslationally in cell cycle arrest after DNA damage. Molecular and Cellular Biology 
10 (12); 6554-6564
Weinert, T and Lydall, D. (1993)
Cell cycle checkpoints genetic instability and cancer. Seminars in Cancer Biology. 4:129- 
140
Weintraub, H., Hauschka, S., Tapscott, S.J. (1991)
The MCK enhancer contains a p53 responsive element. Proceedings of the National 
Academy of Sciences of the United States of America. 88:4570-4571
Weis, K., Griffiths, G., Lamond, A.I. (1994)
The endoplasmic reticulum calcium binding protein of 55kDa is a novel EF hand proein 
retained in the endoplasmic reticulum by a carboxyl-terminal His-Asp-Glu-Leu motif. 
Journal of Biological Chemistry. 269(29): 19142-19150
Wemess, B.A., Levine, A.J., Howley, P.M (1990)
Association of human papillomavirus type 16 and 18 proteins with p53. Science. 248:76-79
Williams, A.C., Browne, S.J., Manning, A.M., Daffada, P., Collard, T.J., Paraskeva, C. 
(1994)
Transfection and expression of mutant p53 protein does not alter the in vivo or in vitro 
growth characteristics of the A A/Cl human adenoma derived cell line, including sensitivity 
to transforming growth factor beta 1. Oncogene. 9(5): 1479-1485
Wynford-Thomas, D„ Bond, J.A., Wyllie, F.S., Jones, C.J. (1995)
Does telomere shortening drive selection for p53 mutation in human cancer? Molecular 
Carcinogenesis. 12:119-123
Xiao, ZX;Chen, J;Levine, AJ;Modjtahedi, M;Xing, J;Sellers, WR;Livingston, DM (1995) 
Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature. 
375:694-698
236
Xiong, Y., Hannon, G.J., Shang, H., Casso, D., Kobayashi, R., Beach, D. (1993) 
p21 is a universal inhibitor of cyclin kinases. Nature. 366:701-704
Yang, Y.C., Okayama, H., Howley, P.M (1985)
Bovine papillomavirus contains multiple transforming genes. Proceedings of the National 
Academy of Sciences of the United States of America. 82:1030-1034
Yasumoto, S., Burkhardt, A.L., Doniger, J. et al. (1986)
Human papillomvirus type 16 DNA induced malignant transformation of NIH3T3 cells. 
Journal of Virology. 57:572-577
Yew, PR and Berk, AJ (1992)
Inhibition of p53 transactivation required for transformation by adenovirus early IB protein 
Nature. 357 (6373); 82-85
Yewdell, J.W., Gannon, J.V., Lane, D.P. (1986)
Monoclonal antibody analysis of p53 expression in normal and transformed cells. Journal of 
Virology. 59(2): 444-452
Yonish-Rouach E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., Oren, M. (1991)
Wild type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin- 
6. Nature. 352:645-347
Zantema, A., Schrier, P.I., Davis-Oliver, A., van Laar, T., Vaessen, RTMJ., van der Eb, A.J. 
(1985)
Adenovirus serotype determines association and localisation of the large E1B tumour antigen 
with cellular tumour antigen p53 in transformed cells. Molecular and Cellular Biology. 
5:3084-3091.
Zauberman A. Barak Y. Ragimov N. Levy N. Oren M. (1993)
Sequence-specific DNA binding by p53: identification of target sites and lack of binding to 
p53 - MDM2 complexes. EMBO Journal. 12(7):2799-808
Zhang. W., Shay, J.W., Deisseroth, A. (1993)
Inactive p53 mutants may enhance the transcriptional activity of wild type p53. Cancer 
Research. 53:4772-4775
Zhou, J and Fraser, I.H (1995)
Papovaviridae: Capsid structure and capsid protein function. [Review]. Papillomavirus 
Report, ed, C. Lacey, published Royal Society of Medicine Services, University of Leeds. 
6(3):59-63
Zhou, J., Stenzel, D.J., Sun, X., Frazer, I.H. (1993)
Synthesis and assembly of infectious bovine papillomavirus particles in vitro. Journal of 
General Virology. 74:763-768
237
